uric acid has been researched along with Arthritis, Gouty in 623 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Arthritis, Gouty: Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular. Acute and chronic gouty arthritis are associated with accumulation of MONOSODIUM URATE in and around affected joints.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial." | 9.69 | A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023) |
| "To observe the clinical effect of Rebixiao granule (RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism." | 9.11 | Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis. ( Ji, W; Lu, Y; Tan, WF; Zhu, XX, 2005) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 9.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| "Low dose daily enteric coated aspirin does not significantly interfere with the uricosuric effects of probenecid in patients with gouty arthritis." | 9.09 | Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. ( Alloway, J; Bryant, LR; Danaher, P; Harris, M, 2000) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 8.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance." | 8.31 | A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 8.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| "Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty arthritis." | 8.12 | Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. ( Al Kury, LT; Alattar, A; Alshaman, R; Atzaz, N; Li, S; Riaz, M; Shah, FA, 2022) |
| "Gouty arthritis could be triggered by the deposition of monosodium uric acid (MSU) crystals." | 8.12 | Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-κB/NLRP3 and Nrf2 Pathways. ( Ai, GX; Chen, XY; Cheng, JJ; Li, YC; Ma, XD; Su, ZR; Xie, JH; Xie, QF; Yan, F; Yu, QX, 2022) |
| "To assess the effects of anethole on monosodium urate (MSU)-induced inflammatory response, investigate its role in acute gouty arthritis (AGA), and verify its molecular mechanism." | 8.12 | Anethole ameliorates inflammation induced by monosodium urate in an acute gouty arthritis model via inhibiting TLRs/MyD88 pathway. ( Cao, Y; Liu, Z; Tang, F; Yao, X; Zhang, X; Zhong, Q, 2022) |
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 8.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "Uric acid is the final product of purine metabolism, and excessive serum uric acid can cause gouty arthritis and uric acid nephropathy." | 8.02 | Bmk9 and Uricase Nanoparticle Complex for the Treatment of Gouty Arthritis and Uric Acid Nephropathy. ( An, M; Fu, H; Han, T; Li, W; Wang, M, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 8.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms." | 8.02 | Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021) |
| "To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis." | 7.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| " Subsequently, he showed increased uric acid levels and developed acute gouty arthritis." | 7.96 | Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. ( Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E, 2020) |
| "These results indicated that curcumin could effectively ameliorate MSU crystal-induced gouty arthritis through NLRP3 inflammasome mediation via inhibiting NF-κB signaling both in vitro and in vivo, suggesting a promising active ingredient for the prevention and treatment of gouty arthritis." | 7.91 | Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling. ( He, X; Li, X; Sun, DY; Xiao, DM; Xu, DQ; Zhang, T, 2019) |
| "Gouty arthritis is an inflammatory disease that is triggered by abnormal uric acid metabolism, which is usually attributed to obesity, a risk factor of hyperuricemia and gout attack." | 7.91 | Leptin Promotes Monosodium Urate Crystal-Induced Inflammation in Human and Murine Models of Gout. ( Fu, S; Liang, M; Lv, L; Wan, W; Xuan, D; Xue, Y; Yang, J; Yu, Y; Zhu, X; Zou, H, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "The present study suggests that luteolin and luteolin-4'-O-glucoside could be developed as therapeutics for treating hyperuricemia and gouty arthritis." | 7.88 | Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. ( Hu, YJ; Liang, WQ; Lin, Y; Liu, PG; Pu, JB; Xu, P; Zhang, HJ; Zhou, J, 2018) |
| "To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level." | 7.88 | Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 7.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| " pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia." | 7.85 | Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. ( Hu, YJ; Jiang, Y; Lin, Y; Pan, HH; Song, XJ; Zhang, HJ, 2017) |
| "The aim of this study was to investigate the anti-inflammatory effect of ferulic acid, a dietary phenol, on monosodium urate (MSU) crystal-induced inflammation in rats, an experimental model for acute gouty arthritis." | 7.83 | Targeting inflammatory mediators with ferulic acid, a dietary polyphenol, for the suppression of monosodium urate crystal-induced inflammation in rats. ( Dey, C; Doss, HM; Rasool, MK; Sudandiradoss, C, 2016) |
| "The anti-inflammatory effect of morin, a dietary bioflavanol was explored on monosodium urate (MSU) crystal-induced inflammation in rats, an experimental model for acute gouty arthritis." | 7.83 | Morin, a dietary bioflavonol suppresses monosodium urate crystal-induced inflammation in an animal model of acute gouty arthritis with reference to NLRP3 inflammasome, hypo-xanthine phospho-ribosyl transferase, and inflammatory mediators. ( Dhanasekar, C; Rasool, M, 2016) |
| "In this study, we investigated the effects of a soft coral-derived anti-inflammatory compound, lemnalol, on mast cell (MC) function and osteoclast activity in rats with monosodium urate (MSU) crystal-induced gouty arthritis." | 7.81 | Lemnalol attenuates mast cell activation and osteoclast activity in a gouty arthritis model. ( Duh, CY; Huang, SY; Jean, YH; Lee, HP; Lin, SC; Lin, YY; Wang, HM; Wen, ZH; Wu, SF, 2015) |
| "The aims of the current study are to describe gadolinium-enhanced MRI features of an acute flare of established gouty arthritis in different joints and to examine a possible association between serum uric acid and MRI signs indicative of ongoing inflammation and/or structural joint damage as well as association with disease characteristics and laboratory findings." | 7.81 | Gadolinium-enhanced MRI features of acute gouty arthritis on top of chronic gouty involvement in different joints. ( Abd-Allah, MA; El-Naggar, A; El-Shaarawy, N; Emad, Y; Fathy, A; Gamal, RM; Hawass, M; Ragab, Y; Rasker, JJ, 2015) |
| "The combination of sodium alginate and resveratrol has better effect over colchicines in treating MSU-induced acute gouty arthritis." | 7.81 | Effect of sodium alginate addition to resveratrol on acute gouty arthritis. ( Chen, Y; Jiang, M; Ren, D; Wang, P; Wang, R; Wang, YG, 2015) |
| " In the present study, we found that treatment with lemnalol (intramuscular [im]), but not colchicine (oral [po]), significantly attenuated MUS-induced mechanical allodynia, paw edema and knee swelling." | 7.79 | Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression. ( Duh, CY; Huang, SY; Jean, YH; Lee, HP; Lin, YY; Wang, HM; Wen, ZH; Wu, SF, 2013) |
| "These results indicated that quercetin exerted a strong anti-inflammatory effect that may be useful for the treatment of acute gouty arthritis." | 7.78 | Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat. ( Chen, J; Huang, J; Li, S; Sun, W; Tao, Y; Wang, S; Zhu, M, 2012) |
| "In the present study, the anti-inflammatory effect of piperine was investigated on monosodium urate crystal-induced inflammation in mice, an experimental model for gouty arthritis, and compared it with that of the nonsteroidal anti-inflammatory drug, indomethacin." | 7.77 | A role of piperine on monosodium urate crystal-induced inflammation--an experimental model of gouty arthritis. ( Nagar, S; Rasool, M; Sabina, EP, 2011) |
| "The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose." | 7.77 | Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout." | 7.77 | Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011) |
| "To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol." | 7.77 | Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011) |
| "To clarify the mechanism of decreased serum uric acid (SUA) concentrations during acute gouty arthritis." | 7.71 | The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. ( Hara, M; Kamatani, N; Matsuda, Y; Nakajima, H; Taniguchi, A; Tsutani, H; Urano, W; Yamanaka, H, 2002) |
| "To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients." | 7.68 | Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 5.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "These results revealed that GPS can treat acute gouty arthritis based on anti-inflammatory and analgesic properties in vivo, which might be ascribed to the inhibition on NLRP3 inflammasome." | 5.72 | Effects of Gentiopicroside on activation of NLRP3 inflammasome in acute gouty arthritis mice induced by MSU. ( Chen, M; Gao, Q; He, M; Hu, C; Li, L; Tian, W, 2022) |
| "The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls." | 5.72 | Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022) |
| "Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage." | 5.72 | Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022) |
| "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues." | 5.72 | Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022) |
| "Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints." | 5.72 | The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022) |
| "To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo-controlled, double-blind trial." | 5.69 | A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. ( Botson, JK; Chamberlain, J; Grewal, S; La, D; LaMoreaux, B; LoCicero, K; Majjhoo, A; Obermeyer, K; Ong, S; Parikh, N; Peterson, J; Saag, K; Sainati, S; Tesser, JRP; Verma, S; Weinblatt, ME; Xin, Y, 2023) |
| "No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine." | 5.69 | Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. ( Chen, HC; Wei, JC; Yang, DH, 2023) |
| "Gouty arthritis is triggered when the deposition of monosodium urate (MSU) crystals in joints induces acute inflammation characterized by the recruitment of macrophages and neutrophils." | 5.62 | Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation. ( Deng, G; Gu, Y; Liu, S; Lv, W; Sun, Y; Zhu, Y, 2021) |
| "Ginsenoside Rb1 (GsRb1) is the best constituent of ginseng and although it shows clinical efficacy as an antineoplastic, antioxidative and antirheumatic agent, its oral bioavailability is poor due to its limited solubility." | 5.56 | Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals. ( Liu, Y; Ye, Q; Zhou, W; Zhu, H, 2020) |
| "Present study was undertaken to investigate the dose-response relationship of berberine in SMW between the articular concentration and anti-inflammatory effect in the knee joint under the lower-guiding of ABR." | 5.48 | Achyranthis bidentatae radix enhanced articular distribution and anti-inflammatory effect of berberine in Sanmiao Wan using an acute gouty arthritis rat model. ( Cheng, W; Li, J; Li, W; Sun, B; Wu, J; Xie, J; Zhang, Q, 2018) |
| "Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints." | 5.46 | The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. ( Balbino, B; Contag, CH; Galli, SJ; Gaudenzio, N; Kang, D; Raghu, H; Reber, LL; Robinson, WH; Rogalla, S; Sensarn, S; Sibilano, R; Sokolove, J; Starkl, P; Tsai, M, 2017) |
| "Gouty arthritis is characterized by inflammation induced by monosodium urate (MSU) crystal deposition, which is resulted by an increase of serum urate concentration." | 5.43 | The effect of resveratrol on the recurrent attacks of gouty arthritis. ( Chen, H; Liu, Q; Qiu, J; Wang, Y; Xue, Y; Zheng, S; Zhu, H; Zhu, X; Zou, H, 2016) |
| "The nanoparticles are safe medications for gouty arthritis which can effectively reduce uric acid levels in rodents." | 5.41 | Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis. ( Guo, L; Guo, Y; Lei, Y; Li, Y; Mao, J; Niu, Y; Wang, S; Xiong, X; Zhou, W; Zhu, R, 2023) |
| "Gouty arthritis (GA), one of the most common forms of inflammatory arthritis, is characterized by elevated serum uric acid concentrations and the consequent deposition of monosodium urate crystals." | 5.41 | Metabolic Regulation of Immune Response and Tissue Remodeling in Gouty Arthritis (Review). ( Chen, Z; Hua, Y; Wang, W, 2023) |
| " The assessed outcomes were total effective rate, uric acid level, pain score, and inflammatory factor levels such as erythrocyte sedimentation rate and C-reactive protein." | 5.41 | Herbal medicine for external use in acute gouty arthritis: A PRISMA-compliant systematic review and meta-analysis. ( Choi, SH; Hwang, J; Song, HS, 2023) |
| "Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints." | 5.30 | Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997) |
| "Among the 44 patients with ADPKD, the serum uric acid (SUA) was 7." | 5.29 | A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. ( Hosoya, T; Ichida, K; Sakai, O; Tabe, A, 1993) |
| " Nevertheless, it remains unclear whether lowering of serum uric acid (UA) alters any of the features of the metabolic syndrome." | 5.27 | Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis. ( Maalouf, NM; Marin, M, 2018) |
| "In the double-blind, randomized, controlled trial, we aimed to evaluate the effects of compound tufuling oral liquid (CoTOL) on serum uric acid (sUA) levels and recurrence of acute gouty arthritis in intercritical and chronic gout treatment." | 5.24 | Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial. ( Fan, Y; Gao, X; Han, Y; Jing, X; Li, X; Li, Y; Sun, J; Tang, X; Wen, C; Wu, H; Xie, Z, 2017) |
| "Gout is well known as an inflammatory rheumatic disease presenting with arthritis and abnormal metabolism of uric acid." | 5.22 | Gout and Diet: A Comprehensive Review of Mechanisms and Management. ( Chen, S; Xu, H; Xu, Y; Yuan, M; Zhang, Y, 2022) |
| "Qigui Tongfengshu granule is significantly effective for gouty arthritis, and has the effect of anti-inflammation, analgesia and reduction in blood uric acid." | 5.17 | [Observation of Qigui Tongfengshu granules in treatment of sixteen cases of gouty arthritis]. ( Ding, G; Yang, BL, 2013) |
| "To observe the clinical effect of a modified Simiao Tang (Modified Decoction of Four Wonderful Drugs) for gouty arthritis and its influence on uric acid in blood." | 5.13 | Treatment of 60 cases of gouty arthritis with modified Simiao Tang. ( Chen, Y; Lin, D; Qiu, R; Shen, R; Ye, H, 2008) |
| "Chronical hyperuricemia, a severe metabolic disease characterized by increased serum uric acid, urea nitrogen, and creatinine, has a positive correlation with the risks of gouty arthritis, diabetes, hypertension, and kidney damage." | 5.12 | [Research progress on anti-hyperuricemia effects and mechanisms of Chinese medicines based on regulation of intestinal flora and metabolites]. ( He, D; Tang, XY; Wen, XY; Zeng, HL; Zhang, HC; Zhang, SH, 2021) |
| "Electroacupuncture combined with point-injection is an effective method for treatment of acute gouty arthritis, and it can decrease blood uric acid content." | 5.12 | [Observation on therapeutic effect of electroacupuncture combined with acupoint-injection on acute gouty arthritis]. ( Xu, Y; Zhang, HX; Zhang, TF; Zou, R, 2007) |
| "72 cases of gouty renal damage were randomly divided into a treatment group of 42 cases and a control group of 30 cases to observe the therapeutic effects and the changes in 24-hour urinary protein content, blood creatinine, uric acid and urea nitrogen in blood before treatment and one month after treatment." | 5.11 | Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage. ( Ma, X, 2004) |
| "To observe the clinical effect of Rebixiao granule (RBXG) in treating repeatedly attacking acute gouty arthritis and through experimental study on blood uric acid to explore RBXG's therapeutic mechanism." | 5.11 | Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis. ( Ji, W; Lu, Y; Tan, WF; Zhu, XX, 2005) |
| "To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout." | 5.10 | Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. ( Ball, SG; Feher, MD; Hepburn, AL; Hogarth, MB; Kaye, SA, 2003) |
| "Low dose daily enteric coated aspirin does not significantly interfere with the uricosuric effects of probenecid in patients with gouty arthritis." | 5.09 | Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. ( Alloway, J; Bryant, LR; Danaher, P; Harris, M, 2000) |
| "It appears that soluble uric acid has a much larger role to play than just being a risk factor for gout." | 4.95 | Factors modulating the inflammatory response in acute gouty arthritis. ( Cleophas, MC; Crişan, TO; Joosten, LA, 2017) |
| " The main pathogens are crystals of monosodium urate (MSU), responsible for the gout, calcium pyrophosphate (CPP), which deposits also in various clinical forms of arthopathies, and basic calcium phosphate associated with osteoarthritis." | 4.90 | Pain and microcrystalline arthritis. ( Frallonardo, P; Lorenzin, MG; Oliviero, F; Ortolan, A; Punzi, L; Ramonda, R; Scanu, A, 2014) |
| " The relationship between hyperuricemia and gout was first documented in the nineteenth century by Alfred Baring Garrod, who demonstrated deposits of uric acid crystals on a linen thread held dipped in acidified blood (the so-called "thread method")." | 4.88 | Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). ( Marson, P; Pasero, G, 2012) |
| "Many patients with acute gout (11%-49%) have normal serum uric acid (SUA) levels." | 4.87 | Clinical inquiry. Are serum uric acid levels always elevated in acute gout? ( Fletcher, A; Leiszler, M; Poddar, S, 2011) |
| "Uric acid crystals [monosodium urate (MSU)] have emerged as an important factor for both gouty arthritis and immune regulation." | 4.86 | Monosodium urate crystals in inflammation and immunity. ( Mucsi, AD; Ng, G; Shi, Y, 2010) |
| " Calcium pyrophosphate deposition disease ("pseudogout") usually affects larger joints and often follows trauma, surgery, or ischemic heart disease." | 4.79 | Gout or 'pseudogout': how to differentiate crystal-induced arthropathies. ( Joseph, J; McGrath, H, 1995) |
| "The most common crystal-related arthropathies-gout, calcium pyrophosphate dihydrate disease or "pseudogout," and calcific periarthritis/tendinitis-may be appropriately diagnosed and managed by the primary care physician." | 4.79 | Crystal-induced arthritis: an overview. ( Schumacher, HR, 1996) |
| "TSDN has an anti-inflammation effect on gouty arthritis in an in vitro model by regulating arachidonic acid signaling pathway." | 4.31 | Effects of Total Saponins from Dioscorea Nipponica Makino on Monosodium Urate-Induced M1-Polarized Macrophages through Arachidonic Acid Signaling Pathway: An in vitro Study. ( Liu, SM; Sun, HJ; Zhou, Q, 2023) |
| "The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance." | 4.31 | A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout. ( Ghang, B; Jeong, W; Kim, J; Lee, J, 2023) |
| "Our findings linked normouricemic erosive gout to attenuated lubricin, with impaired control of cathepsin G activity, compounded by deleterious NLRP3 variants." | 4.31 | Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia. ( Cadzow, M; Campeau, A; Chhana, A; Dalbeth, N; Dambruoso, TJ; Elsaid, K; Elsayed, S; Ghassemian, M; Gonzalez, DJ; Höglund, J; Jay, GD; Karlsson, NG; Karsh, J; Liu-Bryan, R; Maltez, N; Merriman, TR; Miner, M; Phipps-Green, A; Qadri, M; Rossitto, LA; Schmidt, TA; Terkeltaub, R, 2023) |
| "This study aimed to explore the clinical characteristics of perioperative acute gout attacks in patients with varying uric acid levels undergoing orthopedic surgery, identify the risk factors for gout recurrence within the first postoperative year, and provide a disease prevention and diagnostic reference." | 4.31 | Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients. ( Sun, X; Wang, H; Wang, W; Wu, Q; Yan, C; Zeng, H; Zhang, Z, 2023) |
| "Spontaneous serum uric acid (SUA) decrease has been found in many patients during acute gout attacks, but its mechanism remains unclear." | 4.31 | Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. ( Cao, L; Du, X; Lin, C; Wan, W; Xu, R; Yang, X; Zhao, T; Zhou, M; Zhu, X; Zou, H, 2023) |
| "Gout is a form of inflammatory arthritis that results from elevated serum uric acid levels and the deposition of urate crystals in multiple joints." | 4.31 | Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy. ( Fu, N; Li, Q; Quan, J; Zhang, Z, 2023) |
| "Gouty arthritis is generally induced by the accumulation of monosodium urate (MSU) crystals in the joints due to elevated serum uric acid levels, potentially leading to serious pathological disorders such as nephrolithiasis, renal failure, and acute gouty arthritis." | 4.12 | Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. ( Al Kury, LT; Alattar, A; Alshaman, R; Atzaz, N; Li, S; Riaz, M; Shah, FA, 2022) |
| "Gouty arthritis could be triggered by the deposition of monosodium uric acid (MSU) crystals." | 4.12 | Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-κB/NLRP3 and Nrf2 Pathways. ( Ai, GX; Chen, XY; Cheng, JJ; Li, YC; Ma, XD; Su, ZR; Xie, JH; Xie, QF; Yan, F; Yu, QX, 2022) |
| "To assess the effects of anethole on monosodium urate (MSU)-induced inflammatory response, investigate its role in acute gouty arthritis (AGA), and verify its molecular mechanism." | 4.12 | Anethole ameliorates inflammation induced by monosodium urate in an acute gouty arthritis model via inhibiting TLRs/MyD88 pathway. ( Cao, Y; Liu, Z; Tang, F; Yao, X; Zhang, X; Zhong, Q, 2022) |
| "Along with uric acid, which is the primary driving factor of gout, downstream inflammatory mediators have been shown to be involved in the pathogenesis of gouty arthritis flares." | 4.12 | Plasma adsorption in refractory chronic gouty arthritis flare: A case report. ( Cui, TJ; Lei, Y; Tang, C; Wang, XH; Zhang, XM; Zheng, ZH, 2022) |
| " The relationship between the uric acid metabolism target and the NLRP3 inflammasome may be the critical immune response between hyperuricemia and gouty arthritis." | 4.12 | Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail. ( Huang, J; Li, Y; Lin, Z; Ren, Z; Wang, Y; Wu, H; Zhang, B, 2022) |
| "Mouse gouty arthritis model was established by injections of potassium oxonate (PO), monosodium urate (MSU) and pyroptosis suppressor disulfiram." | 4.12 | Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. ( Hou, X; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| " Both WP and EP extracts showed pronounced antihyperuricemia activities, with a remarkable decline in serum uric acid and a marked increase in urine uric acid in hyperuricemic mice." | 4.02 | Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice. ( Chen, TX; Dong, L; Fu, Y; Guan, HY; He, X; Liao, SG; Tang, KF; Xu, GB; Yang, XS; Yang, YX; Zhang, CL; Zhang, JJ; Zhu, QF, 2021) |
| "Uric acid is the final product of purine metabolism, and excessive serum uric acid can cause gouty arthritis and uric acid nephropathy." | 4.02 | Bmk9 and Uricase Nanoparticle Complex for the Treatment of Gouty Arthritis and Uric Acid Nephropathy. ( An, M; Fu, H; Han, T; Li, W; Wang, M, 2021) |
| " However, the mechanism underlying high levels of uric acid inducing gouty arthritis has not been clarified." | 4.02 | Matrix Metalloproteinase-3 induces proteoglycan degradation in gouty arthritis model. ( Chen, AS; Jiang, JQ; Liang, T; Liang, XL; Liu, J; Shi, L; Wu, XW; Yang, F; Yuan, DP; Zhu, FF, 2021) |
| "This study assessed factors associated with achieving target serum uric acid (sUA) level and occurrence of gouty arthritis in Japanese clinical practice." | 4.02 | Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| "Lychnopholide, eremantholide C, and goyazensolide improved the inflammation induced by MSU crystals by inhibiting the migration of neutrophils to the inflamed area and by blocking the release of the pro-inflammatory cytokine TNF-α." | 4.02 | Sesquiterpene lactones from Lychnophora species: Antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout. ( Barros, CH; Bernardes, ACFPF; Costa, DC; de Oliveira Aguiar Soares, RD; de Paula Michel Araújo, MC; Matosinhos, RC; Sachs, D; Saúde-Guimarães, DA, 2021) |
| "The aim of this study was to identify the effects of melatonin on acute gouty inflammation and to investigate the underlying mechanisms." | 4.02 | Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro. ( Cao, L; Xiao, WZ; Zhao, L; Zhu, XX; Zou, HJ, 2021) |
| "To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis." | 3.96 | Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020) |
| " Subsequently, he showed increased uric acid levels and developed acute gouty arthritis." | 3.96 | Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. ( Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E, 2020) |
| " • The mass [mg] of the uric acid burden in a patient with gouty arthritis can be calculated by multiplying volume [ml] with mean density [HU] using a specific gravimetric coefficient." | 3.96 | Development and validation of a quantitative method for estimation of the urate burden in patients with gouty arthritis using dual-energy computed tomography. ( Diekhoff, T; Hamm, B; Hermann, KGA; Kotlyarov, M; Mews, J, 2020) |
| "These results indicated that curcumin could effectively ameliorate MSU crystal-induced gouty arthritis through NLRP3 inflammasome mediation via inhibiting NF-κB signaling both in vitro and in vivo, suggesting a promising active ingredient for the prevention and treatment of gouty arthritis." | 3.91 | Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling. ( He, X; Li, X; Sun, DY; Xiao, DM; Xu, DQ; Zhang, T, 2019) |
| "Gouty arthritis is an inflammatory disease that is triggered by abnormal uric acid metabolism, which is usually attributed to obesity, a risk factor of hyperuricemia and gout attack." | 3.91 | Leptin Promotes Monosodium Urate Crystal-Induced Inflammation in Human and Murine Models of Gout. ( Fu, S; Liang, M; Lv, L; Wan, W; Xuan, D; Xue, Y; Yang, J; Yu, Y; Zhu, X; Zou, H, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| "The present study suggests that luteolin and luteolin-4'-O-glucoside could be developed as therapeutics for treating hyperuricemia and gouty arthritis." | 3.88 | Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models. ( Hu, YJ; Liang, WQ; Lin, Y; Liu, PG; Pu, JB; Xu, P; Zhang, HJ; Zhou, J, 2018) |
| "To retrospectively analyze the efficacy and safety of febuxostat on gout patients with low serum uric acid level." | 3.88 | Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study. ( Chen, X; Gu, B; Li, C; Qian, K; Ren, Q; Shen, M; Su, D; Wang, X; Xu, W; Yang, L; Yuan, H; Zhang, J, 2018) |
| " SUA was downregulated during acute gouty arthritis, which might be associated with increased urinary excretion of uric acid." | 3.88 | Renal excretion is a cause of decreased serum uric acid during acute gout. ( Cao, L; Guo, M; Lv, X; Wan, W; Xue, Y; Zhao, T; Zheng, S; Zhu, X; Zou, H, 2018) |
| " He was diagnosed as primary myelofibrosis and treated with interferon-α, together with urate acid-lowing therapy (febuxostat 60 mg once daily)." | 3.88 | [A case of gout secondary to primary myelofibrosis]. ( Hao, YJ; Ji, LL; Zhang, ZL, 2018) |
| " affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
| " pensylvanicum extract showed activity in reducing serum uric acid (Sur) through effect renal glucose transporter 9 (GLUT9), organic anion transporter 1 (OAT1) and urate transporter 1 (URAT1) mainly and inhibited XO activity in vivo of mice with PO induced hyperuricemia." | 3.85 | Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model. ( Hu, YJ; Jiang, Y; Lin, Y; Pan, HH; Song, XJ; Zhang, HJ, 2017) |
| "The aim of this study was to investigate the anti-inflammatory effect of ferulic acid, a dietary phenol, on monosodium urate (MSU) crystal-induced inflammation in rats, an experimental model for acute gouty arthritis." | 3.83 | Targeting inflammatory mediators with ferulic acid, a dietary polyphenol, for the suppression of monosodium urate crystal-induced inflammation in rats. ( Dey, C; Doss, HM; Rasool, MK; Sudandiradoss, C, 2016) |
| "The anti-inflammatory effect of morin, a dietary bioflavanol was explored on monosodium urate (MSU) crystal-induced inflammation in rats, an experimental model for acute gouty arthritis." | 3.83 | Morin, a dietary bioflavonol suppresses monosodium urate crystal-induced inflammation in an animal model of acute gouty arthritis with reference to NLRP3 inflammasome, hypo-xanthine phospho-ribosyl transferase, and inflammatory mediators. ( Dhanasekar, C; Rasool, M, 2016) |
| "An elevated serum urate level is recognised as a cause of gouty arthritis and uric acid stone." | 3.83 | Nephrolithiasis among male patients with newly diagnosed gout. ( Huang, CS; Ko, MC; Lee, WK; Liu, CK; Wan, KS, 2016) |
| "Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous antioxidant uric acid among smokers and has been reported to decrease incidence of gout." | 3.83 | Risk of acute gout among active smokers: data from nationwide inpatient sample. ( Donato, A; Karmacharya, P; Poudel, DR, 2016) |
| "In this study, we investigated the effects of a soft coral-derived anti-inflammatory compound, lemnalol, on mast cell (MC) function and osteoclast activity in rats with monosodium urate (MSU) crystal-induced gouty arthritis." | 3.81 | Lemnalol attenuates mast cell activation and osteoclast activity in a gouty arthritis model. ( Duh, CY; Huang, SY; Jean, YH; Lee, HP; Lin, SC; Lin, YY; Wang, HM; Wen, ZH; Wu, SF, 2015) |
| "The aims of the current study are to describe gadolinium-enhanced MRI features of an acute flare of established gouty arthritis in different joints and to examine a possible association between serum uric acid and MRI signs indicative of ongoing inflammation and/or structural joint damage as well as association with disease characteristics and laboratory findings." | 3.81 | Gadolinium-enhanced MRI features of acute gouty arthritis on top of chronic gouty involvement in different joints. ( Abd-Allah, MA; El-Naggar, A; El-Shaarawy, N; Emad, Y; Fathy, A; Gamal, RM; Hawass, M; Ragab, Y; Rasker, JJ, 2015) |
| "The combination of sodium alginate and resveratrol has better effect over colchicines in treating MSU-induced acute gouty arthritis." | 3.81 | Effect of sodium alginate addition to resveratrol on acute gouty arthritis. ( Chen, Y; Jiang, M; Ren, D; Wang, P; Wang, R; Wang, YG, 2015) |
| "Among the gouty patients, 36% refrain from the use of allopurinol, only 23% out of them require that its dose be adjusted to achieve the target level of UA." | 3.81 | [Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up]. ( Barskova, VG; Denisov, IS; Eliseev, MS, 2015) |
| "4, and he was also mis-diagnosed with osteochondritis dissecans and underwent medical treatment for JIA, assorted imaging studies, and multiple surgical procedures before the key history of increased pain with red meat ingestion, noticed by the patient, and a subsequent elevated uric acid confirmed his ultimate diagnosis." | 3.80 | Gout in a 15-year-old boy with juvenile idiopathic arthritis: a case study. ( Grant, K; Khanna, G; Morris, H; White, AJ, 2014) |
| "Serum uric acid levels were not significantly different in the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups." | 3.80 | The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. ( Chang, PJ; Chang, ST; Chen, MC; Chung, CM; Hsiao, JF; Lin, CL; Lin, JC; Pan, KL, 2014) |
| " In the present study, we found that treatment with lemnalol (intramuscular [im]), but not colchicine (oral [po]), significantly attenuated MUS-induced mechanical allodynia, paw edema and knee swelling." | 3.79 | Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression. ( Duh, CY; Huang, SY; Jean, YH; Lee, HP; Lin, YY; Wang, HM; Wen, ZH; Wu, SF, 2013) |
| "To evaluate the efficacy of boswellic acid against monosodium urate crystal-induced inflammation in mice." | 3.78 | Efficacy of boswellic acid on lysosomal acid hydrolases, lipid peroxidation and anti-oxidant status in gouty arthritic mice. ( Indu, H; Rasool, M; Sabina, EP, 2012) |
| " Duration of gout, presence of back pain, and serum uric acid levels did not correlate with axial gout." | 3.78 | Correlates of axial gout: a cross-sectional study. ( Jelinek, JS; Konatalapalli, RM; Lumezanu, E; Murphey, MD; Wang, H; Weinstein, A, 2012) |
| " trichocarpha, its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by countering hyperuricemia and inflammation." | 3.78 | Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents. ( de Paula, CA; de Souza Filho, JD; de Souza, MR; Grabe-Guimarães, A; Pereira de Resende, ML; Saúde-Guimarães, DA, 2012) |
| "These results indicated that quercetin exerted a strong anti-inflammatory effect that may be useful for the treatment of acute gouty arthritis." | 3.78 | Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat. ( Chen, J; Huang, J; Li, S; Sun, W; Tao, Y; Wang, S; Zhu, M, 2012) |
| "In the present study, the anti-inflammatory effect of piperine was investigated on monosodium urate crystal-induced inflammation in mice, an experimental model for gouty arthritis, and compared it with that of the nonsteroidal anti-inflammatory drug, indomethacin." | 3.77 | A role of piperine on monosodium urate crystal-induced inflammation--an experimental model of gouty arthritis. ( Nagar, S; Rasool, M; Sabina, EP, 2011) |
| "The treatment of gout requires a lowering of serum urate (SU) levels, and allopurinol is the drug that is most commonly used for this purpose." | 3.77 | Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. ( Barclay, ML; Chapman, PT; Drake, J; Frampton, C; O'Donnell, JL; Stamp, LK; Zhang, M, 2011) |
| "Urate-lowering therapy (ULT), adjusted to achieve and maintain a serum uric acid (SUA) of <6 mg/dl, remains the standard of care for the chronic management of gout." | 3.77 | Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy. ( Gilliland, WR; Keith, MP, 2011) |
| "To identify factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol." | 3.77 | Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study. ( Kim, YG; Lee, CK; Lee, SG; So, MW; Yoo, B, 2011) |
| " Despite continued allopurinol therapy the gouty arthritis of the peripheral joints re-occurred." | 3.76 | [Fever and back pain--a case report of spinal gout]. ( Behr, C; Schorn, C; Schwarting, A, 2010) |
| "The concept that intraarticular crystals of uric acid by themselves trigger episodes of painful gouty arthritis is inconsistent with the clinical reality." | 3.76 | Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. ( Giamarellos-Bourboulis, EJ; Joosten, LA; Kanneganti, TD; Koenders, MI; Malireddi, RK; Mylona, E; Netea, MG; Oosting, M; Stalenhoef, AF; Stienstra, R; van de Veerdonk, FL; van der Meer, JW, 2010) |
| "To enable clinicians to initiate appropriate steps for long-term management of gout, including controlling acute exacerbations and pain and sustaining target serum uric acid (SUA) levels to control hyperuricemia as the underlying metabolic disorder." | 3.76 | The current state of care in gout: Addressing the need for better understanding of an ancient disease. ( Graser, E; Pope, RS; Zychowicz, ME, 2010) |
| "In the present study, we have investigated the efficacy of Indian ayurvedic herbal formulation Triphala on monosodium urate crystal-induced inflammation in mice; an experimental model for gouty arthritis and compared it with that of the non-steroidal anti-inflammatory drug, Indomethacin." | 3.74 | An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice. ( Rasool, M; Sabina, EP, 2008) |
| "To examine the ability of rofecoxib prophylaxis to blunt the effect of monosodium urate (MSU) crystal inflammation induced in the rat subcutaneous air pouch." | 3.73 | Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch. ( Chen, LX; Clayburne, G; Nalbant, S; Schumacher, HR; Sieck, MS, 2005) |
| "To explore the factors influencing serum uric acid concentrations and the prevalence of hyperuricemia in aboriginal children from an area in Taiwan with a high prevalence of gouty arthritis." | 3.72 | The epidemiology of hyperuricemia in children of Taiwan aborigines. ( Li, TC; Lin, CC; Liu, CS, 2003) |
| "To clarify the mechanism of decreased serum uric acid (SUA) concentrations during acute gouty arthritis." | 3.71 | The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. ( Hara, M; Kamatani, N; Matsuda, Y; Nakajima, H; Taniguchi, A; Tsutani, H; Urano, W; Yamanaka, H, 2002) |
| " With the impression of primary hypothyroidism, the patient was started on levothyroxine supplementation at which point he developed a classic gouty arthritis of right first metatarsophalangial joint." | 3.70 | Reversible renal insufficiency, hyperuricemia and gouty arthritis in a case of hypothyroidism. ( Bastani, B; Mooraki, A, 1998) |
| "We estimated xanthine oxidase (XA), xanthine dehydrogenase (XDG), 5'-nucleotidase (5'-NT) activity, esoenzymes of XDG and content of uric acid (UA) in the sera of 44 patients with osteoarthritis and 34 patients with gout arthritis." | 3.70 | [Purine metabolism enzymes in diagnosis and differential diagnosis of osteoarthritis and gout arthritis]. ( Martem'ianov, VF; Stazharov, MIu; Zborovskiĭ, AB, 2000) |
| "To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients." | 3.68 | Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. ( Burack, DA; Griffith, BP; Kahl, LE; Thompson, ME, 1992) |
| " The three main types of crystal arthritis are monosodium urate (gout), calcium pyrophosphate dihydrate, and calcium phosphate (usually hydroxyapatite)." | 3.68 | Crystal arthritis: a clinician's view. ( Hall, S, 1991) |
| " They test its effect on the uric acid serum level in normouraemic subjects as well as in hyperuricaemic syndrome and gouty arthritis." | 3.68 | [The importance of benziodarone in the treatment of gout and hyperuricemic syndrome]. ( Lindusková, M; Vykydal, M, 1990) |
| "To evaluate the frequency and the pathogenesis of hyperuricemia and gout during cyclosporine therapy, we studied renal-transplant recipients who were treated with either cyclosporine and prednisone (n = 129) or azathioprine and prednisone (n = 168)." | 3.67 | Cyclosporine-induced hyperuricemia and gout. ( Fox, IH; Lin, HY; McQuillan, MA; Palella, TD; Rocher, LL; Schmaltz, S, 1989) |
| "It's reported that oral administration of fructose in normal and gouty patients causes a rise in serum uric acid (see "References": Stirpe et al." | 3.67 | [Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism]. ( Della Corte, E; Menghini, S, 1987) |
| "The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg." | 3.63 | Diagnosis and treatment of gouty arthritis. ( TALBOTT, JH, 1953) |
| " The use of recommended first-line treatment agents for AGA may be limited by adverse events." | 3.11 | Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial. ( Dong, X; Huang, JY; Li, XP; Liu, JP; Liu, Y; Shang, YX; Wang, XC; Wei, SF; Xie, ZM, 2022) |
| "If untreated, acute gout may eventually develop into chronic tophaceous gout characterized by tophi, chronic gouty synovitis, and structural joint damage, leading the crushing burden of treatment." | 3.01 | A review on gout: Looking back and looking ahead. ( Liu, W; Mo, Y; Tao, H; Wang, H, 2023) |
| "Gout is an autoimmune disease characterized by acute or chronic inflammation and damage to bone joints induced due to the precipitation of monosodium urate (MSU) crystals." | 3.01 | Immune and inflammatory mechanisms and therapeutic targets of gout: An update. ( Li, H; Liu, W; Peng, J; Wu, R; Wu, Y; Ye, Z; Zong, Z, 2023) |
| "Gout is the most common inflammatory arthritis in the United States." | 2.82 | Management and Cure of Gouty Arthritis. ( Keller, SF; Mandell, BF, 2022) |
| "Gout is a common type of inflammatory arthritis characterized by the presence of monosodium urate crystals (MSU) in the joints." | 2.82 | Recent Insights Into the Role of Macrophages in Acute Gout. ( Liu, L; Liu, M; Shan, L; Xue, Y; Yu, Y; Zhao, L; Zhu, L, 2022) |
| "Gouty arthritis is a common inflammatory disease." | 2.82 | Role of microRNA alternation in the pathogenesis of gouty arthritis. ( Chen, B; Hong, S; Hu, Y; Li, L; Luo, Z; Wang, J; Wang, S; Wu, J; Xu, T; Yang, C; Yang, F; Yang, J; Yao, Y, 2022) |
| "The clinical efficacy, recurrence rate and adverse reactions were recorded and analyzed." | 2.80 | [Traditional Chinese Medicine Treatment of Gouty Arthritis Based on Syndrome Differentiation]. ( Chen, Q; Guo, Q; Lei, XX; Zhao, H; Zhu, RR; Zhu, YX, 2015) |
| " The treatment group was treated by jiawei simiaosan and combined with the external application of Sihuangshuimi." | 2.73 | [A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis]. ( Chen, SQ; Chen, ZX; Sun, BG; Ye, XY; Yin, LR; Zhou, HM, 2007) |
| "To study the therapeutic effect of treatment of acute gouty arthritis (AGA) respectively by electroacupuncture (EA) with different frequency and oral intake of Western medicine." | 2.72 | Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency. ( Zhang, HX; Zhang, TF; Zou, R, 2006) |
| "Hyperuricemia is the main risk factor for gout and is linked to the development of comorbidities." | 2.66 | Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. ( Cabău, G; Crișan, TO; Joosten, LAB; Klück, V; Popp, RA, 2020) |
| " Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment." | 2.66 | Recent approaches to gout drug discovery: an update. ( Anzai, N; Hisatome, I; Kudo, H; Otani, N; Ouchi, M; Tsuruoka, S, 2020) |
| "Gout is the most common inflammatory arthritis and is increasing in relevance due to its rising prevalence and incidence." | 2.58 | Current status of ultrasound and dual-energy computed tomography in the evaluation of gout. ( Garner, HW; Wessell, DE, 2018) |
| "The prevalence of gout is rising and is likely attributed to several factors including increased incidence of comorbidities, lifestyle factors, and increased use of causative medications." | 2.53 | Gouty Arthritis: A Review of Acute Management and Prevention. ( Saseen, JJ; Wilson, L, 2016) |
| "Gouty arthritis is the most common form of arthritis in men." | 2.53 | [Gouty arthritis]. ( Aringer, M; Tausche, AK, 2016) |
| "Acute gout is an auto-inflammatory disease characterized by self-limiting inflammation in response to the deposition of monosodium urate (MSU) crystals in the joints or tissues." | 2.50 | Mechanisms of spontaneous resolution of acute gouty inflammation. ( Harper, JL; Steiger, S, 2014) |
| "Gouty arthritis is an extremely painful condition that causes functional impairment." | 2.49 | Current concepts in the treatment of gouty arthritis. ( Fang, ZH; Waizy, H, 2013) |
| "Gouty arthritis is an inflammatory condition associated with debilitating clinical symptoms, functional impairments, and a substantial impact on quality of life." | 2.48 | An update on the pathology and clinical management of gouty arthritis. ( Gonzalez, EB, 2012) |
| "Acute inflammation is the hallmark of the acute tissue reaction to crystals in both gout and pseudogout." | 2.48 | The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). ( Busso, N; Ea, HK, 2012) |
| "Gout is a metabolic disease characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals in the joints and soft tissues, consisting of a self-limited acute phase characterized by recurrent attacks of synovitis and a chronic phase in which inflammatory and structural changes of the joints and periarticular tissues may lead to persistent symptoms." | 2.48 | Clinical features of gout. ( De Angelis, R; Grassi, W, 2012) |
| "The management of gouty arthritis is focused on treating pain and inflammation associated with acute flares and preventing further acute flares and urate crystal deposition." | 2.48 | Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. ( Schlesinger, N, 2012) |
| "One of the limitations for successful treatment of gout is to consider it as an intermittent disease rather than a chronic inflammatory disease which, if improperly treated, leads to chronic clinical manifestations." | 2.48 | Evaluation and treatment of gout as a chronic disease. ( Herrero-Beites, AM; Perez-Ruiz, F, 2012) |
| "Gouty arthritis is a form of acute joint inflammation provoked by joint deposition of urate crystals." | 2.47 | Role of melanocortin receptors in the regulation of gouty inflammation. ( Montero-Melendez, T; Patel, HB; Perretti, M, 2011) |
| "Uric acid has been identified as a danger signal that triggers a cytosolic sensor, the inflammasome." | 2.46 | Mechanisms of uric acid crystal-mediated autoinflammation. ( Martinon, F, 2010) |
| "Treatment of gout is usually considered after the first attack of arthritis, typically podagra." | 2.44 | Updates in the management of gout. ( Gilliland, WR; Keith, MP, 2007) |
| "There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents such as etoricoxib, febuxostat and pegylated-uricase." | 2.44 | Assessment of outcome in clinical trials of gout--a review of current measures. ( Dalbeth, N; Grainger, R; Schumacher, HR; Singh, JA; Taylor, WJ, 2007) |
| "Gout and calcium pyrophosphate deposition disease are two common causes of inflammatory joint disease." | 2.43 | An update on the treatment options for gout and calcium pyrophosphate deposition. ( Choy, G, 2005) |
| "Asymptomatic hyperuricemia is clearly associated with hypertension, chronic kidney disease, cardiovascular disease, and the insulin resistance syndrome, and the pathogenetic significance of these associations is under intensive study." | 2.43 | Crystal-induced arthropathies: recent investigative advances. ( Becker, MA; Ellman, MH, 2006) |
| "Throughout history, gout has been associated with rich foods and excessive alcohol consumption." | 2.43 | A concise history of gout and hyperuricemia and their treatment. ( Nuki, G; Simkin, PA, 2006) |
| "Gouty arthritis is a characteristically intense acute inflammatory reaction that erupts in response to articular deposits of monosodium urate (MSU) crystals." | 2.43 | The inflammatory process of gout and its treatment. ( Cronstein, BN; Terkeltaub, R, 2006) |
| "Gout is a common form of arthritis, in which many of the risk factors, pathogenetic mechanisms, and clinical features have been recognized for years." | 2.41 | Gout: diagnosis, pathogenesis, and clinical manifestations. ( Agudelo, CA; Wise, CM, 2001) |
| " In renal insufficiency, the drug must be used cautiously and in reduced dosage because increased serum concentration of oxipurinol, active metabolite of allopurinol, may induce severe side effect." | 2.39 | [Metabolic disorder of purine nucleotide in patients with renal disease]. ( Hosoya, T; Ichida, K; Ohno, I; Sakai, O, 1996) |
| "Gout is a chronic disease caused by monosodium urate crystal deposition, typically affecting the big toe, midfoot, and ankle." | 1.91 | Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain. ( Chen, SH; Guo, QH; Li, T; Lu, JG; Zheng, BL, 2023) |
| "Gout is a chronic disease caused by monosodium urate crystal deposition." | 1.91 | Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis. ( Chen, W; Chen, X; Gao, K; Huang, H; Huang, R; Mei, L; Wang, M; Wu, X; Yang, Z; Zhang, X, 2023) |
| "Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities." | 1.91 | Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. ( Cao, Y; Hu, Y; Jin, XF; Liu, Y; Zou, JM, 2023) |
| "could treat hyperuricemia by reducing the production of uric acid via inhibition of xanthine oxidase and increasing the excretion of uric acid via regulation of urate transporters." | 1.91 | In vivo anti-hyperuricemia and anti-gouty arthritis effects of the ethanol extract from Amomumvillosum Lour. ( Chen, L; Dong, L; Dong, Y; Huang, J; Li, L; Long, T; Lu, J; Mao, Y; Qi, Z; Wen, J; Zhang, J; Zhang, S; Zhao, F, 2023) |
| "Acute gouty arthritis is inflammatory joint arthritis." | 1.91 | Phospholipase A2 regulates autophagy in gouty arthritis: proteomic and metabolomic studies. ( Fu, W; Ge, M; Li, J, 2023) |
| "Gout is a common metabolic rheumatic disease, and there have been no reports on the serum levels of interleukin (IL)-41 in gout patients." | 1.91 | Potential clinical value of serum interleukin-41 levels in patients with acute gout. ( Li, M; Li, Y; Meng, S; Shi, S; Wu, X; Zhao, H; Zhou, Y, 2023) |
| "Gouty arthritis is characterized by chronic deposition of monosodium urate (MSU) crystals in the joints and other tissues, resulting in the production of excess reactive oxygen species (ROS) and proinflammatory cytokines that intensify synovial inflammation." | 1.91 | Targeted treatment of gouty arthritis by biomineralized metallic nanozyme-mediated oxidative stress-mitigating nanotherapy. ( Chahal, S; Mohanty, A; Mohapatra, A; Park, IK; Rajendrakumar, SK; Sathiyamoorthy, P; Vijayan, V, 2023) |
| "Gout is a common metabolic disorder characterized by deposits of monosodium urate monohydrate crystals (tophi) in soft tissue, triggering intense and acute arthritis with intolerable pain as well as articular and periarticular inflammation." | 1.91 | Identification of tophi in ultrasound imaging based on transfer learning and clinical practice. ( Chang, CC; Chang, CK; Lee, HY; Lin, KH; Lin, TM; Peng, SJ; Wu, BF, 2023) |
| "Gouty arthritis is characterized by painful inflammation due to the deposition of monosodium urate crystals in joint tissues." | 1.91 | Articular mobilization promotes improvement in functional and inflammatory parameters in a gouty arthritis model. ( Bertolini, GRF; Costa, RM; Hoss, IM; Leal, TSDS; Pradal, LA; Ribeiro, LFC, 2023) |
| "These results revealed that GPS can treat acute gouty arthritis based on anti-inflammatory and analgesic properties in vivo, which might be ascribed to the inhibition on NLRP3 inflammasome." | 1.72 | Effects of Gentiopicroside on activation of NLRP3 inflammasome in acute gouty arthritis mice induced by MSU. ( Chen, M; Gao, Q; He, M; Hu, C; Li, L; Tian, W, 2022) |
| "The gouty ulcers were not completely healed by Day 14 compared with those in the PBS controls." | 1.72 | Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model. ( Bao, W; Cheng, X; Jia, C; Su, Y; Wang, P; Xue, Y; Yin, B, 2022) |
| "Gouty arthritis is the inflammation of tissues and joints caused by the deposition of monosodium urate crystals." | 1.72 | In Vivo Effects of Orally Administered Different Concentrations of Silver Oxide Nanoparticles in Hyperuricemic Mice. ( Abbas, HB; Bokhari, SAI; Butt, MA; Javed, A; Kiyani, MM; Moghul, NB; Rajput, TA; Rehman, H, 2022) |
| "Melatonin (MLT) is a powerful endogenous anti-inflammatory agent and effective in reducing cellular damage." | 1.72 | Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis. ( Altinoz, E; Ballur, AFH; Bicer, Y; Demir, M; Elbe, H; Karayakali, M; Onal, MO; Yigitturk, G, 2022) |
| "Acute gouty arthritis was induced by injection of monosodium urate (MSU) crystals into the ankle joint of mice." | 1.72 | Regulation of TRPV1 channel in monosodium urate-induced gouty arthritis in mice. ( Li, G; Xu, X; Yuan, Z; Zhang, G; Zhang, S, 2022) |
| "Gout is a common arthritis caused by deposition of monosodium urate crystals." | 1.72 | Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages. ( Cao, L; Liu, J; Wan, W; Xu, R; Xuan, D; Xue, Y; Yu, Y; Zhao, L; Zhao, T; Zou, H, 2022) |
| "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition in the joints and surrounding tissues." | 1.72 | Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy. ( Jiang, YJ; Lian, LH; Nan, JX; Piao, MH; Wang, H; Wu, YL, 2022) |
| "Resolvin D1 (RvD1) is a specialized pro-resolving lipid mediator with anti-inflammatory and analgesic proprieties." | 1.72 | RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice. ( Amaral, FA; Andrade, KC; Artero, NA; Badaro-Garcia, S; Bertozzi, MM; Borghi, SM; Casagrande, R; Fattori, V; Ferraz, CR; Manchope, MF; Rasquel-Oliveira, F; Rogers, MS; Saraiva-Santos, T; Staurengo-Ferrari, L; Teixeira, MM; Verri, WA; Zaninelli, TH, 2022) |
| "Gout is the most common cause of inflammatory arthritis in adults." | 1.72 | Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study. ( Becce, F; Fields, T; Mechlin, M; Oh, C; Pillinger, MH; Toprover, M, 2022) |
| "Gout is a self-limiting inflammatory arthritis mediated by the precipitation of monosodium urate (MSU) crystals that further activate the NLRP3 inflammasome and initiate a cascade of inflammatory events." | 1.72 | Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. ( Chen, C; Fu, D; Ge, D; Guo, Y; Li, M; Liang, Z; Liu, Y; Sun, B; Wang, J; Yang, X; Zhang, L, 2022) |
| "Gouty arthritis is an inflammatory disease induced by monosodium urate (MSU), and is closely related to the activation of inflammasomes." | 1.72 | Calycosin represses AIM2 inflammasome-mediated inflammation and pyroptosis to attenuate monosodium urate-induced gouty arthritis through NF-κB and p62-Keap1 pathways. ( Li, Y; Liu, X; Tian, J; Wang, B; Xiang, L; Xie, B; Zhou, D, 2022) |
| "The incidence of fever is high in hospitalised patients with AGA." | 1.72 | Clinical Features and Risk Factors of Fever in Acute Gouty Arthritis. ( Huang, Y; Yuan, F; Zhou, M, 2022) |
| "Gout is a painful form of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints." | 1.72 | The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model. ( Aganetti, M; Amaral, FA; Braga, AD; de Faria, AMC; de Oliveira, VLS; Galvão, I; Georgel, P; Martins, VD; Mastrippolito, D; Mendes, V; Muller, S; Rocha, V; Talamini, L; Verdot, C; Vieira, AT, 2022) |
| "Gouty arthritis is triggered when the deposition of monosodium urate (MSU) crystals in joints induces acute inflammation characterized by the recruitment of macrophages and neutrophils." | 1.62 | Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation. ( Deng, G; Gu, Y; Liu, S; Lv, W; Sun, Y; Zhu, Y, 2021) |
| "Acute gouty arthritis was prepared by injection of monosodium urate in the ankle joint." | 1.62 | Efficacy of fire needle on acute gouty arthritis induced by monosodium urate in rat. ( Chen, H; Chen, JM; Guo, F; He, XJ; Qian, X; Zhou, GX, 2021) |
| "Febuxostat was started postoperatively." | 1.56 | Bilateral Kienböck's disease concomitant with gouty arthritis. ( Ansari, MT; Chouhan, D; Shankar, V, 2020) |
| "The swelling degree reached its maximum at 10 h and the minimum pain threshold was maintained between 8 and 48 h after MSU treatment in mice." | 1.56 | Characteristics of voltage-gated potassium currents in monosodium urate induced gouty arthritis in mice. ( Hong, J; Qiu, J; Wang, X; Zhang, G, 2020) |
| "Acute gouty arthritis is an auto-inflammatory disease caused by the deposition of monosodium urate (MSU) crystals in joints or tissues." | 1.56 | 1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) Mitigates Monosodium Urate (MSU)-Induced Acute Gouty Inflammation in BALB/c Mice. ( Jeong, J; Kim, JH; Kim, JW; Shin, SH; Sohn, KY; Yoon, SY, 2020) |
| "Gout is a heterogeneous inflammatory disease with numerous clinical manifestations." | 1.56 | Development of a multivariable improvement measure for gout. ( Edwards, NL; Lipsky, PE; Schlesinger, N; Yeo, AE, 2020) |
| "Gouty arthritis is the one of the most painful arthritis and is caused by an inflammatory reaction." | 1.56 | Astaxanthin attenuates joint inflammation induced by monosodium urate crystals. ( Ho, YJ; Hsieh, TH; Lee, CH; Lee, HS; Liu, FC; Lu, JW; Peng, YJ; Wang, CC; Wu, CC, 2020) |
| "Pain was determined using the electronic von Frey and static weight bearing." | 1.56 | IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis. ( Alves-Filho, JC; Amaral, FA; Casagrande, R; Cunha, FQ; Cunha, TM; Fattori, V; Louzada-Junior, P; Oliveira, RD; Staurengo-Ferrari, L; Teixeira, MM; Verri, WA; Zaninelli, TH, 2020) |
| "Ginsenoside Rb1 (GsRb1) is the best constituent of ginseng and although it shows clinical efficacy as an antineoplastic, antioxidative and antirheumatic agent, its oral bioavailability is poor due to its limited solubility." | 1.56 | Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals. ( Liu, Y; Ye, Q; Zhou, W; Zhu, H, 2020) |
| "For instance, hypertension is found in 36-41% gout patients, and combined with metabolic syndrome it may reach 80%." | 1.51 | Role of immune system in development and progress of combined arterial hypertension and gout. ( Bychkov, ОА; Bychkova, NG; Bychkova, SA; Kondratiuk, VE; Morozova, ZV; Tarasiuk, AP, 2019) |
| " In this study, the main pharmacodynamics of different dosing methods and dosages of P-b4 was firstly investigated." | 1.51 | LC-MS Analysis of Serum for the Metabolomic Investigation of the Effects of Pulchinenoside b4 Administration in Monosodium Urate Crystal-Induced Gouty Arthritis Rat Model. ( Ding, R; Feng, Y; Liu, P; Lyu, S; OuYang, H; Rao, Y; Yang, S, 2019) |
| " Dosage of urate-lowering therapy is often too low to reach target urate levels, and adherence to therapy is poor." | 1.51 | Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. ( Cleophas, MCP; Crişan, TO; Dinarello, CA; Hoogerbrugge, N; Joosten, LAB; Klück, V; Netea, MG; Netea-Maier, RT, 2019) |
| "Acute gout is an inflammatory response to MSU crystals." | 1.51 | Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway. ( Liu, L; Xue, Y; Yu, Y; Zhao, T; Zhu, X; Zou, H, 2019) |
| "Present study was undertaken to investigate the dose-response relationship of berberine in SMW between the articular concentration and anti-inflammatory effect in the knee joint under the lower-guiding of ABR." | 1.48 | Achyranthis bidentatae radix enhanced articular distribution and anti-inflammatory effect of berberine in Sanmiao Wan using an acute gouty arthritis rat model. ( Cheng, W; Li, J; Li, W; Sun, B; Wu, J; Xie, J; Zhang, Q, 2018) |
| "Gout is a chronic disease, characterised by deposition of monosodium urate crystals in joints and tissues." | 1.48 | [A woman with a white skin lesion of her toe]. ( Hondebrink, LLC; Opstelten, W, 2018) |
| "Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints." | 1.46 | The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. ( Balbino, B; Contag, CH; Galli, SJ; Gaudenzio, N; Kang, D; Raghu, H; Reber, LL; Robinson, WH; Rogalla, S; Sensarn, S; Sibilano, R; Sokolove, J; Starkl, P; Tsai, M, 2017) |
| "Gouty arthritis is characterized by inflammation induced by monosodium urate (MSU) crystal deposition, which is resulted by an increase of serum urate concentration." | 1.43 | The effect of resveratrol on the recurrent attacks of gouty arthritis. ( Chen, H; Liu, Q; Qiu, J; Wang, Y; Xue, Y; Zheng, S; Zhu, H; Zhu, X; Zou, H, 2016) |
| "Acute gouty arthritis is caused by endogenously formed monosodium urate (MSU) crystals, which are potent activators of the NLRP3 inflammasome." | 1.43 | Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. ( Cleophas, MC; Crişan, TO; Dinarello, CA; Fossati, G; Jansen, TL; Joosten, LA; Lemmers, H; Netea, MG; Toenhake-Dijkstra, H, 2016) |
| "Gouty arthritis is a rheumatic disease that is characterized by the deposition of monosodium urate (MSU) in synovial joints cause by the increased serum hyperuricemia." | 1.43 | Kinsenoside screening with a microfluidic chip attenuates gouty arthritis through inactivating NF-κB signaling in macrophages and protecting endothelial cells. ( Bing, W; Di, Y; Han, Q; Hua, L; Qi-Ming, F; Shi-He, L; Shih-Mo, Y; Ting-Ting, T; Xiu-Guo, H; Yu-Gang, W; Yu-Hua, Z, 2016) |
| "Differentiating gout, calcium pyrophosphate deposition disease (CPPD), and non-crystal-related inflammatory arthropathies (non-CRA) is essential but often clinically impossible." | 1.42 | Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. ( Bergner, R; Löffler, C; Löffler, U; Peters, L; Sattler, H; Uppenkamp, M, 2015) |
| "Sixty-one patients with gout, 30 with ankylosing spondylitis and 30 with rheumatoid arthritis were included in the study." | 1.42 | [Value of dual-energy computed tomography in the diagnosis of gouty arthritis]. ( Cai, X; Ren, J; Wu, H; Zhou, Y; Zhu, L, 2015) |
| "Gouty arthritis is uncommon in childhood and adolescence." | 1.42 | Post-streptococcal acute glomerulonephritis complicated by gouty arthritis: a case report. ( Kamura, A; Kuniyoshi, Y; Tashiro, M; Yasuda, S, 2015) |
| "Monitoring blood uric acid (UA) is important in all patients on urate-lowering therapy so that the selection of the effective drugs and dosage adjustments could be made until the target level is reached." | 1.42 | Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy. ( Huang, Y; Zhao, J, 2015) |
| "5% of patients were followed-up > 1 month for second evaluation of uric acid and most of them not receiving dosage up-titration even though not achieving the target." | 1.42 | Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study. ( Hanvivadhanakul, P; Wongdet, R, 2015) |
| "Uric acid crystals were identified with DECT in 140 of 143 (97." | 1.40 | The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis. ( Shi, D; Wu, H; Xu, R; Xue, J; Ye, L; Zhou, Q, 2014) |
| "Gouty arthritis is caused by the precipitation of monosodium urate monohydrate (MSU) crystals in the joints." | 1.40 | Contribution of mast cell-derived interleukin-1β to uric acid crystal-induced acute arthritis in mice. ( Galli, SJ; Gaudenzio, N; Iwakura, Y; Karasuyama, H; Marichal, T; Reber, LL; Robinson, WH; Schwartz, LB; Sokolove, J; Starkl, P; Tsai, M, 2014) |
| "Gout is an ancient disease." | 1.38 | Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency. ( Shmerling, RH, 2012) |
| "Acute gouty arthritis is a common inflammation model with multiple pathogenic mechanisms seen in clinical practice, for which acupuncture may potentially be an alternative therapy." | 1.37 | Effect of acupuncture on rats with acute gouty arthritis inflammation: a metabonomic method for profiling of both urine and plasma metabolic perturbation. ( Liu, YJ; Wen, SL; Xiao, J; Xue, JT; Ye, LM; Yin, HL; Zhang, L; Zhu, HY, 2011) |
| "Most cases of acute gouty arthritis are diagnosed in primary care and without joint fluid analysis in many instances." | 1.36 | A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. ( Fransen, J; Janssen, M; Janssens, HJ; van de Lisdonk, EH; van Riel, PL; van Weel, C, 2010) |
| "A 32-year-old woman with pseudo-Bartter syndrome secondary to excessive use of laxatives, presented with hypokalemia, metabolic alkalosis, hyperuricemia, and gouty arthritis with tophi." | 1.36 | Pregnancy in a patient with gouty arthritis secondary to pseudo-Bartter syndrome. ( Arkfeld, DG; Metyas, S; Rouman, H, 2010) |
| "However, crystal-induced disease (gout, pseudogout) may present with the extact same clinical manifestations, physical examination, and laboratory results as infection." | 1.36 | Acute crystal-induced arthritis following arthroplasty. ( Gertner, E; Gioe, T; Zadaka, A, 2010) |
| "Hyperuricemia and gouty arthritis are commonly seen in adults with BS, but to our knowledge there is no report of gouty arthritis in pediatric literature." | 1.36 | Gouty arthritis in a 15-year-old girl with Bartter's syndrome. ( Basiratnia, M; Derakhshan, A; Derakhshan, D; Derakhshan, N; Fallahzadeh, MH; Hashemi, G, 2010) |
| "We report here a case of tenosynovial chondromatosis with deposits of crystalline material that appeared to be sodium urate (gouty tophi)." | 1.32 | A case of tenosynovial chondromatosis with tophus-like deposits. ( Daa, T; Hisaoka, M; Kashima, K; Kashima, N; Tsuji, K; Ueo, T; Yokoyama, S, 2004) |
| "Gouty arthritis is characterized by the deposition of monosodium urate crystals in the joints and soft tissues." | 1.32 | A rare and asymptomatic case of mitral valve tophus associated with severe gouty tophaceous arthritis. ( Iacobellis, G, 2004) |
| "Hypertension was the most common followed infrequency by dyslipidemia, diabetes mellitus, ischemic heart disease, and chronic obstructive pulmonary disease consecutively." | 1.32 | Clinical manifestations of patients with hyperuricemia. ( Akkasilpa, S; Avihingsanon, Y; Hanvivadhanakul, P; Wonchinsri, J, 2004) |
| "We describe an unusual case of MCTD (SLE-PSS) in a 37-year-old woman who developed acute gouty arthritis." | 1.31 | Gouty arthritis in a female patient with mixed connective tissue disease. ( Huang, CM, 2000) |
| "Rare cases of angiosarcoma have been reported to arise in the setting of retained foreign material or in association with arteriovenous fistulae." | 1.31 | Cutaneous angiosarcoma arising in a gouty tophus: report of a unique case and a review of foreign material-associated angiosarcomas. ( Folpe, AL; Johnston, CA; Weiss, SW, 2000) |
| "So far, only four cases of Bartter's syndrome with gout and/or hyperuricaemia have been described in Japan." | 1.31 | An atypical case of primary renal tubular hypokalaemic metabolic alkalosis with chronic tophaceous gout. ( Hada, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2001) |
| "Gout is an acute rheumatic disorder that occurs in connection with the deposition of monosodium urate (MSU) crystals in the joints." | 1.30 | Altered arachidonic acid metabolism in urate crystal induced inflammation. ( Duffin, KL; Gregory, SA; Isakson, PC; Margalit, A; Shaffer, AF, 1997) |
| "Uric acid levels were elevated but did not follow the course of the attack." | 1.29 | Postsurgical gout. ( Craig, MH; Hauser, CJ; Poole, GV, 1995) |
| "We studied 201 end-stage renal disease (ESRD) patients sustained on maintenance hemodialysis (MD) (n = 164) and chronic ambulatory peritoneal dialysis (CAPD) (n = 37) to determine (1) the frequency of acute attacks of gouty arthritis (GA) in those ESRD patients who had GA before dialytic therapy, and (2) the incidence of new-onset GA in hyperuricemic long-term (> 12 years) ESRD patients on MD." | 1.29 | Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. ( Delano, BG; Dulin, AL; Friedman, EA; Ifudu, O; Tan, CC, 1994) |
| "Osteonecrosis was detected in 10/365 patients (2." | 1.29 | [Rheumatologic manifestations in heart transplant recipients. A cross-sectional study of 365 patients]. ( Bourgeois, P; Cabrol, A; Frih, L; Gandjbackch, I; Koeger, AC; Lang, T; Rozenberg, S, 1993) |
| "Among the 44 patients with ADPKD, the serum uric acid (SUA) was 7." | 1.29 | A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. ( Hosoya, T; Ichida, K; Sakai, O; Tabe, A, 1993) |
| "Gout is a common disease in the primary health care setting." | 1.28 | Gout. ( Feng, PH; Leong, KH, 1992) |
| "A 45-year-old woman with Bartter's syndrome complicated with gouty arthritis is reported." | 1.28 | Bartter's syndrome with gouty arthritis. ( Abiru, M; Fujise, Y; Fukazawa, Y; Iimura, O; Kikuchi, K; Miura, T; Ogawa, T; Shibata, S; Takigami, Y, 1992) |
| "We report the first case of McArdle's disease (muscle phosphorylase deficiency) and tophaceous gout." | 1.28 | McArdle's disease and gout. ( de Miguel, E; Espinosa, A; Gijón, J; Mateos, FA; Miranda, E; Puig, JG; Romera, NM, 1992) |
| "Treatment with colchicine led to prompt resolution of the gouty flare." | 1.28 | Peripheral arthrocentesis in the work-up of acute low back pain. ( Bomalaski, JS; Leventhal, LJ; Levin, RW, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (5.62) | 18.7374 |
| 1990's | 93 (14.93) | 18.2507 |
| 2000's | 105 (16.85) | 29.6817 |
| 2010's | 212 (34.03) | 24.3611 |
| 2020's | 178 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 25 |
| Zhu, W | 1 |
| Lu, D | 1 |
| Zhang, C | 1 |
| Goo, B | 1 |
| Lee, J | 2 |
| Park, C | 1 |
| Yune, T | 1 |
| Park, Y | 1 |
| Wang, CC | 4 |
| Lu, JW | 2 |
| Peng, YJ | 3 |
| Lee, CH | 6 |
| Lee, HS | 3 |
| Chu, YH | 1 |
| Huang, CJ | 1 |
| Ho, YJ | 2 |
| Liu, FC | 2 |
| Wu, CC | 2 |
| He, M | 1 |
| Hu, C | 2 |
| Chen, M | 1 |
| Gao, Q | 2 |
| Li, L | 7 |
| Tian, W | 1 |
| Zhang, CL | 1 |
| Zhang, JJ | 1 |
| Zhu, QF | 1 |
| Guan, HY | 1 |
| Yang, YX | 1 |
| He, X | 2 |
| Fu, Y | 1 |
| Chen, TX | 1 |
| Dong, L | 2 |
| Yang, XS | 1 |
| Tang, KF | 1 |
| Xu, GB | 1 |
| Liao, SG | 1 |
| Huang, Q | 1 |
| Wang, P | 3 |
| Liao, X | 1 |
| Lan, Z | 4 |
| Chen, L | 7 |
| Feng, J | 2 |
| Xie, Z | 3 |
| Liu, Z | 2 |
| Wang, F | 1 |
| Liu, P | 4 |
| Yue, X | 1 |
| Du, L | 1 |
| Zhao, Y | 3 |
| Yang, P | 1 |
| Luo, J | 1 |
| Zhu, Z | 2 |
| Hu, X | 1 |
| Cao, L | 9 |
| Lu, P | 1 |
| Sah, R | 1 |
| Lavine, K | 1 |
| Kim, B | 1 |
| Hu, H | 1 |
| Bao, W | 1 |
| Xue, Y | 12 |
| Cheng, X | 1 |
| Yin, B | 1 |
| Su, Y | 1 |
| Jia, C | 1 |
| Han, T | 1 |
| Wang, M | 4 |
| Li, W | 4 |
| An, M | 1 |
| Fu, H | 1 |
| Kiyani, MM | 4 |
| Moghul, NB | 2 |
| Javed, A | 1 |
| Butt, MA | 3 |
| Abbas, HB | 1 |
| Rehman, H | 4 |
| Rajput, TA | 2 |
| Bokhari, SAI | 4 |
| Zhang, Y | 4 |
| Di, A | 1 |
| Yuan, H | 2 |
| Liu, X | 8 |
| Li, B | 2 |
| Zhang, X | 8 |
| Mo, S | 1 |
| Liang, D | 1 |
| Zhu, J | 2 |
| Gutierrez, M | 1 |
| Sandoval, H | 1 |
| Bertolazzi, C | 1 |
| Soto-Fajardo, C | 1 |
| Tellez-Gastelum, RM | 1 |
| Reginato, AM | 2 |
| Clavijo-Cornejo, D | 1 |
| Zhang, J | 6 |
| Lei, H | 1 |
| Li, X | 7 |
| Wen, XY | 1 |
| Tang, XY | 1 |
| He, D | 1 |
| Zhang, HC | 1 |
| Zhang, SH | 1 |
| Zeng, HL | 1 |
| Accart, N | 1 |
| Dawson, J | 1 |
| Obrecht, M | 1 |
| Lambert, C | 1 |
| Flueckiger, M | 1 |
| Kreider, J | 1 |
| Hatakeyama, S | 1 |
| Richards, PJ | 1 |
| Beckmann, N | 1 |
| Zou, F | 1 |
| Yang, R | 2 |
| Zhang, R | 1 |
| Zhao, X | 2 |
| Jung, J | 1 |
| Bong, JH | 1 |
| Lee, SJ | 1 |
| Kim, MJ | 1 |
| Sung, JS | 1 |
| Lee, M | 1 |
| Kang, MJ | 1 |
| Song, J | 1 |
| Jose, J | 1 |
| Pyun, JC | 1 |
| Zhao, L | 6 |
| Zhao, T | 7 |
| Yang, X | 5 |
| Xu, R | 5 |
| Liu, J | 6 |
| Lin, C | 2 |
| Yu, Y | 7 |
| Xuan, D | 3 |
| Zhu, X | 9 |
| Liu, L | 5 |
| Hua, Y | 4 |
| Deng, C | 1 |
| Wan, W | 6 |
| Zou, H | 9 |
| Ballur, AFH | 1 |
| Altinoz, E | 1 |
| Yigitturk, G | 1 |
| Onal, MO | 1 |
| Elbe, H | 1 |
| Bicer, Y | 1 |
| Karayakali, M | 1 |
| Demir, M | 1 |
| Keenan, RT | 1 |
| Yeo, AE | 2 |
| Lipsky, PE | 2 |
| Lu, Y | 3 |
| Fang, L | 2 |
| Xu, X | 5 |
| Wu, Y | 3 |
| Li, J | 5 |
| Cobo, I | 1 |
| Cheng, A | 1 |
| Murillo-Saich, J | 1 |
| Coras, R | 1 |
| Torres, A | 1 |
| Abe, Y | 1 |
| Lana, AJ | 1 |
| Schlachetzki, J | 1 |
| Liu-Bryan, R | 8 |
| Terkeltaub, R | 8 |
| Sanchez-Lopez, E | 1 |
| Glass, CK | 1 |
| Guma, M | 1 |
| Yu, J | 1 |
| Chen, Z | 3 |
| Russell, MD | 1 |
| Nagra, D | 1 |
| Clarke, BD | 1 |
| Balachandran, S | 1 |
| Buazon, A | 1 |
| Boalch, A | 1 |
| Bechman, K | 1 |
| Adas, MA | 1 |
| Alveyn, EG | 1 |
| Rutherford, AI | 1 |
| Galloway, JB | 1 |
| Dalbeth, N | 10 |
| Becce, F | 3 |
| Botson, JK | 2 |
| Kumar, A | 2 |
| Christiansen, SN | 1 |
| Østergaard, M | 1 |
| Slot, O | 1 |
| Fana, V | 1 |
| Terslev, L | 1 |
| Yuan, Z | 2 |
| Zhang, S | 3 |
| Li, G | 2 |
| Zhang, G | 5 |
| Türker, PF | 1 |
| Hoca, M | 1 |
| Özduran, G | 1 |
| Akçil Ok, M | 1 |
| Demir Çelebi, M | 1 |
| Schlesinger, N | 4 |
| Brunetti, L | 1 |
| Androulakis, IP | 1 |
| Keller, SF | 1 |
| Mandell, BF | 1 |
| Riaz, M | 1 |
| Al Kury, LT | 1 |
| Atzaz, N | 1 |
| Alattar, A | 1 |
| Alshaman, R | 1 |
| Shah, FA | 1 |
| Li, S | 3 |
| Shang, YX | 1 |
| Dong, X | 1 |
| Xie, ZM | 1 |
| Li, XP | 2 |
| Wang, XC | 1 |
| Huang, JY | 1 |
| Wei, SF | 1 |
| Liu, Y | 12 |
| Liu, JP | 1 |
| Jia, E | 1 |
| Hu, S | 1 |
| Geng, H | 1 |
| Zhu, H | 3 |
| Xie, J | 3 |
| Xiao, Y | 1 |
| Jiang, Y | 4 |
| Xiao, M | 1 |
| Zhu, KJ | 1 |
| Deng, GS | 1 |
| Zhang, LY | 1 |
| Yang, YC | 1 |
| Xu, Q | 4 |
| Zhang, MY | 1 |
| Silva, CR | 3 |
| Saraiva, AL | 1 |
| Rossato, MF | 4 |
| Trevisan, G | 4 |
| Oliveira, SM | 3 |
| Li, C | 4 |
| Wang, C | 4 |
| Guo, Y | 7 |
| Wen, R | 1 |
| Yan, L | 1 |
| Zhang, F | 4 |
| Gong, Q | 1 |
| Yu, H | 2 |
| Qian, X | 2 |
| Luo, Y | 2 |
| Ren, L | 1 |
| Li, Q | 3 |
| Li, H | 3 |
| Zhan, X | 1 |
| Li, Z | 5 |
| Fang, Z | 1 |
| Liu, T | 2 |
| Wei, Z | 1 |
| Zhao, J | 2 |
| Lin, L | 1 |
| Mou, W | 1 |
| Dai, W | 1 |
| Bai, Z | 1 |
| Xu, G | 1 |
| Cao, J | 1 |
| Xu, W | 2 |
| Li, F | 3 |
| Wu, C | 1 |
| Yao, Y | 2 |
| Xia, D | 1 |
| Piao, MH | 1 |
| Wang, H | 4 |
| Jiang, YJ | 1 |
| Wu, YL | 1 |
| Nan, JX | 1 |
| Lian, LH | 1 |
| Zaninelli, TH | 3 |
| Fattori, V | 3 |
| Saraiva-Santos, T | 1 |
| Badaro-Garcia, S | 2 |
| Staurengo-Ferrari, L | 3 |
| Andrade, KC | 2 |
| Artero, NA | 1 |
| Ferraz, CR | 1 |
| Bertozzi, MM | 1 |
| Rasquel-Oliveira, F | 1 |
| Manchope, MF | 1 |
| Amaral, FA | 6 |
| Teixeira, MM | 4 |
| Borghi, SM | 2 |
| Rogers, MS | 1 |
| Casagrande, R | 3 |
| Verri, WA | 3 |
| Van Demark, RE | 1 |
| Brown, J | 1 |
| Hayes, M | 2 |
| Smith, VJS | 1 |
| Toprover, M | 2 |
| Mechlin, M | 1 |
| Fields, T | 1 |
| Oh, C | 1 |
| Pillinger, MH | 2 |
| Cheng, JJ | 1 |
| Ma, XD | 1 |
| Ai, GX | 1 |
| Yu, QX | 1 |
| Chen, XY | 1 |
| Yan, F | 1 |
| Li, YC | 1 |
| Xie, JH | 1 |
| Su, ZR | 1 |
| Xie, QF | 1 |
| Zhou, Q | 6 |
| Sun, HJ | 1 |
| Liu, SM | 4 |
| Stauder, SK | 1 |
| Peloso, PM | 1 |
| Zhu, L | 4 |
| Liu, M | 3 |
| Shan, L | 1 |
| Chen, C | 1 |
| Wang, J | 4 |
| Liang, Z | 1 |
| Li, M | 3 |
| Fu, D | 1 |
| Zhang, L | 4 |
| Ge, D | 1 |
| Sun, B | 2 |
| Shen, J | 3 |
| Ren, Y | 1 |
| Xi, Y | 1 |
| Xiao, N | 1 |
| Shao, S | 1 |
| Qin, D | 1 |
| Peng, J | 2 |
| Luo, Z | 1 |
| Yang, F | 3 |
| Hong, S | 2 |
| Chen, B | 2 |
| Yang, J | 4 |
| Yang, C | 2 |
| Hu, Y | 2 |
| Wang, S | 4 |
| Xu, T | 2 |
| Wu, J | 3 |
| Tian, J | 2 |
| Zhou, D | 2 |
| Xiang, L | 2 |
| Xie, B | 2 |
| Wang, B | 3 |
| Li, Y | 7 |
| Chen, S | 2 |
| Yuan, M | 1 |
| Xu, Y | 6 |
| Xu, H | 3 |
| Saag, K | 1 |
| Peterson, J | 1 |
| Parikh, N | 1 |
| Ong, S | 1 |
| La, D | 1 |
| LoCicero, K | 1 |
| Obermeyer, K | 1 |
| Xin, Y | 1 |
| Chamberlain, J | 1 |
| LaMoreaux, B | 1 |
| Verma, S | 1 |
| Sainati, S | 1 |
| Grewal, S | 1 |
| Majjhoo, A | 1 |
| Tesser, JRP | 1 |
| Weinblatt, ME | 1 |
| Wu, H | 7 |
| Zhou, H | 2 |
| Chen, P | 1 |
| Zhang, B | 4 |
| Chen, Y | 4 |
| Zeng, F | 1 |
| Wang, W | 6 |
| Shi, J | 1 |
| Chen, J | 6 |
| He, R | 1 |
| Ji, M | 1 |
| Guo, QH | 1 |
| Lu, JG | 1 |
| Zheng, BL | 1 |
| Li, T | 1 |
| Chen, SH | 1 |
| Li, JC | 1 |
| Li, SY | 1 |
| Song, Q | 1 |
| Ma, EX | 1 |
| Aimaijiang, MK | 1 |
| Huang, Y | 6 |
| Zhou, M | 6 |
| Yuan, F | 1 |
| Hu, J | 2 |
| Jin, C | 1 |
| Sun, S | 2 |
| Sun, Z | 3 |
| Tan, Y | 1 |
| Wang, X | 8 |
| Dong, M | 1 |
| Liu, H | 3 |
| Chen, H | 8 |
| Wang, D | 1 |
| Luo, T | 1 |
| Zhou, X | 4 |
| Qin, M | 1 |
| Lin, Y | 3 |
| Lin, J | 1 |
| Chen, G | 3 |
| Liu, A | 1 |
| Ouyang, D | 1 |
| Chen, D | 1 |
| Pan, H | 2 |
| Kim, J | 1 |
| Ghang, B | 1 |
| Jeong, W | 1 |
| Cao, Y | 2 |
| Zhong, Q | 1 |
| Tang, F | 1 |
| Yao, X | 1 |
| Elsaid, K | 3 |
| Merriman, TR | 3 |
| Rossitto, LA | 3 |
| Karsh, J | 3 |
| Phipps-Green, A | 3 |
| Jay, GD | 3 |
| Elsayed, S | 3 |
| Qadri, M | 4 |
| Miner, M | 3 |
| Cadzow, M | 3 |
| Dambruoso, TJ | 3 |
| Schmidt, TA | 3 |
| Chhana, A | 3 |
| Höglund, J | 3 |
| Ghassemian, M | 3 |
| Campeau, A | 3 |
| Maltez, N | 3 |
| Karlsson, NG | 3 |
| Gonzalez, DJ | 3 |
| Liu, C | 7 |
| Qian, J | 3 |
| Zhang, Z | 8 |
| Hao, K | 3 |
| Jiang, C | 3 |
| Hu, Q | 3 |
| Lin, CS | 3 |
| Shao, P | 2 |
| Xiang, T | 2 |
| Galvão, I | 3 |
| Mastrippolito, D | 2 |
| Talamini, L | 2 |
| Aganetti, M | 2 |
| Rocha, V | 2 |
| Verdot, C | 2 |
| Mendes, V | 2 |
| de Oliveira, VLS | 2 |
| Braga, AD | 3 |
| Martins, VD | 2 |
| de Faria, AMC | 2 |
| Georgel, P | 2 |
| Vieira, AT | 2 |
| Muller, S | 2 |
| Lei, Y | 3 |
| Cui, TJ | 2 |
| Wang, XH | 2 |
| Zhang, XM | 3 |
| Tang, C | 2 |
| Zheng, ZH | 2 |
| Ren, Z | 1 |
| Huang, J | 3 |
| Lin, Z | 1 |
| Ma, N | 1 |
| Wang, T | 2 |
| Sun, Y | 5 |
| Cai, S | 1 |
| Yang, DH | 1 |
| Chen, HC | 1 |
| Wei, JC | 1 |
| Mohapatra, A | 2 |
| Rajendrakumar, SK | 2 |
| Chandrasekaran, G | 1 |
| Revuri, V | 1 |
| Sathiyamoorthy, P | 2 |
| Lee, YK | 1 |
| Lee, JH | 3 |
| Choi, SY | 1 |
| Park, IK | 2 |
| Guo, J | 1 |
| Sun, D | 1 |
| Sun, H | 1 |
| Yan, C | 1 |
| Wu, Q | 1 |
| Zeng, H | 1 |
| Sun, X | 2 |
| Wan, A | 1 |
| Luo, C | 1 |
| Tao, J | 1 |
| Zhong, H | 1 |
| Zhang, H | 3 |
| Huang, Z | 1 |
| Zou, B | 1 |
| Zou, G | 1 |
| Xie, N | 1 |
| Liang, Y | 2 |
| Zhu, Y | 2 |
| Ma, W | 1 |
| Chen, W | 2 |
| Mei, L | 1 |
| Wu, X | 4 |
| Chen, X | 5 |
| Yang, Z | 1 |
| Gao, K | 1 |
| Huang, H | 2 |
| Huang, R | 1 |
| Jin, XF | 1 |
| Zou, JM | 1 |
| Kou, J | 1 |
| Zhang, M | 4 |
| Xie, Q | 1 |
| Wei, M | 1 |
| Zhu, R | 1 |
| Niu, Y | 1 |
| Zhou, W | 2 |
| Mao, J | 1 |
| Xiong, X | 1 |
| Guo, L | 1 |
| Chen, YH | 2 |
| Chen, WY | 2 |
| Yu, CL | 3 |
| Tsai, CY | 3 |
| Hsieh, SC | 2 |
| Lu, J | 1 |
| Zhao, F | 2 |
| Long, T | 1 |
| Wen, J | 1 |
| Mao, Y | 1 |
| Qi, Z | 1 |
| Dong, Y | 1 |
| Tao, H | 1 |
| Mo, Y | 1 |
| Liu, W | 4 |
| Du, X | 2 |
| Fu, W | 1 |
| Ge, M | 1 |
| Fu, N | 1 |
| Quan, J | 1 |
| Du, K | 1 |
| Wang, Z | 5 |
| Mo, C | 1 |
| Dong, W | 2 |
| Wei, N | 1 |
| Zhong, W | 1 |
| You, Y | 1 |
| Lee, YH | 1 |
| Song, GG | 1 |
| Ye, Z | 1 |
| Zong, Z | 1 |
| Wu, R | 1 |
| Lin, X | 1 |
| He, Z | 1 |
| Hao, G | 1 |
| Gao, X | 2 |
| Gao, H | 1 |
| Zhou, Y | 6 |
| Shi, S | 1 |
| Meng, S | 1 |
| Zhao, H | 2 |
| Niessink, T | 1 |
| Giesen, T | 1 |
| Efdé, M | 1 |
| Comarniceanu, A | 1 |
| Janssen, M | 3 |
| Otto, C | 1 |
| Jansen, TL | 2 |
| Qin, DE | 1 |
| Liang, W | 1 |
| Whelan, EC | 1 |
| Yuan, X | 1 |
| Wang, ZL | 1 |
| Wu, XW | 2 |
| Cao, ZR | 1 |
| Hua, SY | 1 |
| Yin, L | 5 |
| Shi, L | 5 |
| Liang, T | 3 |
| Mohanty, A | 1 |
| Chahal, S | 1 |
| Vijayan, V | 1 |
| Kotlyarov, M | 2 |
| Mews, J | 2 |
| Ulas, ST | 1 |
| Ziegeler, K | 1 |
| Hamm, B | 2 |
| Diekhoff, T | 2 |
| Lien, MC | 1 |
| Yeh, IH | 1 |
| Lu, YC | 1 |
| Liu, KK | 1 |
| Lin, TM | 1 |
| Lee, HY | 1 |
| Chang, CK | 1 |
| Lin, KH | 1 |
| Chang, CC | 1 |
| Wu, BF | 1 |
| Peng, SJ | 1 |
| Medina, JP | 1 |
| Bermejo-Álvarez, I | 1 |
| Pérez-Baos, S | 1 |
| Yáñez, R | 1 |
| Fernández-García, M | 1 |
| García-Olmo, D | 1 |
| Mediero, A | 1 |
| Herrero-Beaumont, G | 2 |
| Largo, R | 1 |
| Yuan, W | 1 |
| Wang, YY | 1 |
| He, S | 1 |
| Wang, XB | 1 |
| Deng, SH | 1 |
| Zhang, T | 3 |
| Wu, DM | 1 |
| Choi, SH | 1 |
| Song, HS | 1 |
| Hwang, J | 1 |
| Yang, L | 3 |
| Yan, S | 2 |
| Xiong, S | 1 |
| Bai, X | 1 |
| Yan, Y | 1 |
| Huang, S | 1 |
| Lin, S | 1 |
| Guan, W | 1 |
| Liang, H | 1 |
| Andres Cerezo, L | 1 |
| Navrátilová, A | 1 |
| Hulejová, H | 1 |
| Pavlíková, M | 1 |
| Závada, J | 1 |
| Pavelka, K | 1 |
| Šenolt, L | 1 |
| Stiburkova, B | 1 |
| Hoss, IM | 1 |
| Pradal, LA | 1 |
| Leal, TSDS | 1 |
| Bertolini, GRF | 1 |
| Costa, RM | 1 |
| Ribeiro, LFC | 1 |
| Liu, F | 2 |
| Shen, F | 2 |
| Bai, Y | 1 |
| Wan, Y | 1 |
| Zheng, L | 1 |
| He, J | 1 |
| Xie, Y | 4 |
| Guo, P | 1 |
| Hao, P | 1 |
| Ward, R | 1 |
| Tang, T | 1 |
| Luo, G | 1 |
| Yang, Y | 2 |
| Xiang, C | 1 |
| An, S | 1 |
| Xu, TR | 1 |
| Li, D | 1 |
| Yuan, S | 1 |
| Deng, Y | 1 |
| Wu, S | 1 |
| Ouyang, J | 1 |
| Lin, D | 2 |
| Quan, H | 1 |
| Fu, X | 1 |
| Mao, W | 1 |
| Tavares, LD | 1 |
| Costa, VV | 1 |
| Batista, NV | 2 |
| Rossi, LCR | 1 |
| Brito, CB | 1 |
| Reis, AC | 1 |
| Queiroz-Junior, CM | 1 |
| Coelho, FM | 1 |
| Dias, AC | 1 |
| Zamboni, DS | 1 |
| Pinho, V | 1 |
| Souza, DG | 1 |
| Bychkov, ОА | 1 |
| Kondratiuk, VE | 1 |
| Bychkova, NG | 1 |
| Morozova, ZV | 1 |
| Bychkova, SA | 1 |
| Tarasiuk, AP | 1 |
| Jia, P | 1 |
| Yin, ZY | 1 |
| Kong, SZ | 1 |
| Xiang, ZB | 1 |
| Zheng, XX | 1 |
| Kong, H | 1 |
| Cheng, J | 1 |
| Lu, F | 4 |
| Qu, H | 1 |
| Lyu, S | 2 |
| Ding, R | 2 |
| OuYang, H | 2 |
| Feng, Y | 2 |
| Rao, Y | 2 |
| Yang, S | 3 |
| Kaewput, W | 1 |
| Thongprayoon, C | 1 |
| Rangsin, R | 1 |
| Ruangkanchanasetr, P | 1 |
| Bathini, T | 1 |
| Mao, MA | 1 |
| Cheungpasitporn, W | 1 |
| Gamala, M | 2 |
| Jacobs, JWG | 2 |
| Linn-Rasker, SF | 1 |
| Nix, M | 2 |
| Heggelman, BGF | 2 |
| Pasker-de Jong, PCM | 2 |
| van Laar, JM | 2 |
| Klaasen, R | 2 |
| Strobl, S | 1 |
| Kremser, C | 1 |
| Taljanovic, M | 1 |
| Gruber, J | 1 |
| Stofferin, H | 1 |
| Bellmann-Weiler, R | 1 |
| Klauser, AS | 1 |
| Lai, L | 1 |
| Ju, Y | 1 |
| Meng, D | 1 |
| Zhou, L | 2 |
| Sun, RR | 1 |
| Zhang, ZY | 1 |
| Cabău, G | 1 |
| Crișan, TO | 4 |
| Klück, V | 2 |
| Popp, RA | 1 |
| Joosten, LAB | 2 |
| He, Y | 1 |
| Yang, Q | 2 |
| Jia, A | 1 |
| Xie, W | 2 |
| Zhou, J | 8 |
| Min, HK | 1 |
| Kim, HR | 1 |
| Pei, L | 1 |
| Xie, L | 1 |
| Liu, S | 3 |
| Jin, L | 1 |
| Tang, L | 1 |
| Yang, T | 1 |
| Huo, B | 1 |
| Liu, R | 1 |
| Chouhan, D | 1 |
| Shankar, V | 1 |
| Ansari, MT | 1 |
| Wang, L | 4 |
| Duan, C | 2 |
| Bousoik, E | 1 |
| Elsaid, KA | 1 |
| Lee, YM | 2 |
| Cho, SN | 1 |
| Son, E | 1 |
| Song, CH | 1 |
| Kim, DS | 2 |
| Hong, J | 1 |
| Qiu, J | 3 |
| Bang, HI | 1 |
| Choi, IH | 1 |
| Park, R | 1 |
| Otani, N | 1 |
| Ouchi, M | 1 |
| Kudo, H | 1 |
| Tsuruoka, S | 1 |
| Hisatome, I | 1 |
| Anzai, N | 1 |
| Shin, SH | 1 |
| Jeong, J | 1 |
| Kim, JH | 1 |
| Sohn, KY | 1 |
| Yoon, SY | 1 |
| Kim, JW | 2 |
| Sullivan, JI | 1 |
| Ye, SM | 1 |
| Zhou, MZ | 1 |
| Jiang, WJ | 1 |
| Liu, CX | 1 |
| Zhou, ZW | 1 |
| Sun, MJ | 1 |
| Hu, QH | 1 |
| Edwards, NL | 2 |
| Hsieh, TH | 1 |
| Keyßer, G | 1 |
| Zou, Y | 1 |
| Zheng, J | 1 |
| Ji, S | 1 |
| Wen, X | 1 |
| Ye, F | 1 |
| Lei, J | 1 |
| Qiu, M | 3 |
| Hase, R | 1 |
| Kurata, R | 1 |
| Ishida, K | 1 |
| Kurita, T | 1 |
| Muranaka, E | 1 |
| Mito, H | 1 |
| Han, J | 2 |
| Shi, G | 4 |
| Jiang, D | 2 |
| Ze, K | 1 |
| Hua, L | 2 |
| Kuai, L | 1 |
| Qian, H | 1 |
| Zheng, Q | 2 |
| Chen, R | 2 |
| Guan, J | 1 |
| Huang, XQ | 1 |
| Dong, JL | 1 |
| Lu, HM | 1 |
| Lin, YW | 1 |
| Yi, ZB | 1 |
| Wu, LM | 1 |
| Huang, YM | 1 |
| Lan, T | 1 |
| Zou, Z | 2 |
| Yang, M | 2 |
| Oliveira, RD | 1 |
| Louzada-Junior, P | 2 |
| Cunha, TM | 3 |
| Alves-Filho, JC | 2 |
| Cunha, FQ | 2 |
| Zhu, FF | 1 |
| Jiang, JQ | 1 |
| Chen, AS | 2 |
| Yuan, DP | 1 |
| Liang, XL | 1 |
| Koto, R | 1 |
| Nakajima, A | 1 |
| Horiuchi, H | 1 |
| Yamanaka, H | 5 |
| Fan, X | 1 |
| Chen, K | 1 |
| Yu, X | 1 |
| Sun, G | 1 |
| Ye, Q | 1 |
| Takakubo, Y | 1 |
| Imamura, Y | 1 |
| Tezuka, H | 1 |
| Okada, S | 1 |
| Naganuma, Y | 1 |
| Ito, J | 1 |
| Sugawara, M | 1 |
| Oki, H | 1 |
| Sasaki, A | 1 |
| Sasaki, K | 1 |
| Konta, T | 1 |
| Takagi, M | 1 |
| Yan, CY | 1 |
| Ouyang, SH | 1 |
| Wu, YP | 1 |
| Sun, WY | 1 |
| Duan, WJ | 1 |
| Liang, L | 1 |
| Luo, X | 1 |
| Kurihara, H | 1 |
| Li, YF | 1 |
| He, RR | 1 |
| Schmitt, M | 1 |
| Ramon, A | 1 |
| Ornetti, P | 1 |
| Maillefert, JF | 1 |
| Bernardes, ACFPF | 1 |
| Matosinhos, RC | 1 |
| de Paula Michel Araújo, MC | 1 |
| Barros, CH | 1 |
| de Oliveira Aguiar Soares, RD | 1 |
| Costa, DC | 1 |
| Sachs, D | 1 |
| Saúde-Guimarães, DA | 3 |
| Cai, R | 1 |
| Hasnat, M | 1 |
| Zhao, Q | 1 |
| Wu, M | 1 |
| Huang, X | 2 |
| Gu, Y | 1 |
| Deng, G | 1 |
| Lv, W | 3 |
| Shimizu, T | 2 |
| Rooks, MJ | 1 |
| Ahn, SJ | 1 |
| Zhang, D | 2 |
| Levine, BD | 1 |
| Pool, B | 1 |
| Ranganath, VK | 1 |
| Benhaim, P | 1 |
| Nelson, SD | 1 |
| Hsieh, SS | 1 |
| FitzGerald, JD | 1 |
| Mustafa, M | 1 |
| Sajjad, AG | 1 |
| Shah, SSH | 1 |
| Mahmood, T | 2 |
| Chi, J | 1 |
| Dong, B | 1 |
| Xu, L | 3 |
| Wei, F | 1 |
| Che, K | 1 |
| Meng, Q | 1 |
| Meng, W | 1 |
| Bian, H | 1 |
| Zheng, F | 1 |
| Gu, H | 1 |
| Zuo, R | 1 |
| Miao, X | 1 |
| Zhou, Z | 3 |
| Wen, Z | 2 |
| Ma, J | 1 |
| Su, X | 1 |
| Hou, X | 2 |
| Jeong, JH | 1 |
| Choi, SJ | 2 |
| Ahn, SM | 1 |
| Oh, JS | 1 |
| Kim, YG | 2 |
| Lee, CK | 2 |
| Yoo, B | 2 |
| Luo, R | 1 |
| Xu, F | 1 |
| Lin, H | 1 |
| Xie, C | 1 |
| Zheng, S | 3 |
| Xiao, WZ | 1 |
| Zhu, XX | 2 |
| Zou, HJ | 1 |
| Shang, J | 1 |
| Li, XH | 1 |
| Lu, SQ | 1 |
| Shang, Y | 2 |
| Li, LL | 1 |
| Liu, B | 1 |
| Rasheed Kayani, R | 1 |
| Shamim, R | 1 |
| Sultana Munir, S | 1 |
| Sultana, M | 1 |
| Nazir, SUR | 1 |
| Riaz, H | 1 |
| Nazir, T | 1 |
| Maaz Ali, M | 1 |
| Islam, A | 1 |
| Masood, R | 1 |
| Pascart, T | 1 |
| Carpentier, P | 1 |
| Choi, HK | 3 |
| Norberciak, L | 1 |
| Ducoulombier, V | 1 |
| Luraschi, H | 1 |
| Houvenagel, E | 1 |
| Legrand, J | 1 |
| Verclytte, S | 1 |
| Budzik, JF | 1 |
| Xu, HL | 1 |
| Li, SK | 1 |
| Xue, XA | 1 |
| Chen, ZY | 1 |
| Hua, YH | 1 |
| Uhlig, T | 2 |
| Eskild, T | 2 |
| Karoliussen, LF | 1 |
| Sexton, J | 1 |
| Kvien, TK | 1 |
| Haavardsholm, EA | 1 |
| Hammer, HB | 2 |
| Fan, HF | 1 |
| Fang, XY | 1 |
| Wu, HL | 1 |
| Xu, YQ | 1 |
| Gong, LC | 1 |
| Yu, DR | 1 |
| Jia, H | 1 |
| Tang, XL | 1 |
| Liu, QB | 1 |
| Yen, H | 1 |
| Su, HJ | 1 |
| Chen, WT | 1 |
| Zhong, CS | 1 |
| Zeng, B | 1 |
| Qiu, JH | 1 |
| Xu, LH | 1 |
| Zhong, MY | 1 |
| Huang, YT | 1 |
| Liu, SY | 1 |
| Zha, QB | 1 |
| Hu, B | 2 |
| Ou-Yang, DY | 1 |
| He, XH | 1 |
| Zhou, GX | 1 |
| He, XJ | 1 |
| Guo, F | 1 |
| Chen, JM | 1 |
| Zhang, HJ | 3 |
| Li, LN | 1 |
| Yang, QQ | 1 |
| Liu, PG | 2 |
| Xu, P | 2 |
| Liang, WQ | 2 |
| Cheng, L | 1 |
| Zhang, YQ | 1 |
| Pu, JB | 2 |
| Hu, YJ | 3 |
| Yu, B | 1 |
| Lin, Q | 2 |
| Duan, L | 2 |
| Kong, X | 1 |
| Ma, L | 4 |
| Jiang, L | 3 |
| Gao, Z | 1 |
| Lü, K | 1 |
| Song, XJ | 1 |
| Pan, HH | 1 |
| Desai, J | 1 |
| Steiger, S | 2 |
| Anders, HJ | 1 |
| Shon, EJ | 1 |
| Kim, OS | 1 |
| Yokose, K | 1 |
| Sato, S | 1 |
| Asano, T | 1 |
| Yashiro, M | 1 |
| Kobayashi, H | 1 |
| Watanabe, H | 1 |
| Suzuki, E | 1 |
| Sato, C | 1 |
| Kozuru, H | 1 |
| Yatsuhashi, H | 1 |
| Migita, K | 1 |
| Nam, JS | 1 |
| Jagga, S | 1 |
| Sharma, AR | 1 |
| Park, JB | 1 |
| Jung, JS | 1 |
| Lee, SS | 2 |
| Reber, LL | 3 |
| Starkl, P | 3 |
| Balbino, B | 1 |
| Sibilano, R | 1 |
| Gaudenzio, N | 3 |
| Rogalla, S | 1 |
| Sensarn, S | 1 |
| Kang, D | 1 |
| Raghu, H | 1 |
| Sokolove, J | 2 |
| Robinson, WH | 2 |
| Contag, CH | 1 |
| Tsai, M | 2 |
| Galli, SJ | 3 |
| Kokott, P | 1 |
| Zhou, C | 1 |
| Xue, C | 1 |
| Yang, B | 1 |
| Huang, F | 1 |
| Zhang, N | 2 |
| Yu, DH | 3 |
| Nicolaou, S | 1 |
| Baumgartner, S | 1 |
| Fung, M | 1 |
| Jud, P | 1 |
| Verheyen, N | 1 |
| Fruhwald, F | 1 |
| Linn-Rasker, SP | 1 |
| Ran, B | 1 |
| Wei, J | 1 |
| Ma, T | 1 |
| Cen, Z | 1 |
| Xin, C | 1 |
| Guo, M | 2 |
| Zou, C | 1 |
| Song, W | 1 |
| Xie, R | 1 |
| Wang, K | 1 |
| Bian, C | 1 |
| Cui, K | 1 |
| Wei, YQ | 1 |
| Löffler, C | 2 |
| Sattler, H | 2 |
| Löffler, U | 2 |
| Krämer, BK | 1 |
| Bergner, R | 2 |
| Lee, JK | 1 |
| Kim, YS | 2 |
| Koo, BS | 1 |
| Marin, M | 1 |
| Maalouf, NM | 1 |
| Cheng, W | 1 |
| Zhang, Q | 2 |
| Garner, HW | 1 |
| Wessell, DE | 1 |
| Tang, H | 2 |
| Zhang, QB | 1 |
| Zhu, D | 2 |
| Yi, T | 1 |
| Qing, YF | 1 |
| Zhou, JG | 1 |
| Kupfer, S | 1 |
| Winklhofer, S | 1 |
| Becker, AS | 1 |
| Distler, O | 1 |
| Chung, CB | 1 |
| Alkadhi, H | 3 |
| Finkenstaedt, T | 2 |
| Qing, Y | 2 |
| Mi, Q | 1 |
| Di Matteo, A | 2 |
| Filippucci, E | 2 |
| Cipolletta, E | 2 |
| Ausili, M | 1 |
| Martire, V | 2 |
| Di Carlo, M | 1 |
| Salaffi, F | 2 |
| Grassi, W | 3 |
| Dai, XJ | 1 |
| Tao, JH | 1 |
| Fang, X | 1 |
| Xia, Y | 1 |
| Li, XM | 2 |
| Wang, YP | 1 |
| Shen, M | 1 |
| Qian, K | 1 |
| Gu, B | 1 |
| Ren, Q | 1 |
| Su, D | 1 |
| Nakano, Y | 1 |
| Otsuka, F | 1 |
| Ruiz-Miyazawa, KW | 1 |
| Pinho-Ribeiro, FA | 1 |
| Clemente-Napimoga, JT | 1 |
| Fraceto, LF | 1 |
| Napimoga, MH | 1 |
| Peng, A | 1 |
| Liu, JY | 1 |
| Feng, N | 1 |
| Deng, X | 2 |
| Ji, L | 1 |
| Lv, X | 1 |
| Bouaziz, W | 1 |
| Rekik, MA | 1 |
| Guidara, AR | 1 |
| Keskes, H | 1 |
| Hondebrink, LLC | 1 |
| Opstelten, W | 1 |
| Ji, LL | 1 |
| Hao, YJ | 1 |
| Zhang, ZL | 1 |
| Xu, DQ | 1 |
| Sun, DY | 1 |
| Xiao, DM | 1 |
| Zell, M | 1 |
| FitzGerald, J | 1 |
| Barbagallo, M | 1 |
| Oliveira, VLS | 1 |
| Castro-Gomes, T | 1 |
| Oliveira, RDR | 1 |
| Pinheiro, GRC | 1 |
| Mantovani, A | 1 |
| Garlanda, C | 1 |
| Chaloemwong, J | 1 |
| Tantiworawit, A | 1 |
| Rattanathammethee, T | 1 |
| Chai-Adisaksopha, C | 1 |
| Rattarittamrong, E | 1 |
| Norasetthada, L | 1 |
| Charoenkwan, P | 1 |
| Louthrenoo, W | 3 |
| Cleophas, MCP | 1 |
| Hoogerbrugge, N | 1 |
| Netea-Maier, RT | 1 |
| Dinarello, CA | 2 |
| Netea, MG | 3 |
| Zamudio-Cuevas, Y | 2 |
| Fernández-Torres, J | 1 |
| Martínez-Nava, GA | 1 |
| Martínez-Flores, K | 1 |
| Ramírez Olvera, A | 1 |
| Medina-Luna, D | 1 |
| Hernández Pérez, AD | 1 |
| Landa-Solís, C | 1 |
| López-Reyes, A | 2 |
| Musca, A | 1 |
| Di Donato, E | 1 |
| Jesus, D | 1 |
| Chen, SL | 1 |
| Chen, JR | 1 |
| Yang, SW | 1 |
| Fu, S | 1 |
| Liang, M | 1 |
| Lv, L | 1 |
| Ma, TH | 1 |
| Sheng, T | 1 |
| Tian, CM | 1 |
| Xing, MY | 1 |
| Yan, LJ | 1 |
| Xia, DZ | 1 |
| Liang, G | 1 |
| Nie, Y | 1 |
| Chang, Y | 1 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Zheng, X | 1 |
| Xiao, D | 1 |
| Zhan, S | 1 |
| Üsküdar Cansu, D | 1 |
| Erdoğan, B | 1 |
| Korkmaz, C | 1 |
| Hussain, MA | 1 |
| Jahan, S | 1 |
| Afzal, M | 1 |
| Nawaz, I | 1 |
| El-Tantawy, WH | 1 |
| Yang, TH | 1 |
| Yan, DX | 1 |
| Huang, XY | 1 |
| Hou, B | 1 |
| Ma, YB | 1 |
| Peng, H | 1 |
| Chen, JJ | 1 |
| Geng, CA | 1 |
| Hoffmeister, C | 2 |
| Bezerra, F | 1 |
| Ferreira, J | 3 |
| Bousson, V | 1 |
| Bardin, T | 1 |
| Zeitoun, D | 1 |
| Sverzut, JM | 1 |
| Ea, HK | 3 |
| Hermann, KGA | 1 |
| Miao, Z | 1 |
| Guo, W | 1 |
| Lu, S | 1 |
| Zhao, S | 1 |
| Tao, Z | 1 |
| Fang, ZH | 1 |
| Waizy, H | 1 |
| Lee, WB | 1 |
| Woo, SH | 1 |
| Min, BI | 1 |
| Cho, SH | 1 |
| Elam, A | 1 |
| McCleskey, PE | 1 |
| Von Zingel, M | 1 |
| Sabina, EP | 3 |
| Indu, H | 1 |
| Rasool, M | 8 |
| Ma, S | 1 |
| Li, XZ | 1 |
| Yang, BL | 1 |
| Ding, G | 1 |
| Murunikkara, V | 1 |
| Chen, MC | 3 |
| Chou, YH | 1 |
| Lin, SD | 1 |
| Lai, CS | 1 |
| Chen, YC | 1 |
| Courtney, P | 1 |
| Doherty, M | 2 |
| Aguayo, RS | 1 |
| Baradad, M | 1 |
| Soria, X | 1 |
| Abal, L | 1 |
| Sanmartín, V | 1 |
| Egido, R | 1 |
| Gallel, P | 1 |
| Casanova, JM | 1 |
| Martí, RM | 1 |
| Seifried, RM | 1 |
| Roberts, J | 1 |
| Silva, MA | 1 |
| Ineu, RP | 1 |
| Guerra, GP | 1 |
| Materazzi, S | 1 |
| Fusi, C | 1 |
| Nassini, R | 1 |
| Geppetti, P | 1 |
| Mola, M | 1 |
| Mei, Z | 2 |
| Shu, G | 1 |
| Wei, L | 2 |
| Kodithuwakku, ND | 1 |
| Pan, M | 1 |
| Zhu, YL | 1 |
| Zhang, YY | 1 |
| Feng, YD | 1 |
| Fang, WR | 1 |
| Li, YM | 1 |
| Song, H | 1 |
| Ding, Y | 2 |
| Harper, JL | 3 |
| Morris, H | 1 |
| Grant, K | 1 |
| Khanna, G | 1 |
| White, AJ | 1 |
| Stumpf, J | 1 |
| Toniolo, M | 2 |
| Haller, C | 1 |
| Pan, KL | 1 |
| Lin, JC | 1 |
| Lin, CL | 1 |
| Chang, PJ | 1 |
| Hsiao, JF | 1 |
| Chang, ST | 1 |
| Chung, CM | 1 |
| Choi, H | 1 |
| Xue, J | 1 |
| Ye, L | 2 |
| Shi, D | 2 |
| Xue, Q | 1 |
| Wang, N | 1 |
| Hu, Z | 1 |
| Michels, G | 1 |
| Bunck, AC | 1 |
| Pfister, R | 1 |
| Park, JW | 1 |
| Ko, DJ | 1 |
| Yoo, JJ | 1 |
| Chang, SH | 1 |
| Cho, HJ | 1 |
| Kang, EH | 1 |
| Park, JK | 1 |
| Song, YW | 1 |
| Lee, YJ | 1 |
| Oberhofer, E | 1 |
| Stiefelhagen, P | 3 |
| Xu, JX | 1 |
| Wu, HX | 1 |
| Zhou, QJ | 1 |
| Yu, RS | 1 |
| Ramonda, R | 2 |
| Frallonardo, P | 1 |
| Oliviero, F | 3 |
| Lorenzin, MG | 1 |
| Ortolan, A | 1 |
| Scanu, A | 3 |
| Punzi, L | 3 |
| Marichal, T | 1 |
| Iwakura, Y | 1 |
| Karasuyama, H | 1 |
| Schwartz, LB | 1 |
| Wei, H | 1 |
| Chiang, SL | 2 |
| Ou, TT | 2 |
| Wu, YJ | 1 |
| Tu, HP | 2 |
| Lu, CY | 1 |
| Huang, CM | 2 |
| Kuo, TM | 1 |
| Wang, TN | 1 |
| Chou, CH | 1 |
| Ko, YC | 2 |
| Wangkaew, S | 1 |
| Kasitanon, N | 2 |
| Hongsongkiat, S | 1 |
| Tanasombat, C | 1 |
| Sukittawut, W | 1 |
| Peters, L | 1 |
| Uppenkamp, M | 1 |
| Liu, Q | 1 |
| Mandokhel, R | 1 |
| Pritchard, G | 1 |
| Jones, J | 1 |
| Mead, T | 1 |
| Arabindoo, K | 1 |
| Smith, B | 1 |
| Lemos Lima, Rde C | 1 |
| Ferrari, FC | 1 |
| de Souza, MR | 2 |
| de Sá Pereira, BM | 1 |
| de Paula, CA | 2 |
| Lee, HP | 2 |
| Lin, YY | 2 |
| Duh, CY | 2 |
| Huang, SY | 2 |
| Wang, HM | 2 |
| Wu, SF | 2 |
| Lin, SC | 1 |
| Jean, YH | 2 |
| Wen, ZH | 2 |
| Cleophas, MC | 2 |
| Lemmers, H | 1 |
| Toenhake-Dijkstra, H | 1 |
| Fossati, G | 1 |
| Joosten, LA | 3 |
| Pisetsky, DS | 1 |
| Shah, D | 1 |
| Mohan, G | 1 |
| Flueckiger, P | 1 |
| Corrigan, F | 1 |
| Conn, D | 1 |
| Emad, Y | 1 |
| Ragab, Y | 1 |
| El-Naggar, A | 1 |
| El-Shaarawy, N | 1 |
| Abd-Allah, MA | 1 |
| Gamal, RM | 1 |
| Fathy, A | 1 |
| Hawass, M | 1 |
| Rasker, JJ | 1 |
| Singh, JA | 2 |
| Choi, HJ | 1 |
| Yoon, BY | 1 |
| Kim, HA | 1 |
| Suh, CH | 1 |
| Choi, ST | 2 |
| Song, JS | 2 |
| Joo, H | 1 |
| Lee, JS | 1 |
| Shin, K | 1 |
| Jun, JB | 1 |
| Baek, HJ | 1 |
| Ren, J | 1 |
| Cai, X | 1 |
| Dhaese, S | 1 |
| Stryckers, M | 1 |
| Van Der Meersch, H | 1 |
| Terryn, W | 1 |
| Van Laecke, S | 1 |
| Hernández-Díaz, C | 1 |
| Pineda, C | 1 |
| Cerna-Cortés, JF | 1 |
| Ventura-Ríos, L | 1 |
| Yen, JH | 1 |
| Lin, LC | 1 |
| Sarang, Z | 1 |
| Leong, PY | 1 |
| Chang, IC | 2 |
| Hsu, JD | 1 |
| Chen, JH | 1 |
| Hsieh, YF | 1 |
| Pallai, A | 1 |
| Köröskényi, K | 1 |
| Szondy, Z | 1 |
| Tsay, GJ | 1 |
| Oğuz, AK | 1 |
| Yılmaz, S | 1 |
| Akar, N | 1 |
| Özdağ, H | 1 |
| Gürler, A | 1 |
| Ateş, A | 1 |
| Oygür, ÇŞ | 1 |
| Kılıçoğlu, SS | 1 |
| Demirtaş, S | 1 |
| Ren, D | 1 |
| Jiang, M | 1 |
| Wang, R | 1 |
| Wang, YG | 1 |
| Kuniyoshi, Y | 1 |
| Kamura, A | 1 |
| Yasuda, S | 1 |
| Tashiro, M | 1 |
| Eliseev, MS | 1 |
| Barskova, VG | 1 |
| Denisov, IS | 1 |
| Sigdel, KR | 1 |
| Su, Q | 1 |
| Zhang, YL | 1 |
| Jin, X | 1 |
| Duarte, JH | 1 |
| Abhishek, A | 1 |
| Curran, DJ | 1 |
| Bilwani, F | 1 |
| Jones, AC | 1 |
| Towler, MR | 1 |
| Hanvivadhanakul, P | 2 |
| Wongdet, R | 1 |
| Sun, W | 2 |
| Mittl, GS | 1 |
| Zuckerman, JD | 1 |
| Zeng, M | 1 |
| Dang, W | 1 |
| Zhao, M | 1 |
| Kim, Y | 1 |
| Park, G | 1 |
| Kim, SK | 1 |
| Choe, JY | 1 |
| Park, BL | 1 |
| Kim, HS | 1 |
| Guo, Q | 1 |
| Zhu, YX | 1 |
| Zhu, RR | 1 |
| Lei, XX | 1 |
| Chen, Q | 1 |
| Dhanasekar, C | 2 |
| Kalaiselvan, S | 1 |
| Metzger, SC | 1 |
| Koehm, M | 1 |
| Wichmann, JL | 1 |
| Buettner, S | 1 |
| Scholtz, JE | 1 |
| Beeres, M | 1 |
| Kerl, JM | 1 |
| Albrecht, MH | 1 |
| Hammerstingl, R | 1 |
| Vogl, TJ | 1 |
| Bauer, RW | 1 |
| Manoliou, A | 1 |
| Higashigaito, K | 1 |
| Andreisek, G | 1 |
| Guggenberger, R | 1 |
| Michel, B | 1 |
| Doss, HM | 1 |
| Dey, C | 1 |
| Sudandiradoss, C | 1 |
| Rasool, MK | 1 |
| Hügle, T | 1 |
| Krenn, V | 1 |
| Song, Z | 1 |
| Shi, Y | 2 |
| Gruaz, L | 1 |
| Galozzi, P | 1 |
| Luisetto, R | 1 |
| Burger, D | 1 |
| Füeßl, HS | 1 |
| Zhu, F | 1 |
| Wilson, L | 1 |
| Saseen, JJ | 1 |
| Sui, F | 1 |
| Feng, X | 1 |
| Han, Q | 1 |
| Bing, W | 1 |
| Di, Y | 1 |
| Shi-He, L | 1 |
| Yu-Hua, Z | 1 |
| Xiu-Guo, H | 1 |
| Yu-Gang, W | 1 |
| Qi-Ming, F | 1 |
| Shih-Mo, Y | 1 |
| Ting-Ting, T | 1 |
| Wan, KS | 1 |
| Liu, CK | 1 |
| Ko, MC | 1 |
| Lee, WK | 1 |
| Huang, CS | 1 |
| Poudel, DR | 1 |
| Karmacharya, P | 1 |
| Donato, A | 1 |
| Saigal, R | 1 |
| Agrawal, A | 1 |
| Udhaya Lavinya, B | 1 |
| Bardhan, I | 1 |
| Evan Prince, S | 1 |
| Tausche, AK | 3 |
| Aringer, M | 3 |
| Reinwald, C | 1 |
| Schauer, C | 1 |
| Csepregi, JZ | 1 |
| Kienhöfer, D | 1 |
| Weidner, D | 1 |
| Malissen, M | 1 |
| Mocsai, A | 1 |
| Schett, G | 2 |
| Herrmann, M | 1 |
| Hoffmann, M | 1 |
| Park, M | 1 |
| Jung, H | 1 |
| Jeong, Y | 1 |
| Jeong, KH | 1 |
| Coiffier, G | 1 |
| Albert, JD | 1 |
| Robin, F | 1 |
| Guggenbuhl, P | 1 |
| Liao, M | 1 |
| Dinesh, P | 1 |
| Jing, X | 1 |
| Han, Y | 1 |
| Tang, X | 1 |
| Sun, J | 1 |
| Fan, Y | 1 |
| Wen, C | 1 |
| Resorlu, H | 1 |
| Zateri, C | 1 |
| Akbal, A | 1 |
| Gokmen, F | 1 |
| Adam, G | 1 |
| Bilim, S | 1 |
| Bozkurt, E | 1 |
| Janssens, HJ | 2 |
| van de Lisdonk, EH | 2 |
| van Riel, PL | 2 |
| van Weel, C | 2 |
| Qiu, R | 1 |
| Shen, R | 1 |
| Ye, H | 1 |
| Jiao, B | 1 |
| Huang, C | 1 |
| Lundberg, GD | 1 |
| Keith, MP | 3 |
| Roebuck, JD | 2 |
| Lien, SB | 1 |
| Huang, GS | 1 |
| Pan, RY | 1 |
| Shen, HC | 1 |
| Kuo, CL | 1 |
| Shen, PH | 1 |
| Xie, XQ | 1 |
| Cao, YX | 1 |
| Meng, Y | 1 |
| Deng, L | 1 |
| Martin, WJ | 1 |
| Herst, PM | 1 |
| Chia, EW | 1 |
| Torres, R | 1 |
| Macdonald, L | 1 |
| Croll, SD | 1 |
| Reinhardt, J | 1 |
| Dore, A | 1 |
| Stevens, S | 2 |
| Hylton, DM | 1 |
| Rudge, JS | 1 |
| Terkeltaub, RA | 4 |
| Yancopoulos, GD | 2 |
| Murphy, AJ | 1 |
| Ott, I | 1 |
| Gartenschläger, M | 1 |
| Schmeck, S | 1 |
| Baier, G | 1 |
| Trullàs, JC | 1 |
| Gómez, M | 1 |
| Fraiz, E | 1 |
| Soldevila, F | 1 |
| Ma, Y | 1 |
| Zhou, LL | 1 |
| Yan, HY | 1 |
| Chen, CJ | 1 |
| Tovosia, S | 1 |
| Ko, AM | 1 |
| Lin, GT | 1 |
| Chang, SJ | 1 |
| Chiang, HC | 1 |
| Chen, PH | 1 |
| Wang, SJ | 1 |
| Lai, HM | 1 |
| Gandhi, A | 1 |
| Aggarwal, S | 1 |
| Rajbongshi, A | 1 |
| Arora, VK | 1 |
| Lee, YA | 1 |
| Lee, SH | 2 |
| Yang, HI | 1 |
| Hong, SJ | 1 |
| Kobayashi, S | 1 |
| Taniguchi, A | 2 |
| Okamoto, H | 1 |
| Momohara, S | 1 |
| Tomatsu, T | 1 |
| Yoo, HG | 1 |
| Lee, SI | 1 |
| Chae, HJ | 1 |
| Park, SJ | 1 |
| Lee, YC | 1 |
| Yoo, WH | 1 |
| Schorn, C | 1 |
| Behr, C | 1 |
| Schwarting, A | 1 |
| Kijkunasathian, C | 1 |
| Woratanarat, P | 1 |
| Saengpetch, N | 1 |
| Mucsi, AD | 1 |
| Ng, G | 1 |
| Martinon, F | 1 |
| Nagar, S | 1 |
| Hoffman, HM | 1 |
| Scott, P | 2 |
| Mueller, JL | 1 |
| Misaghi, A | 1 |
| Murphy, A | 1 |
| Valenzuela, DM | 1 |
| Fransen, J | 1 |
| Metyas, S | 1 |
| Rouman, H | 1 |
| Arkfeld, DG | 1 |
| Mylona, E | 1 |
| Koenders, MI | 1 |
| Malireddi, RK | 1 |
| Oosting, M | 1 |
| Stienstra, R | 1 |
| van de Veerdonk, FL | 1 |
| Stalenhoef, AF | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Kanneganti, TD | 1 |
| van der Meer, JW | 1 |
| Zadaka, A | 1 |
| Gioe, T | 1 |
| Gertner, E | 1 |
| Zychowicz, ME | 1 |
| Pope, RS | 1 |
| Graser, E | 1 |
| Derakhshan, N | 1 |
| Derakhshan, D | 1 |
| Basiratnia, M | 1 |
| Fallahzadeh, MH | 1 |
| Hashemi, G | 1 |
| Derakhshan, A | 1 |
| Montero-Melendez, T | 1 |
| Patel, HB | 1 |
| Perretti, M | 3 |
| GUTMAN, AB | 2 |
| YÜ, TF | 2 |
| Rim, PC | 1 |
| Rossman, MG | 1 |
| Wen, SL | 1 |
| Liu, YJ | 1 |
| Yin, HL | 1 |
| Xiao, J | 1 |
| Zhu, HY | 1 |
| Xue, JT | 1 |
| Ye, LM | 1 |
| Ponce, L | 1 |
| Arjona, M | 1 |
| Blanco, G | 1 |
| Alvarez, S | 1 |
| Arcila, E | 1 |
| Ortega, A | 1 |
| Nuñez, D | 1 |
| Verzura, J | 1 |
| Tovar, R | 1 |
| Bethencourt, S | 1 |
| Riera, R | 1 |
| Mora-Orta, S | 1 |
| Corado, J | 1 |
| Li, KJ | 1 |
| Wu, CH | 1 |
| Wu, PC | 1 |
| Stamp, LK | 1 |
| Barclay, ML | 1 |
| O'Donnell, JL | 1 |
| Drake, J | 1 |
| Frampton, C | 1 |
| Chapman, PT | 1 |
| Müller-Ladner, U | 1 |
| Panzner, I | 1 |
| Kriegsmann, J | 1 |
| Lange, U | 1 |
| Manger, B | 1 |
| Lell, M | 1 |
| Wacker, J | 1 |
| Rech, J | 1 |
| Gilliland, WR | 2 |
| So, MW | 1 |
| Lee, SG | 1 |
| Leiszler, M | 1 |
| Poddar, S | 1 |
| Fletcher, A | 1 |
| Gonzalez, EB | 1 |
| Shaw, OM | 1 |
| Malawista, SE | 1 |
| de Boisfleury, AC | 1 |
| Naccache, PH | 2 |
| Salter, DM | 1 |
| Yao, L | 1 |
| Marson, P | 1 |
| Pasero, G | 1 |
| Busso, N | 1 |
| De Angelis, R | 1 |
| Peñaranda-Parada, E | 1 |
| Bejarano, NS | 1 |
| Mejía, J | 1 |
| Forero, JA | 1 |
| Rondón, F | 1 |
| Bacaret, W | 1 |
| Iglesias-Gamarra, A | 1 |
| Konatalapalli, RM | 1 |
| Lumezanu, E | 1 |
| Jelinek, JS | 1 |
| Murphey, MD | 1 |
| Weinstein, A | 1 |
| Forbess, LJ | 1 |
| Fields, TR | 1 |
| Pereira de Resende, ML | 1 |
| Grabe-Guimarães, A | 1 |
| de Souza Filho, JD | 1 |
| Zhu, M | 1 |
| Tao, Y | 1 |
| Füessl, HS | 1 |
| Krüger, K | 1 |
| Perez-Ruiz, F | 3 |
| Herrero-Beites, AM | 1 |
| Fröhlich, JK | 1 |
| Cabreira, TN | 1 |
| Froeder, AL | 1 |
| Bochi, GV | 1 |
| Moresco, RN | 1 |
| Athayde, ML | 1 |
| Shmerling, RH | 1 |
| Houtman, PM | 1 |
| Urano, W | 1 |
| Tsutani, H | 1 |
| Nakajima, H | 1 |
| Matsuda, Y | 1 |
| Hara, M | 1 |
| Kamatani, N | 3 |
| Getting, SJ | 2 |
| Christian, HC | 1 |
| Flower, RJ | 1 |
| Tashiro, S | 1 |
| Sugita, T | 1 |
| Nakamura, S | 1 |
| Kurata, Y | 1 |
| Akahoshi, T | 3 |
| Namai, R | 1 |
| Murakami, Y | 2 |
| Watanabe, M | 1 |
| Matsui, T | 1 |
| Nishimura, A | 1 |
| Kitasato, H | 2 |
| Kameya, T | 1 |
| Kondo, H | 2 |
| Feher, MD | 1 |
| Hepburn, AL | 1 |
| Hogarth, MB | 1 |
| Ball, SG | 1 |
| Kaye, SA | 1 |
| Yamanouchi, T | 1 |
| Liu, CS | 1 |
| Li, TC | 1 |
| Lin, CC | 2 |
| Levine, N | 1 |
| Rull, M | 1 |
| Clayburne, G | 3 |
| Sieck, M | 1 |
| Schumacher, HR | 6 |
| Hsieh, MS | 2 |
| Ho, HC | 2 |
| Chou, DT | 2 |
| Pan, S | 1 |
| Liang, YC | 1 |
| Hsieh, TY | 1 |
| Lan, JL | 1 |
| Tsai, SH | 2 |
| Ryckman, C | 1 |
| McColl, SR | 1 |
| Vandal, K | 1 |
| de Médicis, R | 1 |
| Lussier, A | 1 |
| Poubelle, PE | 1 |
| Tessier, PA | 1 |
| Yu, KH | 1 |
| TALBOTT, JH | 2 |
| BALLABIO, CB | 1 |
| AMIRA, A | 1 |
| DIOGUARDI, N | 1 |
| LASTER, L | 1 |
| MULLER, AF | 1 |
| MARSON, FG | 1 |
| ARONOFF, A | 1 |
| BARKUM, H | 1 |
| BARCELO, P | 1 |
| WYNGAARDEN, JB | 1 |
| MCCARTY, DJ | 2 |
| MUSTARD, JF | 1 |
| MURPHY, EA | 1 |
| OGRYZLO, MA | 1 |
| SMYTHE, HA | 1 |
| ITO, H | 1 |
| OKAZAKI, M | 1 |
| AKAOKA, I | 1 |
| KOYAMA, S | 1 |
| ISHMAEL, WK | 1 |
| OWENS, JN | 1 |
| PAYNE, RW | 1 |
| HONICK, MD | 1 |
| KELLERMEYER, RW | 1 |
| BRECKENRIDGE, RT | 1 |
| BORRACHERO, J | 1 |
| SANCHEZMDEL, C | 1 |
| MONTERO, M | 1 |
| BERMEJILLO, F | 1 |
| VELAYOS, EE | 1 |
| SMYTH, CJ | 1 |
| MORRIS, JB | 1 |
| Hayashi, I | 1 |
| Endo, H | 1 |
| Hashimoto, A | 1 |
| Kono, S | 1 |
| Kawai, S | 1 |
| Inoue, M | 1 |
| Sukitawut, W | 1 |
| Wichainun, R | 1 |
| Shoji, A | 1 |
| Ma, JY | 1 |
| Liu, YZ | 1 |
| Klein, MJ | 1 |
| Stahl, RE | 1 |
| Sanchez, MA | 1 |
| López Jiménez, M | 2 |
| García Puig, J | 1 |
| Kamimura, T | 1 |
| Hatakeyama, M | 1 |
| Okazaki, H | 1 |
| Minota, S | 1 |
| Jaramillo, M | 1 |
| Godbout, M | 1 |
| Olivier, M | 1 |
| Vock, P | 1 |
| Bonel, H | 1 |
| Villiger, PM | 1 |
| Ma, X | 1 |
| Liu, YH | 1 |
| Ueo, T | 1 |
| Kashima, K | 1 |
| Daa, T | 1 |
| Kashima, N | 1 |
| Tsuji, K | 1 |
| Hisaoka, M | 1 |
| Yokoyama, S | 1 |
| Iacobellis, G | 2 |
| Ji, W | 1 |
| Tan, WF | 1 |
| Chang, HR | 1 |
| Lai, CC | 1 |
| Lian, JD | 1 |
| Wang, CJ | 1 |
| Akkasilpa, S | 1 |
| Avihingsanon, Y | 1 |
| Wonchinsri, J | 1 |
| Kobayashi, K | 1 |
| Deie, M | 1 |
| Okuhara, A | 1 |
| Adachi, N | 1 |
| Yasumoto, M | 1 |
| Ochi, M | 1 |
| Chu, YC | 1 |
| Hsieh, YY | 1 |
| Sydlaske, A | 1 |
| Rose, DM | 1 |
| Nalbant, S | 1 |
| Chen, LX | 1 |
| Sieck, MS | 1 |
| Choy, G | 1 |
| Lo, WR | 1 |
| Broocker, G | 1 |
| Grossniklaus, HE | 1 |
| Inokuchi, T | 1 |
| Moriwaki, Y | 2 |
| Tsutsui, H | 1 |
| Yamamoto, A | 1 |
| Takahashi, S | 2 |
| Tsutsumi, Z | 2 |
| Ka, T | 1 |
| Nakanishi, K | 1 |
| Yamamoto, T | 2 |
| Ellman, MH | 1 |
| Becker, MA | 1 |
| Nuki, G | 2 |
| Simkin, PA | 1 |
| Cronstein, BN | 1 |
| Alappatt, C | 1 |
| Schumacher, R | 1 |
| Pouye, A | 1 |
| Fall, S | 1 |
| Diallo, S | 1 |
| Ndongo, S | 1 |
| Leye, Y | 1 |
| Seck, SM | 1 |
| Leye, A | 1 |
| Ka, MM | 1 |
| Niang, A | 1 |
| Moreira Diop, T | 1 |
| Zou, R | 2 |
| Zhang, HX | 2 |
| Zhang, TF | 2 |
| Atxotegi, J | 1 |
| Hernando, I | 1 |
| Calabozo, M | 2 |
| Nolla, JM | 1 |
| Finley, JM | 1 |
| Lam, CW | 1 |
| Grieco, P | 1 |
| Varalakshmi, P | 1 |
| Schueller-Weidekamm, C | 1 |
| Schueller, G | 1 |
| Weber, M | 1 |
| Kainberger, F | 1 |
| So, A | 2 |
| De Smedt, T | 1 |
| Revaz, S | 1 |
| Tschopp, J | 2 |
| Wise, CM | 3 |
| Justiniano, M | 1 |
| Colmegna, I | 1 |
| Cuchacovich, R | 1 |
| Espinoza, LR | 1 |
| Jung, SM | 1 |
| Kim, H | 1 |
| Kim, M | 1 |
| Pessler, F | 1 |
| Taylor, WJ | 1 |
| Grainger, R | 1 |
| Vázquez-Mellado, J | 1 |
| Alvarado-Romano, V | 1 |
| Burgos-Vargas, R | 1 |
| Jiménez-Vaca, AL | 1 |
| Pozo-Molina, G | 1 |
| Cuevas-Covarrubias, SA | 1 |
| Ju, JH | 1 |
| Kim, HY | 1 |
| Park, SH | 1 |
| Klein, HP | 1 |
| Unger, S | 1 |
| Kopprasch, S | 1 |
| Bornstein, SR | 1 |
| Grässler, J | 1 |
| Grusch, B | 1 |
| Rintelen, B | 1 |
| Leeb, BF | 1 |
| Pope, RM | 1 |
| Abrazhda, D | 1 |
| Andras, L | 1 |
| Van Linthoudt, D | 1 |
| Schuh, A | 1 |
| Hönle, W | 1 |
| Kosmoliaptsis, V | 1 |
| Soni, R | 1 |
| Shi, XD | 1 |
| Li, GC | 1 |
| Qian, ZX | 1 |
| Jin, ZQ | 1 |
| Song, Y | 1 |
| Zhou, HM | 1 |
| Chen, SQ | 1 |
| Sun, BG | 1 |
| Yin, LR | 1 |
| Ye, XY | 1 |
| Chen, ZX | 1 |
| Xie, JY | 1 |
| Li, QX | 1 |
| Guevara-López, U | 1 |
| Ayala-Guerrero, F | 1 |
| Covarrubias-Gómez, A | 1 |
| López-Muñoz, FJ | 1 |
| Torres-González, R | 1 |
| Krishnan, E | 1 |
| Svendsen, K | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Kuller, LH | 1 |
| Cohen, MR | 2 |
| Cohen, EP | 1 |
| Puig, JG | 2 |
| Mateos, FA | 2 |
| Miranda, ME | 1 |
| Torres, RJ | 1 |
| de Miguel, E | 2 |
| Pérez de Ayala, C | 1 |
| Gil, A | 1 |
| Joseph, J | 1 |
| McGrath, H | 1 |
| Maass, A | 1 |
| Mohr, K | 1 |
| Peterseim, U | 1 |
| von Gizycki-Nienhaus, B | 1 |
| Schattenkirchner, M | 1 |
| Meurer, M | 1 |
| Craig, MH | 1 |
| Poole, GV | 1 |
| Hauser, CJ | 1 |
| Wuthrich, DA | 1 |
| Lebowitz, AL | 1 |
| Tarng, DC | 1 |
| Lin, HY | 2 |
| Shyong, ML | 1 |
| Wang, JS | 1 |
| Yang, WC | 1 |
| Huang, TP | 1 |
| Lin, JL | 1 |
| Huang, PT | 1 |
| Vandenberg, MK | 1 |
| Moxley, G | 1 |
| Breitbach, SA | 1 |
| Roberts, WN | 1 |
| Pascual, E | 1 |
| Ifudu, O | 1 |
| Tan, CC | 1 |
| Dulin, AL | 1 |
| Delano, BG | 1 |
| Friedman, EA | 2 |
| Mukhin, NA | 1 |
| Balkarov, IM | 3 |
| Maksimov, NA | 1 |
| Guana, A | 1 |
| Kolbusz, RV | 1 |
| Goldberg, LH | 1 |
| Ferraz, MB | 1 |
| Sato, EI | 1 |
| Nishie, IA | 1 |
| Visioni, RA | 1 |
| Marcus, S | 1 |
| Sahlén, S | 1 |
| Lambert, B | 1 |
| Wettrell, G | 1 |
| Rozenberg, S | 1 |
| Frih, L | 1 |
| Lang, T | 1 |
| Koeger, AC | 1 |
| Cabrol, A | 1 |
| Gandjbackch, I | 1 |
| Bourgeois, P | 1 |
| Perloff, JK | 1 |
| Wakamiya, M | 1 |
| Vaishnav, S | 1 |
| Geske, R | 1 |
| Montgomery, C | 1 |
| Jones, P | 1 |
| Bradley, A | 1 |
| Caskey, CT | 1 |
| Hosoya, T | 2 |
| Ichida, K | 2 |
| Tabe, A | 1 |
| Sakai, O | 2 |
| Tan, N | 1 |
| Lertratanakul, Y | 1 |
| Barr, WG | 1 |
| Matsuda, O | 1 |
| Otsuka, M | 1 |
| Yamada, T | 1 |
| Tomita, K | 1 |
| Marumo, F | 1 |
| Daniels, ID | 1 |
| Boyd, RE | 1 |
| Fred, HL | 1 |
| Tsai, ST | 1 |
| Jacobs, JW | 1 |
| Bijlsma, JW | 1 |
| Gerster, JC | 1 |
| Landry, M | 1 |
| Duvoisin, B | 1 |
| Rappoport, G | 1 |
| Gröbner, W | 1 |
| Zöllner, N | 1 |
| Duprez, TP | 1 |
| Malghem, J | 1 |
| Vande Berg, BC | 1 |
| Noel, HM | 1 |
| Munting, EA | 1 |
| Maldague, BE | 1 |
| Becker-Capeller, D | 1 |
| Helker, K | 1 |
| Weber, MH | 1 |
| Agudelo, CA | 3 |
| Miguélez, R | 1 |
| Palacios, I | 1 |
| Navarro, F | 1 |
| Gutierrez, S | 1 |
| Sanchez-Pernaute, O | 1 |
| Egido, J | 1 |
| González, E | 1 |
| Ohno, I | 1 |
| Lorenzo, JP | 1 |
| Csuka, ME | 1 |
| Derfus, BA | 1 |
| Gotoff, RA | 1 |
| McCarthy, GM | 2 |
| McGill, NW | 1 |
| Scott, JT | 2 |
| Ippoliti, G | 1 |
| Negri, M | 1 |
| Campana, C | 1 |
| Vigano, M | 1 |
| Margalit, A | 1 |
| Duffin, KL | 1 |
| Shaffer, AF | 1 |
| Gregory, SA | 1 |
| Isakson, PC | 1 |
| King, JC | 1 |
| Nicholas, C | 1 |
| Baker, DG | 1 |
| Fam, AG | 2 |
| Reis, MD | 1 |
| Szalai, JP | 1 |
| Peichl, P | 1 |
| Pietschmann, P | 1 |
| Pöllmann, G | 1 |
| Kullich, W | 1 |
| Klein, G | 1 |
| De Clerck, LS | 1 |
| Mooraki, A | 1 |
| Bastani, B | 1 |
| Reiter, S | 1 |
| Engelleiter, R | 1 |
| Proske, H | 1 |
| Müller, A | 1 |
| van der Woude, FJ | 1 |
| Duley, JA | 1 |
| Simmonds, HA | 1 |
| Wylie, LM | 1 |
| Gentle, MJ | 2 |
| Duró, JC | 1 |
| Alonso-Ruiz, A | 1 |
| Herrero-Beites, A | 1 |
| Mader, R | 2 |
| Chazerain, P | 1 |
| Ziza, JM | 1 |
| Hoeper, MM | 1 |
| Hohlfeld, JM | 1 |
| Fabel, H | 1 |
| Hocking, PM | 1 |
| Bernard, R | 1 |
| Dunn, LN | 1 |
| Bruin-Weller, MS | 1 |
| Van Vloten, WA | 1 |
| Van Velde, JI | 1 |
| Kaye, PV | 1 |
| Dreyer, MD | 1 |
| Johnson, JR | 1 |
| Zborovskiĭ, AB | 1 |
| Stazharov, MIu | 1 |
| Martem'ianov, VF | 1 |
| Yagnik, DR | 1 |
| Hillyer, P | 1 |
| Marshall, D | 1 |
| Smythe, CD | 1 |
| Krausz, T | 1 |
| Haskard, DO | 1 |
| Landis, RC | 1 |
| Folpe, AL | 1 |
| Johnston, CA | 1 |
| Weiss, SW | 1 |
| Harris, M | 1 |
| Bryant, LR | 1 |
| Danaher, P | 1 |
| Alloway, J | 1 |
| Yoshii, M | 1 |
| Yoshimatsu, T | 1 |
| Miyata, A | 1 |
| Murata, A | 1 |
| Nutahara, K | 1 |
| Higashihara, E | 1 |
| van den Bosch, F | 1 |
| Baeten, D | 1 |
| Kruithof, E | 1 |
| de Keyser, F | 1 |
| Veys, EM | 1 |
| Revelo, MP | 1 |
| Staffeld, C | 1 |
| Copley, JB | 1 |
| Fogo, AB | 1 |
| Nuño Mateo, FJ | 1 |
| Noval Menéndez, J | 1 |
| Mazorra Iraculis, M | 1 |
| Campoamor Serrano, M | 1 |
| Hada, T | 1 |
| Boye, T | 1 |
| Guennoc, B | 1 |
| Carsuzaa, F | 1 |
| Kane, D | 1 |
| Sturrock, R | 1 |
| Wortmann, RL | 2 |
| Mituszova, M | 1 |
| Judák, A | 1 |
| Poór, G | 1 |
| Gyódi, E | 1 |
| Stenszky, V | 1 |
| Leong, KH | 1 |
| Feng, PH | 1 |
| Rühle, H | 1 |
| Gast, LF | 1 |
| Ogawa, T | 1 |
| Fujise, Y | 1 |
| Shibata, S | 1 |
| Abiru, M | 1 |
| Takigami, Y | 1 |
| Miura, T | 1 |
| Kikuchi, K | 1 |
| Fukazawa, Y | 1 |
| Iimura, O | 1 |
| Pons, M | 1 |
| del Blanco, J | 1 |
| Juanola, X | 1 |
| Miquel Nolla, J | 1 |
| Miranda, E | 1 |
| Romera, NM | 1 |
| Espinosa, A | 1 |
| Gijón, J | 1 |
| Burack, DA | 1 |
| Griffith, BP | 1 |
| Thompson, ME | 1 |
| Kahl, LE | 1 |
| Høieggen, A | 1 |
| Adam, RF | 1 |
| Loynes, RD | 1 |
| Kaiser, BA | 1 |
| Mochon, M | 1 |
| de Chadarévian, JP | 1 |
| Barthelemy, CR | 1 |
| Veum, JA | 1 |
| Colomé Pavón, JA | 1 |
| Furió Bacete, V | 1 |
| González Muñoz, MA | 1 |
| Solache, I | 1 |
| Hall, S | 1 |
| Yokota, N | 1 |
| Yamamoto, Y | 1 |
| Fujimoto, S | 1 |
| Eto, T | 1 |
| Tanaka, K | 1 |
| Noordzij, TC | 1 |
| Leunissen, KM | 1 |
| Van Hooff, JP | 1 |
| Gresser, U | 1 |
| Küng, EE | 1 |
| Glauser, T | 1 |
| Staessen, J | 1 |
| Stuart, RA | 1 |
| Gow, PJ | 1 |
| Bellamy, N | 2 |
| Campbell, J | 2 |
| Grigor, R | 1 |
| Zachariae, C | 1 |
| Santoro, D | 1 |
| Martin, J | 1 |
| Peveri, P | 1 |
| Matsushima, K | 1 |
| Leventhal, LJ | 1 |
| Levin, RW | 1 |
| Bomalaski, JS | 1 |
| Lindusková, M | 1 |
| Vykydal, M | 1 |
| Farge, D | 1 |
| Liote, F | 1 |
| Guillemain, R | 1 |
| Vulser, C | 1 |
| Amrein, C | 1 |
| Couetil, JP | 1 |
| Carpentier, A | 1 |
| Singh, YN | 1 |
| Malaviya, AN | 1 |
| Chaudhary, K | 1 |
| Tripathy, S | 1 |
| Snyder, FF | 1 |
| Joyce, JE | 1 |
| Carter-Edwards, T | 1 |
| Joshi, R | 1 |
| Rylance, HL | 1 |
| Wallace, RC | 1 |
| Burt, HM | 1 |
| Jackson, JK | 1 |
| Rowell, J | 1 |
| Hashizume, K | 1 |
| Sasano, M | 1 |
| Goto, M | 1 |
| Miyasaka, N | 1 |
| Nishioka, K | 1 |
| Anna, T | 1 |
| Gabriella, M | 1 |
| Roberto, M | 1 |
| Bull, PW | 1 |
| Rocher, LL | 1 |
| McQuillan, MA | 1 |
| Schmaltz, S | 1 |
| Palella, TD | 1 |
| Fox, IH | 1 |
| Diamond, HS | 1 |
| Ferreira, A | 1 |
| Silva Júnior, BA | 1 |
| Braga, FM | 1 |
| Gargiulo, NM | 1 |
| Stávale, JN | 1 |
| Lally, EV | 1 |
| Zimmermann, B | 1 |
| Ho, G | 1 |
| Kaplan, SR | 1 |
| Anderson, CJ | 1 |
| Cannon, GW | 1 |
| Andrews, JM | 1 |
| Brooks, PM | 1 |
| Emmerson, BT | 1 |
| Gilbert, JR | 1 |
| McCredie, M | 1 |
| Ginsberg, MH | 1 |
| Auvergne, B | 1 |
| Lioté, R | 1 |
| Roucoulès, J | 1 |
| Kuntz, D | 1 |
| Maksimov, NM | 1 |
| Aleksandrovskaia, TN | 1 |
| Poliantseva, LR | 1 |
| Menghini, S | 1 |
| Della Corte, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Open-Label [OL])[NCT03635957] | Phase 4 | 14 participants (Actual) | Interventional | 2018-09-26 | Completed | ||
| Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration[NCT03038386] | 100 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | |||
| Pragmatic, Randomized, Multicenter, Double-blind, Controlled, Clinical Trial of Prednisolone Versus Colchicine for Acute Gout in Primary Care[NCT05698680] | Phase 4 | 314 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome[NCT01654276] | Phase 4 | 24 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Novel Complex Radiodiagnostics of Peripherial Arthropathies[NCT05657847] | 500 participants (Anticipated) | Observational | 2022-03-07 | Recruiting | |||
| ACTH vs Betamethasone for the Treatment of Acute Gout in Hospitalized Patients: A Randomized, Open Label, Comparative Study[NCT04306653] | 60 participants (Anticipated) | Interventional | 2018-01-05 | Recruiting | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout[NCT02600780] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease: An Open Label Trial[NCT00459225] | 0 participants (Actual) | Interventional | 2007-04-30 | Withdrawn (stopped due to Difficulty recruiting subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum uric acid (sUA < 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Serum uric acid (sUA < 5 mg/dL) responders are defined as participants achieving and maintaining sUA < 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Serum uric acid (sUA < 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is < 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6. (NCT03635957)
Timeframe: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion. (NCT03635957)
Timeframe: Month 3 (Weeks 10, 12, and 14)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
Serum uric acid (sUA < 6 mg/dL) responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24. (NCT03635957)
Timeframe: Month 6 (Weeks 20, 22, and 24)
| Intervention | percentage of participants (Number) |
|---|---|
| Pegloticase With Methotrexate (MTX) | 78.6 |
The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis. (NCT03635957)
Timeframe: Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52
| Intervention | mg/dL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Week 14 - pre-infusion | Change at Week 14 - post-infusion | Change at Week 24 - pre-infusion | Change at Week 24 - post-infusion | Change at Week 36 - pre-infusion | Change at Week 36 - post-infusion | Change at Week 52 | |
| Pegloticase With Methotrexate (MTX) | -9.27 | -9.31 | -9.27 | -9.48 | -8.13 | -9.41 | -8.15 |
Diastolic BP by ambulatory blood pressure monitor. (NCT01654276)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Gout and Hyperuricemia | 75 |
Systolic BP by ambulatory blood pressure monitor. (NCT01654276)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| Gout and Hyperuricemia | 126 |
(NCT01654276)
Timeframe: 6 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Gout and Hyperuricemia | 33.4 |
(NCT01654276)
Timeframe: 6 months
| Intervention | % of serum uric acid excreted in urine (Mean) |
|---|---|
| Gout and Hyperuricemia | 0.04 |
(NCT01654276)
Timeframe: 6 months
| Intervention | Homeostatic model assessment for Insulin (Mean) |
|---|---|
| Gout and Hyperuricemia | 1.86 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 0.98 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 107 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 49 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mU/L (Mean) |
|---|---|
| Gout and Hyperuricemia | 14 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 175 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 4.4 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 196 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 1332 |
(NCT01654276)
Timeframe: 6 months
| Intervention | pH (Mean) |
|---|---|
| Gout and Hyperuricemia | 5.58 |
(NCT01654276)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| Gout and Hyperuricemia | 208 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
107 reviews available for uric acid and Arthritis, Gouty
| Article | Year |
|---|---|
Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Ultrasonography; Uric Acid | 2022 |
[Research progress on anti-hyperuricemia effects and mechanisms of Chinese medicines based on regulation of intestinal flora and metabolites].
Topics: Arthritis, Gouty; China; Gastrointestinal Microbiome; Humans; Hyperuricemia; Uric Acid | 2021 |
Effects and underlying mechanisms of food polyphenols in treating gouty arthritis: A review on nutritional intake and joint health.
Topics: Arthritis, Gouty; Eating; Humans; NLR Family, Pyrin Domain-Containing 3 Protein; Polyphenols; Qualit | 2022 |
Does seasonality of the microbiota contribute to the seasonality of acute gout flare?
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Microbiota; Symptom Flare Up; Uric | 2022 |
Management and Cure of Gouty Arthritis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2022 |
Erosive Tophaceous Gouty Arthropathy of the Hand: A Case Report.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Skin Abnormalities; Uric Acid | 2022 |
Dual-Energy Computed Tomography Has Additional Prognostic Value Over Clinical Measures in Gout Including Tophi: A Systematic Literature Review.
Topics: Arthritis, Gouty; Gout; Humans; Prognosis; Prospective Studies; Reproducibility of Results; Tomograp | 2022 |
Recent Insights Into the Role of Macrophages in Acute Gout.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Macrophages; Mice; TRPV Cation Channels; | 2022 |
Role of microRNA alternation in the pathogenesis of gouty arthritis.
Topics: Arthritis, Gouty; Gout; Humans; MicroRNAs; Uric Acid | 2022 |
Gout and Diet: A Comprehensive Review of Mechanisms and Management.
Topics: Arthritis, Gouty; Diet; Gout; Humans; Inflammation; Uric Acid | 2022 |
Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis.
Topics: Allopurinol; Animals; Arthritis, Gouty; Nanoparticles; Uric Acid | 2023 |
A review on gout: Looking back and looking ahead.
Topics: Arthritis, Gouty; Extracellular Traps; Glucose Transport Proteins, Facilitative; Gout; Humans; Infla | 2023 |
Metabolic Regulation of Immune Response and Tissue Remodeling in Gouty Arthritis (Review).
Topics: Arthritis, Gouty; Humans; Immunity; Uric Acid | 2023 |
Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Pain; Uric Acid | 2023 |
Immune and inflammatory mechanisms and therapeutic targets of gout: An update.
Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Inflammasomes; Inflammation; Macrophages; Uric Acid | 2023 |
Herbal medicine for external use in acute gouty arthritis: A PRISMA-compliant systematic review and meta-analysis.
Topics: Arthritis, Gouty; Herbal Medicine; Humans; Pain; Plant Extracts; Plants, Medicinal; Randomized Contr | 2023 |
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inflammation; Uric Acid | 2023 |
Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cellular Reprogramming; Epigenesis, Genetic; Humans; Hyperuricemia; Immun | 2020 |
Recent approaches to gout drug discovery: an update.
Topics: Allopurinol; Arthritis, Gouty; Drug Discovery; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2020 |
[Gout arthritis: Pathogenesis, diagnostics and treatment].
Topics: Acute Disease; Arthritis, Gouty; Chronic Disease; Humans; Incidence; Uric Acid | 2020 |
Role of T cells in the pathogenesis and treatment of gout.
Topics: Animals; Arthritis, Gouty; Autoimmune Diseases; Cytokines; Humans; Inflammasomes; T-Lymphocyte Subse | 2020 |
Medicinal Plants and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Treatment of Arthritis: A Literature Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Psoriatic; Arthritis, Rheumato | 2022 |
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia.
Topics: Arthritis, Gouty; Carotid Artery Diseases; Gout; Humans; Hyperuricemia; Kidney; Non-alcoholic Fatty | 2017 |
Molecular Pathophysiology of Gout.
Topics: Animals; Arthritis, Gouty; Extracellular Traps; Granuloma; Humans; Inflammation; Uric Acid | 2017 |
What makes gouty inflammation so variable?
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Comorbidity; Forecasting; Humans; Inflammation; | 2017 |
Topics: Acute Disease; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchici | 2017 |
[Progress on diagnosis and treatment of tophus].
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Uric Acid | 2017 |
Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.
Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2018 |
Diagnostic advances in synovial fluid analysis and radiographic identification for crystalline arthritis.
Topics: Arthritis, Gouty; Calcium Pyrophosphate; Humans; Microscopy, Polarization; Reproducibility of Result | 2019 |
Painless gouty tophus in the nasal bridge: A case report and literature review.
Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; C-Reactive Protein; Colchicine; Febuxostat; Gout; Gout | 2019 |
Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia).
Topics: Adult; Antirheumatic Agents; Arthritis; Arthritis, Gouty; Diagnosis, Differential; Diagnostic Errors | 2019 |
Natural products for the management of hyperuricaemia and gout: a review.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Biological Products; Double-Blind M | 2021 |
Current concepts in the treatment of gouty arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2013 |
Acupuncture for gouty arthritis: a concise report of a systematic and meta-analysis approach.
Topics: Acupuncture Therapy; Arthritis, Gouty; Combined Modality Therapy; Humans; Pain Measurement; Randomiz | 2013 |
Joint aspiration and injection and synovial fluid analysis.
Topics: Arthritis, Gouty; Calcium Pyrophosphate; Glucocorticoids; Humans; Injections, Intra-Articular; Knee | 2013 |
Mechanisms of spontaneous resolution of acute gouty inflammation.
Topics: Arthritis, Gouty; Cytokines; Gout; Humans; Inflammation; Joints; Macrophages; Neutrophils; Remission | 2014 |
[New aspects of diagnosis and therapy of gout].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Diagnosis, Differential | 2013 |
Pain and microcrystalline arthritis.
Topics: Animals; Arthritis, Gouty; Calcium Pyrophosphate; Chronic Pain; Crystallization; Dinoprostone; Disea | 2014 |
Managing gout: there's more we can do.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Allopurinol; Anti-Inflammator | 2014 |
Molecular basis of oxidative stress in gouty arthropathy.
Topics: Animals; Antioxidants; Arthritis, Gouty; Crystallization; Cytokines; Humans; Hyperuricemia; Immunity | 2015 |
[Histopathophysiology of Gout].
Topics: Arthritis, Gouty; Humans; Hyperplasia; Interleukin-1; Interleukin-10; Lymphocyte Activation; Lymphoc | 2016 |
Gouty Arthritis: A Review of Acute Management and Prevention.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2016 |
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchi | 2015 |
[Gouty arthritis].
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers; Diagnosis, Differential; Early Diagnosis; Ev | 2016 |
[Gout - new approaches to diagnostics and treatment].
Topics: Arthritis, Gouty; Gout Suppressants; Humans; Radiography; Tomography, X-Ray Computed; Ultrasonograph | 2016 |
Factors modulating the inflammatory response in acute gouty arthritis.
Topics: Arthritis, Gouty; Autophagy; Gastrointestinal Microbiome; Gout; Humans; Hyperuricemia; Inflammasomes | 2017 |
Acute phospholipid microspherule associated arthritis: Is it rare?
Topics: Acute Disease; Arthritis; Arthritis, Gouty; Arthritis, Infectious; Calcium Phosphates; Chondrocalcin | 2017 |
Diagnostic accuracy of dual-energy CT and ultrasound in gouty arthritis : A systematic review.
Topics: Arthritis, Gouty; Humans; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography; | 2017 |
Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome.
Topics: Animals; Arthritis, Gouty; Carrier Proteins; Humans; Immunity, Innate; Inflammation; Intracellular S | 2010 |
Monosodium urate crystals in inflammation and immunity.
Topics: Animals; Arthritis, Gouty; Crystallization; Humans; Immunity, Innate; Inflammation Mediators; Signal | 2010 |
Mechanisms of uric acid crystal-mediated autoinflammation.
Topics: Animals; Arthritis, Gouty; Autoimmunity; Crystallization; Humans; Immunity, Innate; Inflammation Med | 2010 |
Role of melanocortin receptors in the regulation of gouty inflammation.
Topics: Allopurinol; Animals; Arthritis, Gouty; Colchicine; Crystallization; Disease Models, Animal; Gout Su | 2011 |
Uric acid metabolism in normal man and in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Inosine Monophosphate; Male; Quaternary Ammonium Comp | 1965 |
[Mechanisms of gout inflammation].
Topics: Apoptosis; Arthritis, Gouty; Endocytosis; Humans; Immunity, Innate; Inflammation Mediators; Interleu | 2011 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxost | 2011 |
Clinical inquiry. Are serum uric acid levels always elevated in acute gout?
Topics: Acute Disease; Allopurinol; Arthritis, Gouty; Biomarkers; Gout; Gout Suppressants; Humans; Hyperuric | 2011 |
An update on the pathology and clinical management of gouty arthritis.
Topics: Aged; Arthritis, Gouty; Female; Gout Suppressants; Humans; Joints; Male; Middle Aged; Rheumatology; | 2012 |
Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis).
Topics: Arthritis, Gouty; Biomarkers; Chondrocalcinosis; Crystallization; Gout; History, 19th Century; Histo | 2012 |
Metabolism of crystals within the joint.
Topics: Arthritis, Gouty; Biomarkers; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Chondroc | 2012 |
The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis).
Topics: Apoptosis; Arthritis, Gouty; Biomarkers; Calcium Phosphates; Carrier Proteins; Chondrocalcinosis; En | 2012 |
Clinical features of gout.
Topics: Acute Disease; Arthritis, Gouty; Biomarkers; Chronic Disease; Crystallization; Diagnosis, Differenti | 2012 |
The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi.
Topics: Arthritis, Gouty; Crystallization; Diagnosis, Differential; Female; Humans; Joints; Male; Sex Factor | 2012 |
Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Evaluation and treatment of gout as a chronic disease.
Topics: Arthritis, Gouty; Chronic Disease; Disease Progression; Evaluation Studies as Topic; Febuxostat; Fem | 2012 |
Dual-energy computed tomography for gout diagnosis and management.
Topics: Arthritis, Gouty; Drug Monitoring; Gout; Gout Suppressants; Humans; Tomography, X-Ray Computed; Uric | 2013 |
[Gouty arthritis].
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; | 2003 |
Clinical practice. Gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Col | 2003 |
[Uratic gout].
Topics: Arthritis, Gouty; Diet; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2004 |
An update on the treatment options for gout and calcium pyrophosphate deposition.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents | 2005 |
Crystal-induced arthropathies: recent investigative advances.
Topics: Aged; Arthritis, Gouty; Chondrocalcinosis; Humans; Hyperuricemia; Organic Anion Transporters; Uric A | 2006 |
A concise history of gout and hyperuricemia and their treatment.
Topics: Arthritis, Gouty; Gout; History, 19th Century; History, Ancient; Humans; Hyperuricemia; Politics; Un | 2006 |
The inflammatory process of gout and its treatment.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Clinical Trials | 2006 |
Updates in the management of gout.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Ster | 2007 |
Crystal-associated arthritis in the elderly.
Topics: Aged; Allopurinol; Arthritis; Arthritis, Gouty; Calcium Pyrophosphate; Chondrocalcinosis; Comorbidit | 2007 |
Assessment of outcome in clinical trials of gout--a review of current measures.
Topics: Arthritis, Gouty; Female; Gout; Humans; Male; Pain Measurement; Prognosis; Randomized Controlled Tri | 2007 |
The role of interleukin-1 and the inflammasome in gout: implications for therapy.
Topics: Animals; Arthritis, Gouty; Carrier Proteins; Colchicine; Gout; Gout Suppressants; Humans; Hyperurice | 2007 |
[New knowledge on the pathophysiology and therapy of gout].
Topics: Animals; Arthritis, Gouty; Endothelium; Humans; Hyperuricemia; Inflammation Mediators; Interleukin-1 | 2007 |
[Pathological mechanisms of gouty arthritis].
Topics: Acute Disease; Arthritis, Gouty; Carrier Proteins; Crystallization; Humans; Immunity, Innate; Interl | 2008 |
Gout or 'pseudogout': how to differentiate crystal-induced arthropathies.
Topics: Adult; Arthritis, Gouty; Calcium Phosphates; Calcium Pyrophosphate; Chondrocalcinosis; Diagnosis, Di | 1995 |
Hyperuricemia and gout.
Topics: Arthritis, Gouty; Child; Child, Preschool; Crystallization; Gout; Humans; Inflammation; Kidney Trans | 1994 |
Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism.
Topics: Arthritis, Gouty; Cyanosis; Heart Defects, Congenital; Hematologic Diseases; Humans; Kidney; Uric Ac | 1993 |
Gout and mechanisms of crystal-induced inflammation.
Topics: Aged; Animals; Arthritis, Gouty; Female; Gout; Humans; Infant; Kidney; Male; Mice; Uric Acid | 1993 |
Crystal-induced arthritis: an overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Gouty; Calcium Pyrophosphate; Chondro | 1996 |
[Hyperuricemia].
Topics: Adult; Aged; Arthritis, Gouty; Combined Modality Therapy; Cross-Sectional Studies; Female; Germany; | 1996 |
Gouty arthritis and uric acid metabolism.
Topics: Arthritis, Gouty; Humans; Uric Acid | 1996 |
[How to select and use urate lowering agents for hyperuricemia].
Topics: Allopurinol; Arthritis, Gouty; Creatinine; Gout Suppressants; Humans; Uric Acid; Uricosuric Agents | 1996 |
[Treatment for gouty arthritis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cry | 1996 |
[Metabolic disorder of purine nucleotide in patients with renal disease].
Topics: Allopurinol; Arthritis, Gouty; Humans; Kidney Diseases; Purine Nucleotides; Uric Acid | 1996 |
Gout and other crystal arthropathies.
Topics: Aged; Arthritis, Gouty; Calcium Pyrophosphate; Chronic Disease; Crystallization; Female; Gout; Human | 1997 |
[Crystal induced arthritis].
Topics: Arthritis, Gouty; Calcium Phosphates; Calcium Pyrophosphate; Crystallization; Durapatite; Humans; Ur | 1997 |
Gouty arthropathy of the lumbar spine: a case report and review of the literature.
Topics: Adult; Arthritis, Gouty; Diagnosis, Differential; Humans; Laminectomy; Lumbar Vertebrae; Magnetic Re | 1997 |
[Clinical aspects and diagnosis of uric acid arthritis].
Topics: Arthritis, Gouty; Arthrography; Diagnosis, Differential; Humans; Uric Acid | 1997 |
[Therapy of hyperuricemia and gout].
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; C | 1997 |
Crystal arthropathies.
Topics: Acute Disease; Aluminum Compounds; Antacids; Anti-Inflammatory Agents; Arthritis, Gouty; Calcium Oxa | 1997 |
[Treatment of gout].
Topics: Acute Disease; Arthritis, Gouty; Gout; Humans; Uric Acid | 1999 |
[Synovial fluid analysis in gout].
Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid | 1998 |
Gout: diagnosis, pathogenesis, and clinical manifestations.
Topics: Arthritis, Gouty; Gout; Humans; Joints; Risk Factors; Uric Acid | 2001 |
Diagnosing gouty arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Infectious; Arthritis, Rheumat | 2002 |
Gout and hyperuricemia.
Topics: Africa; Arthritis, Gouty; Asia; Cardiovascular Diseases; Diet Therapy; Gout; Humans; Prevalence; Uri | 2002 |
[Hyperuricemia and gout].
Topics: Arthritis, Gouty; Energy Metabolism; Gout; Humans; Kidney Calculi; Myocardial Ischemia; Risk Factors | 1992 |
[Treatment of arthritis urica and hyperuricemia].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Glucocorticoids; Humans; Uric | 1992 |
Drugs to lower uric acid levels. How to avoid misuse in gouty arthritis.
Topics: Arthritis, Gouty; Humans; Uric Acid | 1991 |
Strategies and controversies in the treatment of gout and hyperuricaemia.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Col | 1990 |
Control of crystal-induced arthropathies.
Topics: Acute Disease; Arthritis, Gouty; Calcinosis; Gout Suppressants; Humans; Uric Acid | 1989 |
[Paraparesis due to gout].
Topics: Adult; Arthritis, Gouty; Crystallization; Gout; Humans; Male; Paraparesis, Tropical Spastic; Radiogr | 1989 |
Gout and hyperuricemia.
Topics: Arthritis, Gouty; Humans; Uric Acid | 1989 |
The inflammatory reaction to crystals.
Topics: Antibody Formation; Arthritis, Gouty; Cell Membrane; Crystallization; Crystallography; Gout; Humans; | 1988 |
28 trials available for uric acid and Arthritis, Gouty
| Article | Year |
|---|---|
Influence of intervention treatment by "heat-clearing and diuresis-promoting" prescription on NALP3, an inflammatory factor in acute gouty arthritis.
Topics: Adult; Aged; Arthritis, Gouty; Colchicine; Diuresis; Female; Gout Suppressants; Herbal Medicine; Hot | 2022 |
Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Arthralgia; Arthritis, Gouty; Double-Blind Method; Drugs, Chinese Herbal; Edema; Humans; Medi | 2022 |
Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
Topics: Arthritis, Gouty; Colchicine; Delayed-Action Preparations; Double-Blind Method; Drugs, Chinese Herba | 2022 |
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Topics: Adult; Anaphylaxis; Arthritis, Gouty; Double-Blind Method; Gout; Gout Suppressants; Humans; Methotre | 2023 |
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial.
Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Probenecid; Symptom | 2023 |
New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy.
Topics: Acute Disease; Adult; Allopurinol; Arthritis, Gouty; Biomarkers; C-Reactive Protein; Febuxostat; Fem | 2017 |
Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis.
Topics: Arthritis, Gouty; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Fe | 2018 |
Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients.
Topics: Adolescent; Adult; Arthritis, Gouty; beta-Thalassemia; Cross-Sectional Studies; Female; Glomerular F | 2019 |
[Observation of Qigui Tongfengshu granules in treatment of sixteen cases of gouty arthritis].
Topics: Adult; Aged; Analgesia; Anti-Inflammatory Agents; Arthritis, Gouty; Drugs, Chinese Herbal; Female; H | 2013 |
[Traditional Chinese Medicine Treatment of Gouty Arthritis Based on Syndrome Differentiation].
Topics: Arthritis, Gouty; Blood Urea Nitrogen; Cholesterol; Creatinine; Drug Therapy, Combination; Drugs, Ch | 2015 |
Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.
Topics: Adult; Aged; Arthritis, Gouty; Double-Blind Method; Drugs, Chinese Herbal; Female; Gout; Gout Suppre | 2017 |
Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Double-Blind Method; Female; Humans; Male; Middle Aged; | 2008 |
Treatment of 60 cases of gouty arthritis with modified Simiao Tang.
Topics: Adult; Arthritis, Gouty; C-Reactive Protein; Drugs, Chinese Herbal; Female; Humans; Male; Middle Age | 2008 |
Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout.
Topics: Adult; Arthritis, Gouty; Arthroscopy; Bone Transplantation; Debridement; Follow-Up Studies; Gout Sup | 2009 |
[Observation on therapeutic effect of surrounded needling therapy on acute gouty arthritis].
Topics: Acupuncture Points; Acupuncture Therapy; Acute Disease; Adult; Aged; Allopurinol; Arthritis, Gouty; | 2009 |
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Topics: Acute Disease; Adult; Aged; Alkaline Phosphatase; Allopurinol; Arthritis, Gouty; Chronic Disease; Cr | 2003 |
[Clinical observation on treatment of acute gouty arthritis by tongfengkang].
Topics: Acute Disease; Adolescent; Adult; Aged; Arthritis, Gouty; Drugs, Chinese Herbal; Female; Humans; Mal | 2004 |
Clinical analysis for the acupuncture treatment in 42 cases of gouty renal damage.
Topics: Acupuncture Therapy; Adult; Aged; Arthritis, Gouty; Blood Urea Nitrogen; Creatinine; Female; Gout; H | 2004 |
Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Dicl | 2005 |
Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency.
Topics: Acupuncture Analgesia; Acute Disease; Adult; Aged; Arthritis, Gouty; Electroacupuncture; Female; Hum | 2006 |
Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Arthrography; Blood Sedimentation; C-Reactive Prot | 2007 |
A pilot study of IL-1 inhibition by anakinra in acute gout.
Topics: Adult; Aged; Animals; Arthritis, Gouty; Chemotaxis, Leukocyte; Female; Humans; Interleukin 1 Recepto | 2007 |
[Observation on therapeutic effect of electroacupuncture combined with acupoint-injection on acute gouty arthritis].
Topics: Acupuncture Points; Adult; Aged; Arthritis, Gouty; Electroacupuncture; Female; Humans; Injections; M | 2007 |
Randomized and controlled clinical study of modified prescriptions of Simiao Pill in the treatment of acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Drugs, Chinese Herbal; Female; Humans; Male; Medicine, | 2008 |
[A clinical research of Jiawei simiaosan oral administration combined with the external application of Sihuangshuimi in the treatment of acute gouty arthritis].
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adult; Aged; Arthritis, Gouty; Body Te | 2007 |
[Study on mechanisms of electroacupuncture treatment of acute gouty arthritis].
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Electroacupuncture; Female; Humans; Male; Middle Aged; | 2007 |
Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Aspirin; Cross-O | 2000 |
The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial.
Topics: Aged; Arthritis, Gouty; Blood Glucose; Cardiovascular Diseases; Cholesterol; Creatinine; Drug Therap | 1991 |
488 other studies available for uric acid and Arthritis, Gouty
| Article | Year |
|---|---|
Tetrahydropalmatine attenuates MSU crystal-induced gouty arthritis by inhibiting ROS-mediated NLRP3 inflammasome activation.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Berberine Alkaloids; | 2021 |
Bee Venom Alleviated Edema and Pain in Monosodium Urate Crystals-Induced Gouty Arthritis in Rat by Inhibiting Inflammation.
Topics: Animals; Arthritis, Gouty; Bee Venoms; Disease Models, Animal; Edema; Humans; Inflammation; Male; Pa | 2021 |
Ameliorative Effects of Cardamonin on Monosodium Urate-Induced Gouty Arthritis through Inhibiting NLRP3 Inflammasome Mediation.
Topics: Animals; Arthritis, Gouty; Chalcones; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; | 2021 |
Effects of Gentiopicroside on activation of NLRP3 inflammasome in acute gouty arthritis mice induced by MSU.
Topics: Animals; Arthritis, Gouty; Inflammasomes; Iridoid Glucosides; Mice; NLR Family, Pyrin Domain-Contain | 2022 |
Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice.
Topics: Animals; Arthritis, Gouty; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xanthine Oxi | 2021 |
Pseudo-tumor of the patella due to gout tophi.
Topics: Arthritis, Gouty; Gout; Humans; Neoplasms; Patella; Uric Acid | 2022 |
Mechanosensitive TRPV4 is required for crystal-induced inflammation.
Topics: Adult; Animals; Arthralgia; Arthritis; Arthritis, Gouty; Crystal Arthropathies; Gout; Humans; Inflam | 2021 |
Gout-associated uric acid crystals induce tophi ulcerations and impair wound healing in a novel gouty ulcer model.
Topics: Animals; Arthritis, Gouty; Gout; Rats; Ulcer; Uric Acid; Wound Healing | 2022 |
Bmk9 and Uricase Nanoparticle Complex for the Treatment of Gouty Arthritis and Uric Acid Nephropathy.
Topics: Arthritis, Gouty; Humans; Kidney Diseases; Nanoparticles; Urate Oxidase; Uric Acid | 2021 |
In Vivo Effects of Orally Administered Different Concentrations of Silver Oxide Nanoparticles in Hyperuricemic Mice.
Topics: Allopurinol; Animals; Antioxidants; Arthritis, Gouty; Hyperuricemia; Lipids; Metal Nanoparticles; Mi | 2022 |
Characteristics of monosodium urate crystal deposition in the foot in the different stages of gout by dual-energy computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Disease Progression; Female; Foot; Humans; Male; M | 2022 |
Factors associated with bone erosion in patients with gout: A dual-energy gemstone spectral imaging computed tomography study.
Topics: Arthritis, Gouty; Bone and Bones; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2022 |
The protective effects of S14G-humanin (HNG) against mono-sodium urate (MSU) crystals- induced gouty arthritis.
Topics: Animals; Arthritis, Gouty; Cells, Cultured; Colchicine; Disease Models, Animal; Macrophages; Malondi | 2022 |
Degenerative joint disease induced by repeated intra-articular injections of monosodium urate crystals in rats as investigated by translational imaging.
Topics: Animals; Arthritis, Gouty; Biopsy; Crystallization; Cytokines; Disease Models, Animal; Disease Progr | 2022 |
Screening of Fv Antibodies with Specific Binding Activities to Monosodium Urate and Calcium Pyrophosphate Dihydrate Crystals for the Diagnosis of Gout and Pseudogout.
Topics: Arthritis, Gouty; Binding Sites; Biocompatible Materials; Calcium Pyrophosphate; Escherichia coli; H | 2021 |
IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype.
Topics: Animals; Arthritis, Gouty; Glycogen Synthase Kinase 3 beta; Gout; Humans; Inflammation; Interleukin- | 2022 |
Influence of Pinealectomy and Long-term Melatonin Administration on Inflammation and Oxidative Stress in Experimental Gouty Arthritis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Gout; Inflammation; Melatonin; Ox | 2022 |
Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Pain; Polyethylene Glycols; Trea | 2022 |
MicroRNA-142-3p facilitates inflammatory response by targeting ZEB2 and activating NF-κB signaling in gouty arthritis.
Topics: Animals; Arthritis, Gouty; Male; Mice; Mice, Inbred C57BL; MicroRNAs; NF-kappa B; Uric Acid | 2022 |
Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response.
Topics: Animals; Arthritis, Gouty; Inflammation; Lipopolysaccharides; Macrophages; Mice; Uric Acid | 2022 |
Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission.
Topics: Aftercare; Arthritis, Gouty; Gout; Gout Suppressants; Hospitalization; Humans; Inpatients; Patient D | 2022 |
Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.
Topics: Adult; Arthritis, Gouty; Gout; Humans; Male; Methotrexate; Middle Aged; Tomography, X-Ray Computed; | 2022 |
Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system.
Topics: Arthritis, Gouty; Gout; Humans; Retrospective Studies; Ultrasonography; Uric Acid | 2022 |
Regulation of TRPV1 channel in monosodium urate-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Calcium; Edema; Hyperalgesia; Mice; Pain; Transient Receptor Potential Ch | 2022 |
The correlation of uric acid levels with biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty arthritis.
Topics: Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Male; Triglycerides; Uric Acid; Vitamins | 2022 |
Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt.
Topics: Allopurinol; Animals; Arthritis, Gouty; Cymenes; Hyperuricemia; Inflammation; Male; NF-kappa B; NLR | 2022 |
Association of neutrophil-to-lymphocyte ratio with renal impairment among patients with acute gouty arthritis.
Topics: Adult; Arthritis, Gouty; Biomarkers; C-Reactive Protein; Creatinine; Female; Humans; Lipoproteins, H | 2022 |
What do we know about Toll-Like Receptors Involvement in Gout Arthritis?
Topics: Adaptor Proteins, Signal Transducing; Animals; Arthritis, Gouty; Gout; Humans; Mice; Toll-Like Recep | 2023 |
Research on the effect and underlying molecular mechanism of Cangzhu in the treatment of gouty arthritis.
Topics: Animals; Arthritis, Gouty; Drugs, Chinese Herbal; Molecular Docking Simulation; Protein Interaction | 2022 |
Natural Adrenocorticotropic Hormone (ACTH) Relieves Acute Inflammation in Gout Patients by Changing the Function of Macrophages.
Topics: Adrenocorticotropic Hormone; Animals; Arthritis, Gouty; Dexamethasone; Gout; Humans; Hydrocortisone; | 2022 |
The Anti-hyperuricemia and Anti-inflammatory Effects of Atractylodes Macrocephala in Hyperuricemia and Gouty Arthritis Rat Models.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Atractylodes; Hy | 2023 |
Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis.
Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Macrophages; Mice; NLR Family, Py | 2022 |
The Protective Effects of Neoastilbin on Monosodium Urate Stimulated THP-1-Derived Macrophages and Gouty Arthritis in Mice through NF-κB and NLRP3 Inflammasome Pathways.
Topics: Animals; Arthritis, Gouty; Edema; Flavonoids; Humans; Inflammasomes; Macrophages; Mice; NF-kappa B; | 2022 |
Taxifolin blocks monosodium urate crystal-induced gouty inflammation by regulating phagocytosis and autophagy.
Topics: Arthritis, Gouty; Autophagy; Gout; Humans; Inflammation; Interleukin-1beta; Phagocytosis; Quercetin; | 2022 |
RvD1 disrupts nociceptor neuron and macrophage activation and neuroimmune communication, reducing pain and inflammation in gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Calcitonin Gene-Related Peptide; Docosahexaenoic Acids; Hyperalgesia; Inf | 2022 |
Monosodium urate deposition in the lumbosacral spine of patients with gout compared with non-gout controls: A dual-energy CT study.
Topics: Adult; Arthritis, Gouty; Case-Control Studies; Gout; Humans; Prevalence; Tomography, X-Ray Computed; | 2022 |
Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-κB/NLRP3 and Nrf2 Pathways.
Topics: Animals; Antioxidants; Arthritis, Gouty; Berberine Alkaloids; Cytokines; Inflammation; Interleukin-1 | 2022 |
Effects of Total Saponins from Dioscorea Nipponica Makino on Monosodium Urate-Induced M1-Polarized Macrophages through Arachidonic Acid Signaling Pathway: An in vitro Study.
Topics: Arachidonic Acid; Arthritis, Gouty; Dioscorea; Lipopolysaccharides; Macrophages; RNA, Messenger; Sap | 2023 |
Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout.
Topics: Arthritis, Gouty; Gout; Humans; Inflammasomes; Macrophages; Uric Acid | 2022 |
Aberrant messenger RNA expression in peripheral blood mononuclear cells is associated with gouty arthritis.
Topics: Arthritis, Gouty; Cytokines; Humans; Leukocytes, Mononuclear; Receptors, Cytokine; RNA, Long Noncodi | 2022 |
Calycosin represses AIM2 inflammasome-mediated inflammation and pyroptosis to attenuate monosodium urate-induced gouty arthritis through NF-κB and p62-Keap1 pathways.
Topics: Animals; Arthritis, Gouty; Caspase 1; Disease Models, Animal; DNA-Binding Proteins; Inflammasomes; I | 2022 |
Correlation of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and mean platelet volume (MPV) with gout activity: A monocentric and retrospective study.
Topics: Arthritis, Gouty; C-Reactive Protein; Humans; Lymphocytes; Mean Platelet Volume; Neutrophils; Retros | 2022 |
Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment.
Topics: Arthritis, Gouty; Collagen Type II; Cytokines; Gout; Humans; Inflammation; Matrilin Proteins; Uric A | 2023 |
Gouty sacroiliitis: A case report of an often-overlooked cause of inflammatory back pain.
Topics: Arthritis, Gouty; Back Pain; Gout; Humans; Sacroiliac Joint; Sacroiliitis; Uric Acid | 2023 |
[Mechanism of total flavonoids from Ampelopsis grossedentata against gouty arthritis based on multi-level interactive network and in vivo experimental validation].
Topics: Ampelopsis; Animals; Arthritis, Gouty; Flavonoids; Interleukin-1beta; Interleukin-6; Myeloid Differe | 2022 |
Clinical Features and Risk Factors of Fever in Acute Gouty Arthritis.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Gouty; Betamethasone; Blood Sedimentation; C-Reactive Pro | 2022 |
MicroRNA-486-5p suppresses inflammatory response by targeting FOXO1 in MSU-treated macrophages.
Topics: Arthritis, Gouty; Cytokines; Forkhead Box Protein O1; Humans; Interleukin-8; Macrophages; MicroRNAs; | 2022 |
Anti-Gouty Arthritis and Anti-Hyperuricemia Properties of
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Edema; Hyperuricemia; Interleukin | 2022 |
Corilagin Restrains NLRP3 Inflammasome Activation and Pyroptosis through the ROS/TXNIP/NLRP3 Pathway to Prevent Inflammation.
Topics: Adenine; Adenosine Triphosphate; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Caspase 1 | 2022 |
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Mal | 2023 |
Anethole ameliorates inflammation induced by monosodium urate in an acute gouty arthritis model via inhibiting TLRs/MyD88 pathway.
Topics: Animals; Arthritis, Gouty; Inflammasomes; Inflammation; Interleukin-1beta; Mice; Myeloid Differentia | 2022 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.
Topics: Animals; Arthritis, Gouty; Cathepsin G; Female; Gout; Humans; Hyperuricemia; Inflammation; Interleuk | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
HQL6 serves as a novel P2Y
Topics: Animals; Arthritis, Gouty; Gout; Macrophages; Pyroptosis; Rats; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
An interesting tophus in gingiva.
Topics: Arthritis, Gouty; Gingiva; Gout; Humans; Uric Acid | 2023 |
LncRNA HOTTIP promotes inflammatory response in acute gouty arthritis via miR-101-3p/BRD4 axis.
Topics: Arthritis, Gouty; Cell Cycle Proteins; Humans; Inflammation; MicroRNAs; Nuclear Proteins; RNA, Long | 2023 |
LncRNA HOTTIP promotes inflammatory response in acute gouty arthritis via miR-101-3p/BRD4 axis.
Topics: Arthritis, Gouty; Cell Cycle Proteins; Humans; Inflammation; MicroRNAs; Nuclear Proteins; RNA, Long | 2023 |
LncRNA HOTTIP promotes inflammatory response in acute gouty arthritis via miR-101-3p/BRD4 axis.
Topics: Arthritis, Gouty; Cell Cycle Proteins; Humans; Inflammation; MicroRNAs; Nuclear Proteins; RNA, Long | 2023 |
LncRNA HOTTIP promotes inflammatory response in acute gouty arthritis via miR-101-3p/BRD4 axis.
Topics: Arthritis, Gouty; Cell Cycle Proteins; Humans; Inflammation; MicroRNAs; Nuclear Proteins; RNA, Long | 2023 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
The Therapeutic Effect of Phosphopeptide P140 Attenuates Inflammation Induced by Uric Acid Crystals in Gout Arthritis Mouse Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Mice; Neutrophils; Ph | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Plasma adsorption in refractory chronic gouty arthritis flare: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Cytokines; Gout; Humans; Infl | 2022 |
Overnutrition-induced gout: An immune response to NLRP3 inflammasome dysregulation by XOD activity increased in quail.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Gout; Hyperuricemia; Immunity; Inflammasomes; NLR Fami | 2022 |
The preventive effect of Chinese sumac fruit against monosodium urate-induced gouty arthritis in rats by regulating several inflammatory pathways.
Topics: Animals; Arthritis, Gouty; Fruit; Plant Extracts; Rats; Rhus; Uric Acid | 2023 |
Biomineralized Nanoscavenger Abrogates Proinflammatory Macrophage Polarization and Induces Neutrophil Clearance through Reverse Migration during Gouty Arthritis.
Topics: Animals; Arthritis, Gouty; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Inflammation; Macrop | 2023 |
Relief effects of Laoshan cherry extracts as a dietary supplement against the symptoms of acute gouty arthritis in rats induced by urate crystals.
Topics: Animals; Antioxidants; Arthritis, Gouty; Dietary Supplements; Inflammation; Rats; Uric Acid | 2023 |
Acute gout attacks during the perioperative period and risk factors of recurrence after orthopedic surgery among untreated gout patients.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Orthopedic Procedures; Perioperative Period; Retrospe | 2023 |
P2X7R Mediates the Synergistic Effect of ATP and MSU Crystals to Induce Acute Gouty Arthritis.
Topics: Adenosine Triphosphate; Animals; Arthritis, Gouty; Gout; Inflammasomes; Leukocytes, Mononuclear; NLR | 2023 |
Gout of feet and ankles in different stages: The potentiality of a new semiquantitative DECT scoring system in monitoring urate deposition.
Topics: Ankle; Arthritis, Gouty; Foot; Gout; Humans; Uric Acid | 2023 |
Single-Cell Analysis in Blood Reveals Distinct Immune Cell Profiles in Gouty Arthritis.
Topics: Arthritis, Gouty; Gout; Humans; Monocytes; Single-Cell Analysis; Uric Acid | 2023 |
Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress.
Topics: Animals; Arthritis, Gouty; Caspases; Cytokines; Dimethyl Fumarate; Gout; Inflammasomes; Lipopolysacc | 2023 |
The application of a novel hydrodynamic cavitation device to debride intra-articular monosodium urate crystals.
Topics: Animals; Arthritis, Gouty; Hydrodynamics; Prospective Studies; Rats; Uric Acid | 2023 |
A metabonomic study to explore potential markers of asymptomatic hyperuricemia and acute gouty arthritis.
Topics: Arthritis, Gouty; Biomarkers; Gout; Humans; Hyperuricemia; Metabolomics; Uric Acid | 2023 |
Gouty arthritis involves impairment of autophagic degradation via cathepsin D inactivation-mediated lysosomal dysfunction that promotes apoptosis in macrophages.
Topics: Apoptosis; Arthritis, Gouty; Autophagy; Caspase 3; Cathepsin D; Humans; Lysosomes; Macrophages; Uric | 2023 |
In vivo anti-hyperuricemia and anti-gouty arthritis effects of the ethanol extract from Amomumvillosum Lour.
Topics: Arthritis, Gouty; Ethanol; Humans; Hyperuricemia; Plant Extracts; Uric Acid; Xanthine Oxidase | 2023 |
Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
Topics: Animals; Arthritis, Gouty; ATP-Binding Cassette Transporters; Caco-2 Cells; Gout; Humans; Hyperurice | 2023 |
Phospholipase A2 regulates autophagy in gouty arthritis: proteomic and metabolomic studies.
Topics: Arthritis, Gouty; Humans; Inflammation; Lipids; Metabolomics; Phospholipases A2; Proteomics; Uric Ac | 2023 |
Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Gout; Half-Life; Inflammasomes; Mice; Urate Oxi | 2023 |
Polydatin ameliorates inflammation and oxidative stress associated with MSU-induced gouty arthritis in mice by regulating PPAR-γ and ferritin activation.
Topics: Animals; Arthritis, Gouty; Cytokines; Gout; Humans; Inflammasomes; Inflammation; Mice; Mice, Inbred | 2023 |
Gut microbiota mediated the therapeutic efficiency of Simiao decoction in the treatment of gout arthritis mice.
Topics: Allopurinol; Animals; Arthritis, Gouty; Gastrointestinal Microbiome; Inflammation; Mice; Uric Acid | 2023 |
Comparison of diagnostic efficacy of dual-energy CT and ultrasound in gouty arthritis.
Topics: Adult; Aged; Arthritis, Gouty; Female; Humans; Male; Middle Aged; Retrospective Studies; ROC Curve; | 2023 |
Potential clinical value of serum interleukin-41 levels in patients with acute gout.
Topics: Arthritis, Gouty; C-Reactive Protein; Gout; Humans; Interleukins; Uric Acid | 2023 |
Test characteristics of Raman spectroscopy integrated with polarized light microscopy for the diagnosis of acute gouty arthritis.
Topics: Arthritis, Gouty; Gout; Humans; Microscopy, Polarization; Prospective Studies; Sensitivity and Speci | 2023 |
Modified Simiaowan prevents and treats gouty arthritis via the Nrf2/NLRP3 inflammasome signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Cytokines; Inflammasomes; Mice; N | 2024 |
Targeted treatment of gouty arthritis by biomineralized metallic nanozyme-mediated oxidative stress-mitigating nanotherapy.
Topics: Arthritis, Gouty; Humans; Inflammation; Oxidative Stress; Reactive Oxygen Species; Uric Acid | 2023 |
Influence of contrast medium on tophus detection using dual-energy CT: phantom study and clinical illustration.
Topics: Arthritis, Gouty; Contrast Media; Humans; Iodine; Tomography, X-Ray Computed; Uric Acid | 2023 |
Plasmonic nanomaterials-based flexible strips for the SERS detection of gouty arthritis.
Topics: Arthritis, Gouty; Gold; Humans; Metal Nanoparticles; Nanostructures; Spectrum Analysis, Raman; Uric | 2023 |
Identification of tophi in ultrasound imaging based on transfer learning and clinical practice.
Topics: Arthritis, Gouty; Gout; Humans; Inflammation; Machine Learning; Reproducibility of Results; Tomograp | 2023 |
MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cyclooxygenase 2; Humans; Inflammasomes; Inflam | 2023 |
Autophagy induced by PP121 alleviates MSU crystal-induced acute gouty arthritis via inhibition of the NLRP3 inflammasome.
Topics: Animals; Arthritis, Gouty; Autophagy; Humans; Inflammasomes; Mice; Mice, Inbred C57BL; NLR Family, P | 2023 |
Highly expressed long non-coding RNA SNHG14 activated MSU-induced inflammatory response in acute gout arthritis through targeting miR-223-3p.
Topics: Arthritis, Gouty; Humans; Luciferases; MicroRNAs; RNA, Long Noncoding; Uric Acid | 2023 |
Neutrophil autophagy induced by monosodium urate crystals facilitates neutrophil extracellular traps formation and inflammation remission in gouty arthritis.
Topics: Animals; Arthritis, Gouty; Extracellular Traps; Inflammation; Mice; Neutrophils; Uric Acid | 2023 |
Interleukin-37: associations of plasma levels and genetic variants in gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Interleukin-1beta; Uric Acid | 2023 |
Articular mobilization promotes improvement in functional and inflammatory parameters in a gouty arthritis model.
Topics: Animals; Arthritis, Gouty; Edema; Humans; Inflammation; Male; Pain; Rats; Rats, Wistar; Uric Acid | 2023 |
Mechanism of DaiTongXiao in the treatment of gouty arthritis through the NLRP3 signaling pathway.
Topics: Adenosine Triphosphate; Animals; Arthritis, Gouty; Caspase 1; Edema; Inflammasomes; Interleukin-6; I | 2024 |
New animal model of chronic gout reproduces pathological features of the disease in humans.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Gout Suppressants; Humans; Mice; Uric Acid | 2023 |
Phosphoinositide-3 kinase gamma regulates caspase-1 activation and leukocyte recruitment in acute murine gout.
Topics: Acute Disease; Animals; Arthritis, Gouty; Caspase 1; Cell Adhesion; Cell Movement; Class Ib Phosphat | 2019 |
Role of immune system in development and progress of combined arterial hypertension and gout.
Topics: Arthritis, Gouty; Gout; Humans; Hypertension; Immune System; Male; Middle Aged; Uric Acid | 2019 |
Paeonol ameliorates monosodium urate-induced arthritis in rats through inhibiting nuclear factor-κB-mediated proinflammatory cytokine production.
Topics: Acetophenones; Animals; Arthritis, Gouty; Cytokines; Down-Regulation; Drugs, Chinese Herbal; Gait; G | 2019 |
Antihyperuricemic and anti-gouty arthritis activities of
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Carbon; Drugs, Chinese Herbal; Hyperuricemia; I | 2019 |
LC-MS Analysis of Serum for the Metabolomic Investigation of the Effects of Pulchinenoside b4 Administration in Monosodium Urate Crystal-Induced Gouty Arthritis Rat Model.
Topics: Animals; Arthritis, Gouty; Biomarkers; Chromatography, Liquid; Crystallization; Discriminant Analysi | 2019 |
Association between serum uric acid and chronic kidney disease in patients with hypertension: A multicenter nationwide cross-sectional study.
Topics: Aged; Arthritis, Gouty; Cross-Sectional Studies; Female; Humans; Hypertension; Male; Middle Aged; Pr | 2019 |
The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.
Topics: Aged; Area Under Curve; Arthritis, Gouty; Female; Gout; Humans; Male; Microscopy, Polarization; Midd | 2020 |
Impact of Dual-Energy CT Postprocessing Protocol for the Detection of Gouty Arthritis and Quantification of Tophi in Patients Presenting With Podagra: Comparison With Ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Female; Humans; Male; Metatarsophalangeal Joint; M | 2019 |
Chemical constituents and synergistic anti-gout studies on Eurycoma longifolia and potential mechanisms evaluation based on systemic analysis approach.
Topics: Acute Disease; Alkaloids; Animals; Arthritis, Gouty; Coumarins; Dose-Response Relationship, Drug; Eu | 2019 |
MiR-146a alleviates inflammation of acute gouty arthritis rats through TLR4/MyD88 signal transduction pathway.
Topics: Animals; Ankle Joint; Arthritis, Gouty; Inflammation; Inflammation Mediators; Male; MicroRNAs; Myelo | 2019 |
Inhibition of Triggering Receptor Expressed on Myeloid Cell-1 Alleviates Acute Gouty Inflammation.
Topics: Adult; Arthritis, Gouty; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Humans; Infla | 2019 |
Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate.
Topics: Arthritis, Gouty; Gout; Humans; Uric Acid | 2020 |
Study on the relationship between FFA and gout flare.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Biomarkers; Cholesterol, LDL; Fatty Acids, Noneste | 2020 |
Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
Topics: Aminopyridines; Analgesics; Animals; Arthritis, Experimental; Arthritis, Gouty; Behavior, Animal; Ca | 2020 |
Bilateral Kienböck's disease concomitant with gouty arthritis.
Topics: Adult; Arthritis, Gouty; Diagnosis, Differential; Febuxostat; Gout Suppressants; Humans; Male; Osteo | 2020 |
Total saponin of Dioscorea collettii attenuates MSU crystal‑induced inflammation via inhibiting the activation of the NALP3 inflammasome and caspase‑1 in THP‑1 macrophages.
Topics: Arthritis, Gouty; Caspase 1; Cytokines; Dioscorea; Drugs, Chinese Herbal; Gene Expression Regulation | 2020 |
CD44 Receptor Mediates Urate Crystal Phagocytosis by Macrophages and Regulates Inflammation in A Murine Peritoneal Model of Acute Gout.
Topics: Animals; Arthritis, Gouty; Cell Line; Cells, Cultured; Crystallization; Disease Models, Animal; Huma | 2020 |
Apamin from bee venom suppresses inflammation in a murine model of gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Apamin; Arthritis, Experimental; Arthritis, Gouty; Bee Venoms; Cy | 2020 |
Characteristics of voltage-gated potassium currents in monosodium urate induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Ganglia, Spinal; Male; Mice, Inbred ICR; Neurons; Pain; Potassium Channel | 2020 |
Bone Marrow Gouty Tophi With Plasma Cell Myeloma.
Topics: Aged; Arthritis, Gouty; Bone Marrow; Chromosome Aberrations; Crystallization; Female; Humans; Immuno | 2020 |
1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol (PLAG) Mitigates Monosodium Urate (MSU)-Induced Acute Gouty Inflammation in BALB/c Mice.
Topics: Acute Disease; Animals; Arthritis, Gouty; Cell Movement; Diglycerides; Disease Models, Animal; Human | 2020 |
Spinal Urate Deposition in a Patient With Gout and Nonspecific Low Back Pain: Response to Initiation of Gout Therapy.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Low Back Pain; Uric Acid | 2021 |
Silencing of Gasdermin D by siRNA-Loaded PEI-Chol Lipopolymers Potently Relieves Acute Gouty Arthritis through Inhibiting Pyroptosis.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Cells, Cultured; Cholesterol; Drug Carriers; Gen | 2021 |
Development of a multivariable improvement measure for gout.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Treatment | 2020 |
Astaxanthin attenuates joint inflammation induced by monosodium urate crystals.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cells, Cultured; Chondrocytes; Cyclooxygenase 2 | 2020 |
lncRNA‑MM2P downregulates the production of pro‑inflammatory cytokines in acute gouty arthritis.
Topics: Animals; Arthritis, Gouty; Cytokines; Down-Regulation; Gene Knockdown Techniques; Humans; Lipopolysa | 2020 |
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Topics: Adult; Amides; Antiviral Agents; Arthritis, Gouty; Betacoronavirus; Coronavirus Infections; COVID-19 | 2020 |
Preventive effect of dioscin against monosodium urate-mediated gouty arthritis through inhibiting inflammasome NLRP3 and TLR4/NF-κB signaling pathway activation: an in vivo and in vitro study.
Topics: Animals; Arthritis, Gouty; Diosgenin; Humans; Inflammasomes; Inflammation; Male; Mice; NLR Family, P | 2021 |
Cyr61 Promotes Inflammation of a Gouty Arthritis Model in Rats.
Topics: Animals; Arthritis, Gouty; Blotting, Western; Cysteine-Rich Protein 61; Cytokines; Fluorescent Antib | 2020 |
A novel mouse model of hyperuricemia and gouty nephropathy.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Hyperuricemia; Mice; Uric Acid | 2020 |
Gout of ankle and foot: DECT versus US for crystal detection.
Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2021 |
IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis.
Topics: Animals; Arthritis, Gouty; Female; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Inte | 2020 |
Matrix Metalloproteinase-3 induces proteoglycan degradation in gouty arthritis model.
Topics: Animals; Arthritis, Gouty; Chondrocytes; Cytokines; Disease Models, Animal; Hyperuricemia; Interleuk | 2021 |
Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Topics: Arthritis, Gouty; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Insurance, Health; Japan; | 2021 |
Efficacy of Xixiancao (Herba Siegesbeckiae Orientalis) on interactions between nuclear factor kappa-B and inflammatory cytokines in inflammatory reactions of rat synovial cells induced by sodium urate.
Topics: Animals; Arthritis, Gouty; Drugs, Chinese Herbal; Humans; Interleukin-1beta; Interleukin-8; Male; NF | 2020 |
Association of urate deposition shown by ultrasound and frequent gout attacks.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Ultrasonography; Uric Acid | 2021 |
Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Blood Sedimentation; Bone and Bones; C-Reactive | 2020 |
Rapid disappearance of gouty tophi of the foot by resection of massive gouty tophi of the opposite foot in a patient with hyperuricaemia: a case report.
Topics: Adult; Arthritis, Gouty; Female; Gout; Humans; Hyperuricemia; Uric Acid | 2020 |
Celastrol ameliorates Propionibacterium acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; HEK293 Cells; Humans; Inflammaso | 2021 |
Validation of a Dutch diagnostic rule for gout without joint fluid analysis in patients hospitalized for acute monoarthritis.
Topics: Aged; Arthritis, Gouty; Arthrocentesis; Clinical Decision Rules; Female; France; Hospitalization; Hu | 2021 |
Sesquiterpene lactones from Lychnophora species: Antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Asteraceae; Bridged-R | 2021 |
Modified Simiaowan prevents articular cartilage injury in experimental gouty arthritis by negative regulation of STAT3 pathway.
Topics: Animals; Arthritis, Gouty; Cell Line; Chondrocytes; Cytokines; Disease Models, Animal; Drugs, Chines | 2021 |
Modulations of Na
Topics: Animals; Arthritis, Gouty; Ganglia, Spinal; Hyperalgesia; Male; Mice; Mice, Inbred ICR; NAV1.8 Volta | 2021 |
Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation.
Topics: Animals; Arthritis, Gouty; Cathepsin B; Curcumin; Female; Humans; Inflammasomes; Mice, Inbred C57BL; | 2021 |
Slowly melting the urate snow in joints: Explaining gout attacks to patients.
Topics: Arthritis, Gouty; Biomarkers; Gout Suppressants; Humans; Joints; Remission Induction; Synovial Fluid | 2021 |
Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi.
Topics: Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Ultrasonography; Uric Acid | 2021 |
Tripterine ameliorates monosodium urate crystal-induced gouty arthritis by altering macrophage polarization via the miR-449a/NLRP3 axis.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Gouty; Cytokines; HEK293 Cells; Humans; I | 2021 |
Evaluation of Antioxidant Activity and Histopathological Changes Occurred by the Oral Ingestion of CuO Nanoparticles in Monosodium Urate Crystal-Induced Hyperuricemic BALB/c Mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Copper; Eating; Mice; Mice, Inbred BALB C; Nanoparticles; U | 2022 |
MiR-223-3p and miR-22-3p inhibit monosodium urate-induced gouty inflammation by targeting NLRP3.
Topics: 3' Untranslated Regions; Animals; Arthritis, Gouty; Binding Sites; Disease Models, Animal; Down-Regu | 2021 |
Total glucosides of paeony protects THP-1 macrophages against monosodium urate-induced inflammation via MALAT1/miR-876-5p/NLRP3 signaling cascade in gouty arthritis.
Topics: Arthritis, Gouty; Glucosides; Humans; Inflammation Mediators; Macrophages; MicroRNAs; NLR Family, Py | 2021 |
Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Creatinine; Cytokines; Disease Models, Animal; Disulfiram; Humans; Mice; | 2022 |
Neutrophil extracellular trap clearance by synovial macrophages in gout.
Topics: Arthritis, Gouty; Extracellular Traps; Gout; Humans; Macrophages; Uric Acid | 2021 |
Diagnostic efficacy of joint ultrasonography, dual-energy computed tomography and minimally invasive arthroscopy on knee gouty arthritis, a comparative study.
Topics: Arthritis, Gouty; Arthroscopy; Female; Humans; Knee Joint; Male; Middle Aged; Odds Ratio; Prospectiv | 2021 |
Establishment of a clinical diagnostic model for gouty arthritis based on the serum biochemical profile: A case-control study.
Topics: Adult; Area Under Curve; Arthritis, Gouty; Biomarkers; Blood Sedimentation; Blood Urea Nitrogen; C-R | 2021 |
Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Asymptomatic Diseases; Female; Gout; Humans; Hyperuricemi | 2021 |
Melatonin Alleviates Acute Gouty Inflammation In Vivo and In Vitro.
Topics: Acute Disease; Animals; Arthritis, Gouty; Disease Models, Animal; Gout; Humans; Inflammation; Interl | 2021 |
Gout of feet and ankles in different disease durations: diagnostic value of single-source DECT and evaluation of urate deposition with a novel semi-quantitative DECT scoring system.
Topics: Ankle; Arthritis, Gouty; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2021 |
Anti-Hyperuricemic Effect of Iron Oxide Nanoparticles against Monosodium Urate Crystals Induced Gouty Arthritis in BALB/c Mice.
Topics: Animals; Arthritis, Gouty; Hyperuricemia; Magnetic Iron Oxide Nanoparticles; Mice; Mice, Inbred BALB | 2022 |
Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study.
Topics: Arthritis, Gouty; Follow-Up Studies; Gout; Humans; Tomography, X-Ray Computed; Uric Acid | 2021 |
Minimally Invasive Embedding of Saturated MSU Induces Persistent Gouty Arthritis in Modified Rat Model.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Hyperalgesia; Inflammation; Injections, Intra-Art | 2021 |
Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
Topics: Arthritis, Gouty; Gout; Gout Suppressants; Humans; Longitudinal Studies; Symptom Flare Up; Tomograph | 2022 |
Effects of Stephania hainanensis alkaloids on MSU-induced acute gouty arthritis in mice.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Mice; Stephania; Uric | 2021 |
Chalky urate in a patient with bullous tophi.
Topics: Aged, 80 and over; Arthritis, Gouty; Humans; Male; Skin Diseases, Vesiculobullous; Uric Acid | 2021 |
Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways.
Topics: Animals; Arthritis, Gouty; Gout; Inflammasomes; Interleukin-1beta; Mice; Necrosis; NLR Family, Pyrin | 2022 |
Efficacy of fire needle on acute gouty arthritis induced by monosodium urate in rat.
Topics: Animals; Arthritis, Gouty; Male; Needles; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transductio | 2021 |
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Serum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population.
Topics: Adult; Apolipoprotein A-I; Arthritis, Gouty; Arthritis, Rheumatoid; Asian People; Biomarkers; Blood | 2017 |
Caffeoylquinic acid derivatives rich extract from Gnaphalium pensylvanicum willd. Ameliorates hyperuricemia and acute gouty arthritis in animal model.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Disease Models, Animal; Glucose Transport Prote | 2017 |
Effects of Mollugo pentaphylla extract on monosodium urate crystal-induced gouty arthritis in mice.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Behavior, Animal; Cytokines; Edema; Foot; Male; | 2017 |
TNF-α potentiates uric acid-induced interleukin-1β (IL-1β) secretion in human neutrophils.
Topics: Arthritis, Gouty; Cells, Cultured; Humans; Interleukin-1beta; Neutrophils; Tumor Necrosis Factor-alp | 2018 |
Anti-inflammatory effects of traditional mixed extract of medicinal herbs (MEMH) on monosodium urate crystal-induced gouty arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Cell Line; Chondrocytes; Drugs, Chinese Herbal; Humans; | 2017 |
The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Crystallization; Imatinib Mesylate; Injections, Intraperitoneal; Mice; Mi | 2017 |
Amputation of the first metatarsophalangeal joint due to a giant gouty tophi: A case report.
Topics: Adult; Amputation, Surgical; Arthritis, Gouty; Creatinine; Humans; Male; Metatarsophalangeal Joint; | 2017 |
[Liver metabonomics of acute gouty arthritis treated by Diosocorea nipponica].
Topics: Animals; Arthritis, Gouty; Dioscorea; Liver; Metabolomics; Plant Extracts; Rats; Uric Acid | 2017 |
Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Female; Gout Suppressants; Humans; Male; Middle Aged; Ne | 2018 |
Multiple Chronic Gouty Tophi.
Topics: Aged; Arthritis, Gouty; Humans; Kidney Failure, Chronic; Male; Uric Acid | 2018 |
Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.
Topics: Adult; Aged; Arthritis, Gouty; Clinical Decision-Making; Female; Gout; Humans; Male; Middle Aged; Ne | 2018 |
MicroRNA-302b negatively regulates IL-1β production in response to MSU crystals by targeting IRAK4 and EphA2.
Topics: 3' Untranslated Regions; Animals; Antioxidants; Arthritis, Gouty; Crystallization; Gene Expression R | 2018 |
Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Glucose Transport P | 2018 |
Size matters: observations regarding the sonographic double contour sign in different joint sizes in acute gouty arthritis.
Topics: Arthritis, Gouty; Humans; Male; Reproducibility of Results; Retrospective Studies; Ultrasonography; | 2018 |
A case of severe gouty tophi-induced carpal tunnel syndrome: Operative finding and its outcome.
Topics: Arthritis, Gouty; Carpal Tunnel Syndrome; Diagnosis, Differential; Humans; Uric Acid | 2018 |
Achyranthis bidentatae radix enhanced articular distribution and anti-inflammatory effect of berberine in Sanmiao Wan using an acute gouty arthritis rat model.
Topics: Achyranthes; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; ATP Binding Cassette Transporter, | 2018 |
Inhibition of COX-2/mPGES-1 and 5-LOX in macrophages by leonurine ameliorates monosodium urate crystal-induced inflammation.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arthritis, Gouty; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2018 |
High Levels of Serum Uric Acid, Cystain C and Lipids Concentration and their Clinical Significance in Primary Gouty Arthritis Patients.
Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Cystatin C; Female; Humans; Lipids; Male; Middle Aged; Ur | 2019 |
Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs?
Topics: Adult; Aged; Algorithms; Arthritis, Gouty; False Negative Reactions; Female; Gout; Humans; Male; Mid | 2018 |
miR-155 is dispensable in monosodium urate-induced gouty inflammation in mice.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Gene Knock-In Techniques; Mice; Mice, Inbred C57 | 2018 |
The popliteal groove region: A new target for the detection of monosodium urate crystal deposits in patients with gout. An ultrasound study.
Topics: Aged; Arthritis, Gouty; Cartilage, Articular; Female; Femur; Humans; Imaging, Three-Dimensional; Kne | 2019 |
Changes of Treg/Th17 Ratio in Spleen of Acute Gouty Arthritis Rat Induced by MSU Crystals.
Topics: Animals; Arthritis, Gouty; Cytokines; Inflammation; Lymphocyte Count; Rats; Spleen; T-Lymphocytes, R | 2018 |
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
Topics: Aged; Arthritis, Gouty; Creatinine; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middl | 2018 |
Auricle Pain Due to Tophi.
Topics: Arthritis, Gouty; Ear Auricle; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Pain; Uric | 2019 |
15d-PGJ
Topics: Animals; Antioxidants; Arthritis, Experimental; Arthritis, Gouty; Inflammation; Male; Mice; Mice, In | 2018 |
Metabolic profiling of human plasma reveals the activation of 5-lipoxygenase in the acute attack of gouty arthritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Arachidonate 5-Lipoxygenase; Arthritis, Gouty; Case-Control | 2019 |
Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arthritis, Gouty; Cell Movement; Cell Polari | 2019 |
Detection of uric acid crystal deposition by ultrasonography and dual-energy computed tomography: A cross-sectional study in patients with clinically diagnosed gout.
Topics: Aged; Ankle Joint; Arthritis, Gouty; Cross-Sectional Studies; Crystallization; Female; Foot; Humans; | 2018 |
Renal excretion is a cause of decreased serum uric acid during acute gout.
Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Down-Regulation; Female; Gout; Humans; Hyperuricemia; Kid | 2018 |
Infection of a tophaceous nodule of the wirst and hand.
Topics: Adult; Anti-Bacterial Agents; Arthritis, Gouty; Fingers; Gout; Hand; Humans; Male; Treatment Outcome | 2018 |
[A woman with a white skin lesion of her toe].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chronic Disease; Colchicine; Female | 2018 |
[A case of gout secondary to primary myelofibrosis].
Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibro | 2018 |
Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Gouty; Cell Proliferation | 2019 |
The Long Pentraxin 3 Contributes to Joint Inflammation in Gout by Facilitating the Phagocytosis of Monosodium Urate Crystals.
Topics: Animals; Arthritis, Gouty; C-Reactive Protein; Humans; Interleukin-1beta; Mice; Mice, Inbred C57BL; | 2019 |
Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.
Topics: Antineoplastic Agents; Arthritis, Gouty; Cells, Cultured; Cytokines; Depsipeptides; Gene Expression | 2019 |
Phagocytosis of monosodium urate crystals by human synoviocytes induces inflammation.
Topics: Arthritis, Gouty; Cells, Cultured; Humans; Inflammation; Phagocytosis; Synoviocytes; Uric Acid | 2019 |
Ultrasound and clinical features of hip involvement in patients with gout.
Topics: Aged; Arthritis, Gouty; Biomarkers; Female; Hip Joint; Humans; Male; Middle Aged; Reproducibility of | 2019 |
Leptin Promotes Monosodium Urate Crystal-Induced Inflammation in Human and Murine Models of Gout.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Female; HL-60 Cells; Humans; Inflammation; Leptin | 2019 |
[Effect of ethanolic extract of Polygonum cuspidatum on acute gouty arthritis in mice through NLRP3/ASC/caspase-1 axis].
Topics: Animals; Ankle Joint; Arthritis, Gouty; CARD Signaling Adaptor Proteins; Caspase 1; Fallopia japonic | 2019 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Inhibition of Hyperuricemia and Gouty Arthritis in BALB/c Mice Using Copper Oxide Nanoparticles.
Topics: Administration, Oral; Animals; Arthritis, Gouty; Copper; Disease Models, Animal; Humans; Hyperuricem | 2020 |
Sirt1 ameliorates monosodium urate crystal-induced inflammation by altering macrophage polarization via the PI3K/Akt/STAT6 pathway.
Topics: Acute Disease; Adult; Animals; Arthritis, Experimental; Arthritis, Gouty; Cell Polarity; Gout; Human | 2019 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Monosodium urate crystal interleukin-1β release is dependent on Toll-like receptor 4 and transient receptor potential V1 activation.
Topics: Animals; Arthritis, Gouty; Cells, Cultured; Disease Models, Animal; Female; Interleukin-18; Macropha | 2020 |
Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis.
Topics: Arthritis, Gouty; Cartilage, Articular; Chondrocalcinosis; Gout; Humans; Meniscus; Uric Acid | 2020 |
Development and validation of a quantitative method for estimation of the urate burden in patients with gouty arthritis using dual-energy computed tomography.
Topics: Algorithms; Animals; Arthritis, Gouty; Humans; Male; Phantoms, Imaging; Radiography, Dual-Energy Sca | 2020 |
Hypothermia induced by adenosine 5'-monophosphate attenuates early stage injury in an acute gouty arthritis rat model.
Topics: Animals; Ankle Joint; Arthritis, Gouty; Disease Models, Animal; Hyperuricemia; Hypothermia, Induced; | 2013 |
Curettage as an acceptable treatment for gouty tophi on the ear.
Topics: Arthritis, Gouty; Curettage; Ear Diseases; Ear, External; Humans; Male; Middle Aged; Treatment Outco | 2013 |
[Case presentation--tophaceous gout].
Topics: Aged, 80 and over; Arthritis, Gouty; Drug Therapy, Combination; Febuxostat; Female; Follow-Up Studie | 2012 |
Efficacy of boswellic acid on lysosomal acid hydrolases, lipid peroxidation and anti-oxidant status in gouty arthritic mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Female; Glucuronidase; Hydrolases | 2012 |
Attenuation of gouty arthritis by emodinol in monosodium urate crystal-treated mice.
Topics: Animals; Arthritis, Gouty; Elaeagnaceae; Enzyme-Linked Immunosorbent Assay; Interleukin-1beta; Inter | 2013 |
Therapeutic effect of Rhizoma Dioscoreae Nipponicae on gouty arthritis based on the SDF-1/CXCR 4 and p38 MAPK pathway: an in vivo and in vitro study.
Topics: Animals; Arthritis, Gouty; Chemokine CXCL12; Dioscorea; Diosgenin; Drugs, Chinese Herbal; Fibroblast | 2014 |
Trikatu, a herbal compound that suppresses monosodium urate crystal-induced inflammation in rats, an experimental model for acute gouty arthritis.
Topics: Acute Disease; Alkenes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Female; | 2014 |
Timing of intra-lesion shaving for surgical treatment of chronic tophus.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; C-Reactive Protein; Calculi; Chronic Disease; Fema | 2013 |
Unilateral milia-type intradermal tophi associated with underlying urate subcutaneous deposition: an uncommon cutaneous presentation of gout.
Topics: Arthritis, Gouty; Arthritis, Psoriatic; Female; Humans; Leg; Middle Aged; Skin Diseases; Uric Acid | 2013 |
Pegloticase for treatment of tophaceous polyarticular gout.
Topics: Adult; Arthritis, Gouty; Febuxostat; Gout Suppressants; Humans; Male; Polyethylene Glycols; Thiazole | 2013 |
Transient receptor potential ankyrin 1 receptor stimulation by hydrogen peroxide is critical to trigger pain during monosodium urate-induced inflammation in rodents.
Topics: Acetanilides; Acute Pain; Animals; Arthritis, Gouty; Disease Models, Animal; Hydrogen Peroxide; Infl | 2013 |
Dolichos falcata Klein attenuated the inflammation induced by monosodium urate crystals in vivo and in vitro.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Gouty; Cell Line; Cytokines; Dolichos; Fe | 2013 |
Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Capsules; Cells, Cultu | 2013 |
Suppressive effect of modified Simiaowan on experimental gouty arthritis: an in vivo and in vitro study.
Topics: Acetic Acid; Analgesics; Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Gouty; Cell Surv | 2013 |
Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Calcaneus; Female; Foot; Humans; Hyperuricemia; Ma | 2015 |
Gout in a 15-year-old boy with juvenile idiopathic arthritis: a case study.
Topics: Adolescent; Allopurinol; Ankle Joint; Arthritis, Gouty; Arthritis, Juvenile; Colchicine; Delayed Dia | 2014 |
The effects of gout on left atrial volume remodelling: a prospective echocardiographic study.
Topics: Adult; Aged; Arthritis, Gouty; Atrial Remodeling; Cardiac Volume; Case-Control Studies; Cross-Sectio | 2014 |
Crystal deposition diseases.
Topics: Arthritis, Gouty; Crystallization; Gout Suppressants; Humans; Uric Acid | 2014 |
The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Case-Control Studies; Female; Follow-Up Studies; H | 2014 |
MicroPure imaging for the evaluation of microcalcifications in gouty arthritis involving the first metatarsophalangeal joint: a preliminary study.
Topics: Adult; Aged; Arthritis, Gouty; Calcinosis; Female; Humans; Male; Metatarsophalangeal Joint; Middle A | 2014 |
[82-year-old man with acute coronary syndrome and unclear arthropathy].
Topics: Absorptiometry, Photon; Acute Coronary Syndrome; Aged, 80 and over; Arthritis, Gouty; Comorbidity; C | 2014 |
Clinical factors and treatment outcomes associated with failure in the detection of urate crystal in patients with acute gouty arthritis.
Topics: Acute Disease; Aged; Arthritis, Gouty; Arthroscopy; Biomarkers; Crystallization; False Negative Reac | 2014 |
[Which drugs? Which diet? Treating your gout patient properly].
Topics: Arthritis, Gouty; Combined Modality Therapy; Feeding Behavior; Germany; Gout Suppressants; Humans; L | 2014 |
Methods of assessment of tophus and bone erosions in gout using dual-energy CT: reproducibility analysis.
Topics: Adult; Aged; Aged, 80 and over; Ankle; Arthritis, Gouty; Bone Diseases; C-Reactive Protein; Female; | 2015 |
Contribution of mast cell-derived interleukin-1β to uric acid crystal-induced acute arthritis in mice.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Humans; Immunity, Innate; Inflammation; Interleu | 2014 |
Doliroside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents; Arthritis, Gouty; Carrier Proteins; Caspase 1; Dinop | 2014 |
Increased level of MSU crystal-bound protein apolipoprotein A-I in acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Apolipoprotein A-I; Arthritis, Gouty; Crystallization; Electrophoresis, | 2014 |
A comparative study of serum and synovial fluid levels of uric acid between patients with gout and other arthritides.
Topics: Adult; Aged; Aged, 80 and over; Arthritis; Arthritis, Gouty; Arthritis, Infectious; Arthritis, Rheum | 2014 |
Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Human | 2015 |
The effect of resveratrol on the recurrent attacks of gouty arthritis.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Female; Kidney; Male; Mice; Mice, Inbred C57BL; R | 2016 |
Gouty tophi: here today gone tomorrow.
Topics: Aged, 80 and over; Arthritis, Gouty; Female; Gout Suppressants; Humans; Hyperuricemia; Infusions, In | 2015 |
Effects of extracts of leaves from Sparattosperma leucanthum on hyperuricemia and gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Bignoniaceae; Gout Suppressants; Hyperuricemia; | 2015 |
Lemnalol attenuates mast cell activation and osteoclast activity in a gouty arthritis model.
Topics: Animals; Ankle; Ankle Joint; Anthozoa; Anti-Inflammatory Agents; Arthritis, Gouty; Biological Produc | 2015 |
Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.
Topics: Adult; Antioxidants; Arthritis, Gouty; Butyrates; Carbamates; Crystallization; Cytokines; Enzyme Inh | 2016 |
Gout, tophi and the wonders of NETs.
Topics: Animals; Arthritis, Gouty; Extracellular Traps; Gout; Humans; Inflammation; Uric Acid | 2014 |
Polyarticular Gout Flare Masquerading as Sepsis.
Topics: Arthritis; Arthritis, Gouty; Blood Chemical Analysis; Diagnosis, Differential; Disease Progression; | 2015 |
Gadolinium-enhanced MRI features of acute gouty arthritis on top of chronic gouty involvement in different joints.
Topics: Adult; Ankle; Arthritis, Gouty; Foot; Gadolinium; Humans; Knee; Magnetic Resonance Imaging; Male; Mi | 2015 |
Is the double contour sign specific for gout? Or only for crystal arthritis?
Topics: Arthritis, Gouty; Chondrocalcinosis; Female; Gout; Humans; Male; Uric Acid | 2015 |
Seasonality of gout in Korea: a multicenter study.
Topics: Alcohol Drinking; Arthritis, Gouty; Blood Pressure; Body Mass Index; Comorbidity; Female; Gout Suppr | 2015 |
[Value of dual-energy computed tomography in the diagnosis of gouty arthritis].
Topics: Arthritis, Gouty; Arthritis, Rheumatoid; Color; Diagnosis, Differential; Humans; Hyperuricemia; Spon | 2015 |
Gouty arthritis of the spine in a renal transplant patient: a clinical case report: an unusual presentation of a common disorder.
Topics: Arthritis, Gouty; C-Reactive Protein; Diagnosis, Differential; Fever; Humans; Kidney Transplantation | 2015 |
The metastatic tumor antigen 1-transglutaminase-2 pathway is involved in self-limitation of monosodium urate crystal-induced inflammation by upregulating TGF-β1.
Topics: Animals; Arthritis, Gouty; Cell Line; GTP-Binding Proteins; Histone Deacetylases; Humans; Inflammati | 2015 |
C-type lectin domain family 12, member A: A common denominator in Behçet's syndrome and acute gouty arthritis.
Topics: Acute Disease; Arthritis, Gouty; Behcet Syndrome; Humans; Immunity, Innate; Immunologic Factors; Lec | 2015 |
Effect of sodium alginate addition to resveratrol on acute gouty arthritis.
Topics: Alginates; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Chemokine CXCL10; Colc | 2015 |
Post-streptococcal acute glomerulonephritis complicated by gouty arthritis: a case report.
Topics: Acute Disease; Arthritis, Gouty; Child; Complement C3; Glomerulonephritis; Humans; Male; Metatarsoph | 2015 |
[Time course of changes in the clinical manifestations of gout in men: data of a 7-year retrospective follow-up].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Follow-Up Studies; Gout; Gout Suppressants; Humans; Midd | 2015 |
High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population.
Topics: Adult; Aged; Arthritis, Gouty; Arthritis, Rheumatoid; Asian People; Biomarkers; Blood Sedimentation; | 2015 |
Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis.
Topics: Adult; Aged; Arthritis, Gouty; Biomarkers; Crystallization; Drug Monitoring; Female; Foot Bones; Gou | 2015 |
Therapy: New fusion protein reduces IL-1-mediated inflammation.
Topics: alpha 1-Antitrypsin; Animals; Arthritis, Gouty; Disease Models, Animal; Fatty Acids; Immunoglobulin | 2015 |
Salivary uric acid as a noninvasive biomarker for monitoring the efficacy of urate-lowering therapy in a patient with chronic gouty arthropathy.
Topics: Arthritis, Gouty; Benzbromarone; Biomarkers; Chronic Disease; Feasibility Studies; Humans; Hyperuric | 2015 |
In vivo detection of monosodium urate crystal deposits by Raman spectroscopy-a pilot study.
Topics: Arthritis, Gouty; Humans; Pilot Projects; Reproducibility of Results; Spectrum Analysis, Raman; Uric | 2016 |
Outcome of Treatment in Gouty Arthritis Patients: A Retrospective Study.
Topics: Alcohol Drinking; Allopurinol; Arthritis, Gouty; Benzbromarone; Female; Follow-Up Studies; Gout Supp | 2015 |
Comparison Between Dual-Energy Computed Tomography and Ultrasound in the Diagnosis of Gout of Various Joints.
Topics: Aged; Arthritis, Gouty; Female; Humans; Joints; Male; Middle Aged; Prospective Studies; Tomography, | 2015 |
The Unique Macroscopic Appearance of Gouty Arthritis of the Knee.
Topics: Aged; Arthritis, Gouty; Arthroplasty, Replacement, Knee; Humans; Knee Joint; Male; Uric Acid | 2015 |
IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response.
Topics: Arthritis, Gouty; Humans; Interleukin-1; Interleukin-10; Interleukin-1beta; Interleukin-6; Leukocyte | 2016 |
Genetic analysis of ABCG2 and SLC2A9 gene polymorphisms in gouty arthritis in a Korean population.
Topics: Arthritis, Gouty; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2015 |
Morin, a Bioflavonoid Suppresses Monosodium Urate Crystal-Induced Inflammatory Immune Response in RAW 264.7 Macrophages through the Inhibition of Inflammatory Mediators, Intracellular ROS Levels and NF-κB Activation.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cell Line; Chemokine CCL2; Colchicine; Cyclooxy | 2015 |
Dual-Energy CT in Patients with Suspected Gouty Arthritis: Effects on Treatment Regimen and Clinical Outcome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ar | 2016 |
Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Female; Follow-Up Studies; Humans; Male; Middle Ag | 2016 |
Targeting inflammatory mediators with ferulic acid, a dietary polyphenol, for the suppression of monosodium urate crystal-induced inflammation in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Coumaric Acids; Drug Delivery Systems; Edema; F | 2016 |
SHEsisPlus, a toolset for genetic studies on polyploid species.
Topics: Algorithms; Arthritis, Gouty; China; Computer Simulation; Diploidy; Epistasis, Genetic; Genetic Mark | 2016 |
[Painless new nodules on the thumb].
Topics: Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Hand Deformities, Acquired; Humans; Thumb; | 2016 |
Synovial fluid proteins are required for the induction of interleukin-1β production by monosodium urate crystals.
Topics: Arthritis, Gouty; Case-Control Studies; Cell Line; Enzyme-Linked Immunosorbent Assay; Gout; Humans; | 2016 |
[Extreme gout can get out of hand].
Topics: Arthritis, Gouty; China; Disease Progression; Febuxostat; Germany; Gout Suppressants; Hand Deformiti | 2016 |
Traditional Chinese Medicine Formula "Xiaofeng granules" suppressed gouty arthritis animal models and inhibited the proteoglycan degradation on chondrocytes induced by monosodium urate.
Topics: ADAMTS4 Protein; Animals; Arthritis, Gouty; Cells, Cultured; Chondrocytes; Cytokines; Disease Models | 2016 |
Morin, a dietary bioflavonol suppresses monosodium urate crystal-induced inflammation in an animal model of acute gouty arthritis with reference to NLRP3 inflammasome, hypo-xanthine phospho-ribosyl transferase, and inflammatory mediators.
Topics: Acute Disease; Animals; Antioxidants; Arthritis, Gouty; Cyclooxygenase 2; Cytokines; Diet; Disease M | 2016 |
Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection.
Topics: Area Under Curve; Arthritis, Gouty; Bacterial Infections; Biomarkers; Blood Sedimentation; C-Reactiv | 2016 |
Zisheng Shenqi decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Biomarkers; Cytokines; Disease Mo | 2016 |
Kinsenoside screening with a microfluidic chip attenuates gouty arthritis through inactivating NF-κB signaling in macrophages and protecting endothelial cells.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Crystallization; Culture Media | 2016 |
Nephrolithiasis among male patients with newly diagnosed gout.
Topics: Adult; Arthritis, Gouty; Blood Urea Nitrogen; Creatinine; Humans; Kidney Calculi; Male; Middle Aged; | 2016 |
Risk of acute gout among active smokers: data from nationwide inpatient sample.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Databases, Factual; Female; Gout; Hospitalization; Hum | 2016 |
Efficacy of CoenzymeQ10 in inhibiting monosodium urate crystal-induced inflammation in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Edema; Female; Inflammation; Lipid Peroxidation | 2016 |
Reply to "Neutrophils are not required for resolution of acute gouty arthritis in mice".
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Mice; Neutrophils; Uric Acid | 2016 |
Neutrophils are not required for resolution of acute gouty arthritis in mice.
Topics: Animals; Arthritis, Gouty; Disease Models, Animal; Mice; Neutrophils; Uric Acid | 2016 |
Plasmonic Schirmer Strip for Human Tear-Based Gouty Arthritis Diagnosis Using Surface-Enhanced Raman Scattering.
Topics: Adult; Arthritis, Gouty; Biomarkers; Biosensing Techniques; Cellulose; Gold; Humans; Metal Nanoparti | 2017 |
Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats.
Topics: Alkaloids; Animals; Arthritis, Gouty; Berberine; Carrier Proteins; Female; Inflammation; Isoquinolin | 2017 |
Anti-inflammatory Effect of Total Saponin Fraction from Dioscorea nipponica Makino on Gouty Arthritis and Its Influence on NALP3 Inflammasome.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Crystallization; Dioscorea; Indom | 2019 |
Cubital tunnel syndrome secondary to gouty tophi: A case report.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Cubital Tunnel Syndrome; Decompression, Surgical; Humans | 2017 |
Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzofurans; Depsid | 2008 |
Prednisolone and naproxen both work for pain relief in acute gout.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Clinical Trials as Topic; Double-Blind Method; Female; H | 2008 |
A 31-year-old Army specialist presenting with acute oligoarthritis.
Topics: Acute Disease; Adult; Allopurinol; Arthritis, Gouty; Gout Suppressants; Humans; Male; Military Medic | 2008 |
Sesquiterpene dialdehydes inhibit MSU crystal-induced superoxide production by infiltrating neutrophils in an in vivo model of gouty inflammation.
Topics: Aldehydes; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cells, Cultured; Crystallization; Do | 2009 |
Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Biomarkers; Colchicine; Cytokines; Disease Model | 2009 |
[Atypical gout tophi for differential diagnosis of head and neck tumors : case report and review of the literature].
Topics: Aged; Arthritis, Gouty; Biopsy, Fine-Needle; Diagnosis, Differential; Humans; Magnetic Resonance Ima | 2009 |
[Tophaceous gout with chronic and deforming arthropathy].
Topics: Arthritis, Gouty; Foot Deformities, Acquired; Hand Deformities, Acquired; Humans; Male; Microscopy, | 2010 |
Effects of extracts from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on MSU crystal-induced rats gouty arthritis.
Topics: Animals; Arthritis, Gouty; Crystallization; Cyclopentane Monoterpenes; Dose-Response Relationship, D | 2009 |
Associations of a non-synonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders.
Topics: Adult; Aged; Arthritis, Gouty; Asian People; Black People; Case-Control Studies; Female; Genotype; G | 2010 |
Bursal gouty tophus: fine-needle aspiration cytology intrabursal tophus on FNAC.
Topics: Adult; Arthritis, Gouty; Biopsy, Fine-Needle; Elbow Joint; Humans; Male; Uric Acid | 2010 |
Clinical images: Aggressive gouty arthritis with concurrent involvement of the ankle and cervical spine.
Topics: Administration, Oral; Allopurinol; Ankle; Arthritis, Gouty; Cervical Vertebrae; Drug Therapy, Combin | 2009 |
A case of isolated gouty tophus in a patient without a previous history of gouty arthritis.
Topics: Arthritis, Gouty; Diagnosis, Differential; Gout; Humans; Joint Diseases; Magnetic Resonance Imaging; | 2009 |
Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis.
Topics: Adiposity; Adult; Aged; Arthritis, Gouty; Case-Control Studies; Female; Humans; Insulin Resistance; | 2011 |
[Fever and back pain--a case report of spinal gout].
Topics: Aged; Allopurinol; Arthritis, Gouty; Arthroscopy; Back Pain; Colchicine; Diagnosis, Differential; Dr | 2010 |
Gouty tophi caused limited knee range of motion: a case report.
Topics: Adult; Allopurinol; Arthritis, Gouty; Arthroscopy; Diagnosis, Differential; Gout Suppressants; Human | 2009 |
A role of piperine on monosodium urate crystal-induced inflammation--an experimental model of gouty arthritis.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Gouty; Benzodi | 2011 |
Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice.
Topics: Animals; Arthritis, Gouty; Bone Marrow Cells; Carrier Proteins; Cells, Cultured; Cytokines; Female; | 2010 |
A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis.
Topics: Acute Disease; Arthritis, Gouty; Diagnosis, Differential; Disease Progression; Female; Follow-Up Stu | 2010 |
Pregnancy in a patient with gouty arthritis secondary to pseudo-Bartter syndrome.
Topics: Adult; Arthritis, Gouty; Bartter Syndrome; Biopsy, Fine-Needle; Female; Humans; Laxatives; Pregnancy | 2010 |
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.
Topics: Animals; Apoptosis Regulatory Proteins; Arthritis, Gouty; CARD Signaling Adaptor Proteins; Caspase 1 | 2010 |
Acute crystal-induced arthritis following arthroplasty.
Topics: Aged; Arthritis, Gouty; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Blood Sedimentation; | 2010 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthrit | 2010 |
Gouty arthritis in a 15-year-old girl with Bartter's syndrome.
Topics: Adolescent; Arthritis, Gouty; Bartter Syndrome; Biomarkers; Female; Gout Suppressants; Humans; Hyper | 2010 |
Gout spherules.
Topics: Arthritis, Gouty; Birefringence; Humans; Male; Metacarpophalangeal Joint; Middle Aged; Uric Acid | 2011 |
Effect of acupuncture on rats with acute gouty arthritis inflammation: a metabonomic method for profiling of both urine and plasma metabolic perturbation.
Topics: Acupuncture Therapy; Animals; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease Models | 2011 |
The effect of montelukast in a model of gouty arthritis induced by sodium monourate crystals.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Cell Migration Assays, | 2011 |
Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3.
Topics: Acute Disease; Animals; Arthritis, Gouty; Cells, Cultured; Cytokines; Humans; Inflammation Mediators | 2011 |
Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Chronic Disease; Creatinine; Dose-Res | 2011 |
Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Humans; Middle Aged; Tomography, X-Ray Computed; Uric | 2012 |
Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Topics: Allopurinol; Arthritis, Gouty; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Humans; Male; Oxy | 2011 |
Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
Topics: Acute Disease; Aged; Allopurinol; Arthritis, Gouty; Gout; Gout Suppressants; Humans; Male; Middle Ag | 2011 |
Bradykinin receptor 2 extends inflammatory cell recruitment in a model of acute gouty arthritis.
Topics: Acute Disease; Animals; Arthritis, Gouty; Bradykinin; Bradykinin B2 Receptor Antagonists; Cell Movem | 2011 |
Inflammatory gout: observations over a half-century.
Topics: Animals; Arthritis, Gouty; Crystallization; History, 20th Century; History, 21st Century; Humans; In | 2011 |
Pycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Cells, Cultured; Chondrocytes; Cyclooxygenase 2 | 2012 |
An improved acute gouty arthritis rat model and therapeutic effect of rhizoma Dioscoreae nipponicae on acute gouty arthritis based on the protein-chip methods.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Dioscorea; Disease Models, Anima | 2012 |
Gouty arthritis and panniculitis: extensive involvement of the dermis and severe joint damage.
Topics: Adult; Allopurinol; Anti-Bacterial Agents; Arthritis, Gouty; Biopsy; Bone Cysts; Gout Suppressants; | 2012 |
Correlates of axial gout: a cross-sectional study.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Back Pain; Cross-Sectional Studies; Female; Foot D | 2012 |
Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Ethanol; Flavonoids; Hype | 2012 |
Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat.
Topics: Animals; Ankle Joint; Anti-Inflammatory Agents; Antioxidants; Arthritis, Gouty; Chemokines; Disease | 2012 |
[Attack of gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Gouty; Diagnosis, Diffe | 2012 |
[Therapy of gout. "Uric acid less than 6 mg/dl is the general consensus" (interview by Wiebke Kathmann)].
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Colchicine; Consensus; Gout; Gout Suppressants; Guidelin | 2012 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
Management of gout: a 57-year-old man with a history of podagra, hyperuricemia, and mild renal insufficiency.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Gout | 2012 |
Soft coral-derived lemnalol alleviates monosodium urate-induced gouty arthritis in rats by inhibiting leukocyte infiltration and iNOS, COX-2 and c-Fos protein expression.
Topics: Animals; Anthozoa; Anti-Inflammatory Agents; Arthritis, Gouty; Colchicine; Cyclooxygenase 2; Edema; | 2013 |
[Diagnostic image (100). A man with migrating joint complaints. Tophaceous gout].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Foot Diseases; Humans; Male; Toe Joint; Uric Acid | 2002 |
The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; C-Reactive Protein; Female; Humans; Hydrocortisone; In | 2002 |
Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis.
Topics: Adrenocorticotropic Hormone; Animals; Arthritis, Gouty; Disease Models, Animal; gamma-MSH; Knee Join | 2002 |
Gout tophus in the bipartite patella.
Topics: Adult; Arthritis, Gouty; Biopsy, Needle; Humans; Immunohistochemistry; Knee Joint; Male; Orthopedic | 2002 |
Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals.
Topics: Acute Disease; Animals; Arthritis, Gouty; CD36 Antigens; Crystallization; Cytokines; Gene Expression | 2003 |
The epidemiology of hyperuricemia in children of Taiwan aborigines.
Topics: Arthritis, Gouty; Blood Pressure; Body Mass Index; Child; Cross-Sectional Studies; Family Health; Fe | 2003 |
Lesions on the fingertips. Nodules extrude through the skin and express a chalky material.
Topics: Aged; Arthritis, Gouty; Diagnosis, Differential; Elbow Joint; Female; Fingers; Humans; Uric Acid | 2003 |
Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Betamethasone; Crystallization; Delayed-Action | 2003 |
Expression of matrix metalloproteinase-9 (gelatinase B) in gouty arthritis and stimulation of MMP-9 by urate crystals in macrophages.
Topics: Animals; Arthritis, Gouty; Arthritis, Rheumatoid; Blotting, Western; Enzyme Inhibitors; Enzyme Precu | 2003 |
Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis.
Topics: Acute Disease; Air; Animals; Antibodies; Arthritis, Gouty; Calgranulin A; Calgranulin B; Cell Moveme | 2003 |
Intraarticular tophi in a joint without a previous gouty attack.
Topics: Adult; Arthritis, Gouty; Arthroscopy; Crystallization; Early Diagnosis; Humans; Knee Joint; Male; Po | 2003 |
Diagnosis and treatment of gouty arthritis.
Topics: Arthritis; Arthritis, Gouty; Colchicine; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; | 1953 |
[Relations between cortisone and uricosuria in uratic disease (acute and chronic gout)].
Topics: Arthritis, Gouty; Chronic Disease; Cortisone; Gout; Humans; Uric Acid | 1953 |
Uric acid production in a case of myeloid metaplasia associated with gouty arthritis, studied with N15 labeled glycine.
Topics: Arthritis, Gouty; Glycine; Gout; Humans; Metaplasia; Primary Myelofibrosis; Research; Uric Acid | 1953 |
Sodium salicylate and probenecid in the treatment of chronic gout; assessment of their relative effects in lowering serum uric acid levels.
Topics: Arthritis, Gouty; Blood; Chronic Disease; Gout; Humans; Probenecid; Salicylates; Sodium Salicylate; | 1954 |
Hyperuricemia and acute gouty arthritis precipitated by thiazide derivatives.
Topics: Antihypertensive Agents; Arthritis, Gouty; Chlorothiazide; Gout; Humans; Hyperuricemia; Uric Acid | 1961 |
[Theoretical concepts and practical applications of liver catalase in the treatment of chronic gout].
Topics: Arthritis, Gouty; Catalase; Chronic Disease; Gout; Liver; Uric Acid | 1961 |
On the dual etiology of hyperuricemia in primary gout.
Topics: Arthritis, Gouty; Gout; Humans; Hyperuricemia; Uric Acid | 1960 |
Diagnosis of gouty arthritis. 18 months' experience with a pathognomonic test.
Topics: Arthritis, Gouty; Gout; Humans; Synovial Fluid; Uric Acid | 1963 |
BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.
Topics: Arteriosclerosis; Arthritis, Gouty; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Gou | 1963 |
[CASE OF CHRONIC TOPHOCEOUS GOUT].
Topics: Arthritis, Gouty; Aspirin; Diet; Diet Therapy; Gout; Humans; Phenylbutazone; Prednisolone; Sulfinpyr | 1963 |
DIABETES MELLITUS IN PATIENTS WITH GOUTY ARTHRITIS.
Topics: Arthritis; Arthritis, Gouty; Blood; Diabetes Mellitus; Drug Therapy; Gout; Humans; Hyperglycemia; Ur | 1964 |
THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS.
Topics: Arthritis; Arthritis, Gouty; Blood Coagulation Factors; Factor XII; Gout; Humans; Inflammation; Phar | 1965 |
PATHOGENIC AND THERAPEUTIC CONSIDERATIONS ON CHRONIC GOUT.
Topics: Arthritis, Gouty; Drug Therapy; Gout; Physiology; Sulfinpyrazone; Toxicology; Uric Acid | 1964 |
URATE DIURETIC THERAPY IN CHRONIC GOUT; A COMPARATIVE STUDY OF PROBENECID AND SULFINPYRAZONE.
Topics: Arthritis, Gouty; Biomedical Research; Blood; Diuretics; Drug Therapy; Gout; Humans; Kidney Calculi; | 1965 |
Uricosuric agents in the management of chronic tophaceous gout with renal impairment.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Renal Insufficiency; Uric Acid; Uricosuric Agents | 1961 |
Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase.
Topics: Acute Disease; Animals; Arthritis, Gouty; Cell Line, Tumor; Chemokine CXCL2; Chemokines; Crystalliza | 2003 |
A clinical study of crystal-proven gouty arthritis in a university hospital.
Topics: Arthritis, Gouty; Female; Hospitals, University; Humans; Incidence; Male; Thailand; Uric Acid | 2003 |
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis.
Topics: Arthritis, Gouty; Benzoic Acid; Body Fluids; Chronic Disease; Gout; Probenecid; Uric Acid; Uricosuri | 1951 |
Experimental observations in acute and chronic gout.
Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Uric Acid | 1951 |
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Female; Humans; Logistic Models; Male; | 2004 |
Intestinal pseudotumorous gouty nodulosis: a colonic tophus without manifestation of gouty arthritis.
Topics: Adult; Arthritis, Gouty; Colectomy; Colon; Colonic Diseases; Female; Humans; Intestinal Obstruction; | 2004 |
Acute gout attack in the wrist joint.
Topics: Arthritis, Gouty; Follow-Up Studies; Gout Suppressants; Humans; Male; Middle Aged; Pain Measurement; | 2004 |
Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals.
Topics: Animals; Arthritis, Gouty; Cell Line; Chemokines; Gene Expression; Humans; Macrophages; MAP Kinase S | 2004 |
[Uric acid, a neglected molecule--the value of imaging].
Topics: Arthritis, Gouty; Diagnosis, Differential; Diagnostic Imaging; Gout; Humans; Hyperuricemia; Joints; | 2004 |
[Gout and its differential diagnosis].
Topics: Arthritis, Gouty; Crystallization; Diagnosis, Differential; Gout; Humans; Joints; Microscopy, Polari | 2004 |
Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis.
Topics: Animals; Arthritis, Gouty; Cell Line; Crystallization; Enzyme Induction; Humans; Macrophages; Mice; | 2004 |
A case of tenosynovial chondromatosis with tophus-like deposits.
Topics: Adult; Arthritis, Gouty; Chondromatosis, Synovial; Fingers; Humans; Male; Soft Tissue Neoplasms; Uri | 2004 |
A rare and asymptomatic case of mitral valve tophus associated with severe gouty tophaceous arthritis.
Topics: Arthritis, Gouty; Echocardiography; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; U | 2004 |
Surgical versus pharmacologic treatment of intraspinal gout.
Topics: Aged; Arthritis, Gouty; Decompression, Surgical; Female; Follow-Up Studies; Humans; Laminectomy; Low | 2005 |
Formation of 8-nitroguanine in blood of patients with inflammatory gouty arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Gouty; C-Reactive Protein; Chromatography, Hi | 2005 |
Clinical manifestations of patients with hyperuricemia.
Topics: Age Distribution; Aged; Arthritis, Gouty; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans | 2004 |
Tophaceous gout in the bipartite patella with intra-osseous and intra-articular lesions: a case report.
Topics: Adult; Arthralgia; Arthritis, Gouty; Arthroscopy; Biopsy, Needle; Follow-Up Studies; Humans; Immunoh | 2005 |
Medial canthal tophus associated with gout.
Topics: Adult; Arthritis, Gouty; Birefringence; Eyelid Diseases; Humans; Male; Uric Acid | 2005 |
Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Differentiation; Arthritis, Gouty; Bone Mar | 2005 |
Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch.
Topics: Animals; Arthritis, Gouty; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Inflammation; | 2005 |
Histopathologic examination of conjunctival tophi in gouty arthritis.
Topics: Arthritis, Gouty; Biopsy; Conjunctival Diseases; Eosinophils; Female; Giant Cells, Foreign-Body; His | 2005 |
Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18.
Topics: Adult; Animals; Arthritis, Gouty; C-Reactive Protein; Caspase 1; Cells, Cultured; Cytokines; Humans; | 2006 |
[Diagnosis at a glance. This hand speaks volumes].
Topics: Arthritis, Gouty; Crystallization; Finger Joint; Gout; Hand Deformities, Acquired; Humans; Male; Per | 2006 |
Concomitant polyarticular septic and gouty arthritis.
Topics: Aged; Arthritis, Gouty; Arthritis, Infectious; Fatal Outcome; Humans; Kidney Failure, Chronic; Male; | 2006 |
[Polyarticular gout in young adults: a curable rheumatic disease].
Topics: Adult; Allopurinol; Arthritis; Arthritis, Gouty; Colchicine; Diagnosis, Differential; Humans; Male; | 2006 |
Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Benzbromarone; Dose-Response Relation | 2006 |
Case 8: initiation of urate-lowering therapy for standard advanced gout.
Topics: Arthritis, Gouty; Febuxostat; Humans; Male; Middle Aged; Oxypurinol; Thiazoles; Uric Acid; Uricosuri | 2006 |
Melanocortin 3 receptors control crystal-induced inflammation.
Topics: Animals; Arthritis, Experimental; Arthritis, Gouty; Disease Models, Animal; Gene Expression Regulati | 2006 |
Suppressive effect of Withania somnifera root powder on experimental gouty arthritis: An in vivo and in vitro study.
Topics: Acetic Acid; Animals; Arthritis, Experimental; Arthritis, Gouty; Cell Line; Humans; Indomethacin; In | 2006 |
Spondyloarthritis as a presentation of gouty arthritis.
Topics: Arthritis, Gouty; Colchicine; Diagnosis, Differential; Female; Gout Suppressants; Humans; Lumbar Ver | 2007 |
Reduction of urate crystal-induced inflammation by root extracts from traditional oriental medicinal plants: elevation of prostaglandin D2 levels.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Dinoprostone; Disease Models, Animal; Eleuthero | 2007 |
Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid.
Topics: Adult; Arthritis, Gouty; Frameshift Mutation; Gout; Homozygote; Humans; Hyperuricemia; Male; Mutagen | 2007 |
Clinical Images: Earth, moon, and stars in a patient with gouty arthritis.
Topics: Ankle Joint; Arthritis, Gouty; Humans; Knee Joint; Male; Microscopy, Polarization; Middle Aged; Uric | 2007 |
[Red swollen thumb. Soft tissue abscess or joint inflammation].
Topics: Abscess; Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Humans; Osteoarthritis; Soft Tissu | 2007 |
[Molecular basis of primary renal hyperuricemia : role of the human urate transporter hURAT1].
Topics: Arthritis, Gouty; Genetic Markers; Genetic Variation; Humans; Hyperuricemia; Kidney Tubules, Proxima | 2007 |
[European League Against Rheumatism evidence-based recommendations for diagnosis and management of gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Delphi Technique | 2007 |
[Concomitant septic and gouty olecranon bursitis].
Topics: Arthritis, Gouty; Arthritis, Infectious; Bursitis; Comorbidity; Crystallization; Elbow Joint; Humans | 2007 |
[No symptoms for a long time. Gout tophi].
Topics: Aged; Arthritis, Gouty; Calcinosis; Diagnosis, Differential; Humans; Knee Joint; Male; Patella; Radi | 2007 |
An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice.
Topics: Acetylglucosaminidase; Acid Phosphatase; Administration, Oral; Animals; Ankle Injuries; Anti-Inflamm | 2008 |
Tophaceous gout mass distending the prepatellar bursa.
Topics: Adult; Arthritis, Gouty; Bursa, Synovial; Bursitis; Diagnosis, Differential; Follow-Up Studies; Huma | 2007 |
Urate crystals, inflammation, and colchicine.
Topics: Animals; Arthritis, Gouty; Colchicine; Disease Models, Animal; Gout; Gout Suppressants; History, 20t | 2008 |
Effect of acute gouty arthritis on sleep patterns: a preclinical study.
Topics: Animals; Arousal; Arthritis, Gouty; Behavior, Animal; Electrodes, Implanted; Electroencephalography; | 2009 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Long-term cardiovascular mortality among middle-aged men with gout.
Topics: Adult; Arthritis, Gouty; Cardiovascular Diseases; Follow-Up Studies; Humans; Hyperuricemia; Male; Mi | 2008 |
Enthesopathy and atypical gouty arthritis following renal transplantation: a case control study.
Topics: Adult; Arthritis, Gouty; Case-Control Studies; Creatinine; Female; Humans; Kidney Diseases; Kidney T | 1995 |
Purine metabolism in female patients with primary gout.
Topics: Adenine; Arthritis, Gouty; Creatinine; Female; Gout; Humans; Hypoxanthine; Hypoxanthines; Male; Puri | 1994 |
[Allopurinol].
Topics: Allopurinol; Arthritis, Gouty; Humans; Uric Acid; Urinary Calculi | 1994 |
[Gout tophi and Heberden nodules in hyperuricemia].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Female; Fingers; Gout; Hand Deformities, Acquired; Humans | 1994 |
Postsurgical gout.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, G | 1995 |
Images in clinical medicine. Tophaceous gout.
Topics: Adult; Arthritis, Gouty; Female; Finger Joint; Hand Deformities, Acquired; Humans; Uric Acid | 1995 |
Renal function in gout patients.
Topics: Arthritis, Gouty; Biopsy; Humans; Hypertension; Kidney; Male; Middle Aged; Ultrasonography; Uric Aci | 1995 |
Proximal gout following renal transplantation.
Topics: Adult; Arthritis, Gouty; Calcium Pyrophosphate; Female; Humans; Kidney Transplantation; Male; Middle | 1994 |
Body lead stores and urate excretion in men with chronic renal disease.
Topics: Adult; Arthritis, Gouty; Body Burden; Creatinine; Humans; Kidney Failure, Chronic; Lead; Male; Middl | 1994 |
Gout attacks in chronic alcoholics occur at lower serum urate levels than in nonalcoholics.
Topics: Aged; Alcoholism; Arthritis, Gouty; Creatinine; Humans; Middle Aged; Retrospective Studies; Risk Fac | 1994 |
Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases.
Topics: Adult; Aged; Arthritis, Gouty; Chi-Square Distribution; Female; Humans; Kidney Failure, Chronic; Mal | 1994 |
[The clinical manifestations of a purine metabolic disorder in the practice of the internist].
Topics: Adult; Arthritis, Gouty; Glomerulonephritis; Gout; Humans; Liver Cirrhosis, Alcoholic; Middle Aged; | 1994 |
[The use of Allomaron in treating hyperuricemia].
Topics: Adult; Allopurinol; Arthritis, Gouty; Benzbromarone; Creatinine; Drug Combinations; Drug Evaluation; | 1994 |
Stump the experts.
Topics: Aged; Arthritis, Gouty; Diagnosis, Differential; Humans; Male; Skin; Uric Acid | 1994 |
A survey of current prescribing practices in gouty arthritis and asymptomatic hyperuricemia in San Paulo, Brazil.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Brazil; Colchicine; Data Collection; Drug | 1994 |
A missense mutation in the hypoxanthine phosphoribosyltransferase gene in a pediatric patient with hyperuricemia.
Topics: Adult; Arthritis, Gouty; Cells, Cultured; Chronic Disease; DNA; Female; Humans; Hypoxanthine Phospho | 1993 |
[Rheumatologic manifestations in heart transplant recipients. A cross-sectional study of 365 patients].
Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Arthritis, Rheumatoid; Child; Female; Heart Transplantati | 1993 |
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
Topics: Allopurinol; Animals; Arthritis, Gouty; Disease Models, Animal; Genes, Lethal; Humans; Kidney Calcul | 1994 |
A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney.
Topics: Adult; Arthritis, Gouty; Female; Humans; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; U | 1993 |
Acute gouty arthritis. Modern approaches to an ancient disease.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; C | 1993 |
[Therapeutic effect of hemodialysis on gouty arthritis and tophi in 2 patients with chronic renal failure].
Topics: Adult; Aged; Arthritis, Gouty; Finger Joint; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; | 1993 |
Missed diagnosis of acute arthritic gout in kidney transplant recipients.
Topics: Acute Disease; Adult; Allopurinol; Arthritis, Gouty; Colchicine; Female; Humans; Kidney Transplantat | 1993 |
Gout: modern management of an ancient malady.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Infectious; Gout; | 1993 |
Case in point. Tophaceous gout.
Topics: Arthritis, Gouty; Female; Humans; Microscopy, Polarization; Middle Aged; Recurrence; Uric Acid | 1995 |
Bilateral carpal tunnel syndrome secondary to tophaceous compression of the median nerves.
Topics: Arthritis, Gouty; Carpal Tunnel Syndrome; Humans; Male; Median Nerve; Middle Aged; Nerve Compression | 1996 |
[Gout: current aspects of etiology, diagnosis and therapy].
Topics: Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Female; Gout; Gou | 1996 |
Computed tomography of the knee joint as an indicator of intraarticular tophi in gout.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Cartilage; Humans; Knee Joint; Male; Middle Aged; | 1996 |
Gout in the cervical spine: MR pattern mimicking diskovertebral infection.
Topics: Arthritis, Gouty; Cervical Vertebrae; Diagnosis, Differential; Discitis; Gout; Humans; Intervertebra | 1996 |
[Polyarticular gout--change in the clinical picture?].
Topics: Adult; Aged; Arthritis, Gouty; Diagnosis, Differential; Follow-Up Studies; Humans; Joints; Male; Mic | 1996 |
Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Azepines; C-React | 1996 |
Concurrent gout and Mycobacterium tuberculosis arthritis.
Topics: Adult; Arthritis, Gouty; Arthritis, Infectious; Humans; Knee Joint; Male; Mycobacterium tuberculosis | 1997 |
Gout: the last 50 years.
Topics: Arthritis, Gouty; Colchicine; Crystallization; Gout; Gout Suppressants; History, 20th Century; Human | 1996 |
Urate oxidase in hyperuricemic heart transplant recipients treated with azathioprine.
Topics: Arthritis, Gouty; Azathioprine; Cyclosporine; Female; Heart Transplantation; Humans; Immunosuppressi | 1997 |
Altered arachidonic acid metabolism in urate crystal induced inflammation.
Topics: Animals; Arachidonic Acid; Arthritis, Gouty; Crystallization; Disease Models, Animal; Eicosanoids; F | 1997 |
Serum urate during bouts of acute gouty arthritis.
Topics: Acute Disease; Allopurinol; Arthritis, Gouty; Gout Suppressants; Humans; Male; Prospective Studies; | 1997 |
Acute gouty synovitis associated with "urate milk".
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Gouty; Bursitis; Crystallization; E | 1997 |
[Uric acid crystals and chemotactic cytokines--pathogenesis of an acute gout attack].
Topics: Arthritis, Gouty; Chemokines; Cytokines; Humans; Neutrophils; Synovial Fluid; Uric Acid | 1997 |
Reversible renal insufficiency, hyperuricemia and gouty arthritis in a case of hypothyroidism.
Topics: Adult; Arthritis, Gouty; Creatinine; Humans; Hypercholesterolemia; Hypothyroidism; Male; Renal Insuf | 1998 |
Severe debilitating polyarticular gout and terminal renal failure in an allopurinol 'non-responder'.
Topics: Adult; Allopurinol; Arthritis, Gouty; Combined Modality Therapy; Drug Resistance; Fatal Outcome; Gou | 1998 |
Feeding-induced tonic pain suppression in the chicken: reversal by naloxone.
Topics: Adaptation, Psychological; Analgesia; Animals; Arthritis, Gouty; Behavior, Animal; Chickens; Eating; | 1998 |
Urate milk.
Topics: Arthritis, Gouty; Humans; Male; Middle Aged; Synovial Fluid; Uric Acid | 1998 |
Controlling hyperuricemia.
Topics: Arthritis, Gouty; Gout Suppressants; Humans; Uric Acid | 1998 |
Repeated synovial fluid analysis may be needed to find crystals in gout.
Topics: Adult; Arthritis, Gouty; Crystallization; Humans; Joints; Male; Microscopy, Polarization; Synovial F | 1998 |
[Gout: physiopathology, diagnosis, course, treatment].
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Diagnosis, Differential; Female; Gout; Go | 1998 |
Hyperuricaemia in patients with right or left heart failure.
Topics: Adult; Aged; Arthritis, Gouty; Cardiomyopathy, Dilated; Diuretics; Female; Hemodynamics; Humans; Hyp | 1999 |
Evaluation of intraarticular opioid analgesia for the relief of articular pain in the domestic fowl.
Topics: Analgesia; Analgesics; Animals; Arthritis, Gouty; Buprenorphine; Chickens; Disease Models, Animal; F | 1999 |
[Disseminated skin abnormalities due to gout].
Topics: Aged; Arthritis, Gouty; Biopsy; Crystallization; Gout; Humans; Male; Skin; Skin Diseases, Metabolic; | 1999 |
Spinal gout: an unusual clinical and cytological presentation.
Topics: Arthritis, Gouty; Back Pain; Female; Histiocytes; Humans; Middle Aged; Spinal Diseases; Spine; Uric | 1999 |
Gouty arthritis in a female patient with mixed connective tissue disease.
Topics: Adult; Arthritis, Gouty; Diagnosis, Differential; Fatal Outcome; Female; Humans; Mixed Connective Ti | 2000 |
Diagnosis of intercritical gout.
Topics: Arthritis, Gouty; Crystallization; Gout; Humans; Synovial Fluid; Uric Acid | 2000 |
[Purine metabolism enzymes in diagnosis and differential diagnosis of osteoarthritis and gout arthritis].
Topics: 5'-Nucleotidase; Arthritis, Gouty; Biomarkers; Diagnosis, Differential; Female; Humans; Isoenzymes; | 2000 |
Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout.
Topics: Animals; Arthritis, Gouty; Cell Differentiation; Cell Extracts; Cell Line; Endothelium, Vascular; In | 2000 |
Cutaneous angiosarcoma arising in a gouty tophus: report of a unique case and a review of foreign material-associated angiosarcomas.
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Foreign Bodies; Hemangiosarcoma; Humans; Immunoenzyme Tec | 2000 |
[A case of familial juvenile gouty nephropathy associated with a right renal tumor].
Topics: Adenoma; Adult; Arthritis, Gouty; Diagnosis, Differential; Female; Humans; Kidney Neoplasms; Nephros | 2000 |
Characteristic marco- and microscopic aspect of the synovial membrane in crystal induced arthritis.
Topics: Adult; Arthritis, Gouty; Arthroscopy; Chondrocalcinosis; Female; Humans; Knee Joint; Male; Middle Ag | 2001 |
A 26-year-old man with kidney allograft failure and foot pain.
Topics: Adult; Arthritis, Gouty; Foot Diseases; Graft Rejection; Humans; Kidney Transplantation; Male; Pain; | 2001 |
[A 40-year-old man with left knee pain and tumefaction].
Topics: Acute Disease; Adult; Arthritis, Gouty; Humans; Knee Joint; Male; Pain; Synovitis; Uric Acid | 2001 |
An atypical case of primary renal tubular hypokalaemic metabolic alkalosis with chronic tophaceous gout.
Topics: Arthritis, Gouty; Bartter Syndrome; Chronic Disease; Female; Follow-Up Studies; Humans; Kidney Funct | 2001 |
[Gout tophus].
Topics: Aged; Aged, 80 and over; Arthritis, Gouty; Crystallization; Female; Gout; Humans; Uric Acid | 2001 |
Clinical and family studies in Hungarian patients with gout.
Topics: Adult; Arthritis, Gouty; Female; Gout; HLA Antigens; Humans; Male; Uric Acid | 1992 |
Gout.
Topics: Adult; Aged; Arthritis, Gouty; Female; Gout; Humans; Male; Middle Aged; Uric Acid | 1992 |
Reduce serum uric acid levels before withdrawing antihyperuricemic therapy in patients with tophaceous gout.
Topics: Allopurinol; Arthritis, Gouty; Humans; Uric Acid | 1992 |
Bartter's syndrome with gouty arthritis.
Topics: Arthritis, Gouty; Bartter Syndrome; Female; Humans; Kidney Tubules; Middle Aged; Renin-Angiotensin S | 1992 |
[Tophaceous deposit in the fingertips of patients without gouty arthritis].
Topics: Aged; Aged, 80 and over; Arthritis; Arthritis, Gouty; Creatinine; Diagnosis, Differential; Diuretics | 1992 |
McArdle's disease and gout.
Topics: Adenine Nucleotides; Arthritis, Gouty; Exercise Test; Glycogen Storage Disease Type V; Humans; Male; | 1992 |
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine.
Topics: Arthritis, Gouty; Chi-Square Distribution; Cyclosporine; Female; Gout; Heart Transplantation; Heart- | 1992 |
The incidence of gout in patients with Dupuytren's disease.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; Dupuytren Contracture; Female; Gout; Humans; Incid | 1992 |
Eleven-year-old girl with acute renal failure, arthritis, hyperuricemia, and family history of rheumatic disorders.
Topics: Acute Kidney Injury; Arthritis, Gouty; Child; Female; Humans; Kidney; Kidney Neoplasms; Lymphoma, No | 1992 |
Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout.
Topics: Aged; Aged, 80 and over; Allopurinol; Arthritis, Gouty; Humans; Middle Aged; Probenecid; Radiography | 1991 |
[Ultrastructural study of synovial fluid in gouty arthritis].
Topics: Arthritis, Gouty; Humans; Male; Microscopy, Electron; Middle Aged; Synovial Fluid; Uric Acid | 1991 |
Crystal arthritis: a clinician's view.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, | 1991 |
Autosomal dominant transmission of gouty arthritis with renal disease in a large Japanese family.
Topics: Adult; Arthritis, Gouty; Female; Genes, Dominant; Humans; Hypoxanthine Phosphoribosyltransferase; Ja | 1991 |
Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use.
Topics: Arthritis, Gouty; Azathioprine; Creatinine; Cyclosporins; Follow-Up Studies; Furosemide; Humans; Kid | 1991 |
[Uric acid level in blood donors of southern Germany--almost constant since 1971].
Topics: Adult; Arthritis, Gouty; Benzbromarone; Benzimidazoles; Blood Donors; Cross-Sectional Studies; Femal | 1991 |
[Ulcerating gout tophi. Surgical therapy in a patient with hyperuricemia, hyperlipidemia and alcohol abuse].
Topics: Alcoholism; Arthritis, Gouty; Cholesterol; Foot Ulcer; Humans; Hyperlipidemias; Liver Function Tests | 1991 |
A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.
Topics: Acute Disease; Arthritis, Gouty; Chronic Disease; Evaluation Studies as Topic; Family Practice; Gout | 1991 |
Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation.
Topics: Arthritis, Gouty; Crystallization; Humans; Inflammation; Interleukin-8; Monocytes; Synovial Fluid; U | 1991 |
Peripheral arthrocentesis in the work-up of acute low back pain.
Topics: Arthritis, Gouty; Back Pain; Colchicine; Humans; Knee Joint; Male; Middle Aged; Synovial Fluid; Uric | 1990 |
[The importance of benziodarone in the treatment of gout and hyperuricemic syndrome].
Topics: Arthritis, Gouty; Benzofurans; Female; Humans; Male; Uric Acid; Uricosuric Agents | 1990 |
Hyperuricemia and gouty arthritis in heart transplant recipients.
Topics: Arthritis, Gouty; Heart Transplantation; Humans; Postoperative Complications; Uric Acid | 1990 |
Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India.
Topics: Adult; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Evaluation Studies as | 1990 |
Hypoxanthine-guanine phosphoribosyltransferase deficiency in three brothers with gout: characterization of a variant, HPRTEdinburgh, having altered isoelectric point, increased thermal lability and normal levels of messenger RNA.
Topics: Adolescent; Adult; Arthritis, Gouty; Cell Line; Child, Preschool; Enzyme Activation; Genetic Variati | 1989 |
Calcium pyrophosphate and monosodium urate crystal interactions with neutrophils: effect of crystal size and lipoprotein binding to crystals.
Topics: Apolipoproteins; Arthritis, Gouty; Calcium Pyrophosphate; Diphosphates; Humans; In Vitro Techniques; | 1989 |
Polyarticular gout.
Topics: Acute Disease; Arthritis, Gouty; Diagnostic Errors; Female; Humans; Male; Recurrence; Sex Factors; U | 1989 |
A role of interleukin-1 (IL-1) in crystal-induced arthritis.
Topics: Arthritis, Gouty; Cells, Cultured; Clone Cells; Crystallization; Humans; Interleukin-1; Monocytes; S | 1989 |
Is gout related to an alteration of the uric acid protein binding?
Topics: Arthritis, Gouty; Blood Proteins; Gout; Humans; Hypoxanthines; Kidney Diseases; Uric Acid | 1989 |
Intermittent control of hyperuricaemia in the treatment of gout.
Topics: Allopurinol; Arthritis, Gouty; Gout; Humans; Middle Aged; Uric Acid | 1989 |
Cyclosporine-induced hyperuricemia and gout.
Topics: Adult; Arthritis, Gouty; Azathioprine; Creatinine; Cyclosporins; Drug Therapy, Combination; Female; | 1989 |
Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Gouty; Female; Finger Joint; | 1989 |
Gouty tophus presenting as "pseudo-Baker's cyst".
Topics: Aged; Arthritis, Gouty; Diagnosis, Differential; Humans; Knee Joint; Male; Popliteal Cyst; Radiograp | 1989 |
A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Drug Utilization | 1989 |
[Pyrazinamide, hyperuricemia and gouty arthritis].
Topics: Adult; Arthritis, Gouty; Humans; Male; Pyrazinamide; Tuberculosis; Uric Acid | 1988 |
[Disorders of purine metabolism as an etiological factor in renal pathology].
Topics: Arthritis, Gouty; Humans; Kidney; Metabolic Clearance Rate; Nephritis; Uric Acid | 1988 |
[Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism].
Topics: Adult; Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Fructose; Gout; Humans; Male; Metabo | 1987 |